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Abstract 
 
A better understanding of the molecular mechanisms that control pluripotency, 
differentiation and epithelial phenotypical plasticity is crucial for the development of 
the current knowledge in many general processes such as cell identity maintenance 
and cell fate decision-making. 
Embryonic stem cells (ESC) pluripotency maintenance and differentiation are of key 
importance to the embryonic development, as well as to the progress in stem cells 
technologies. The role of miR-290-295 cluster members in preserving the pluripotent 
state and differentiation potential of mouse ESC is well established. Nevertheless, the 
precise list of targets translating the microRNAs functionality is incomplete. In our 
study we, firstly, identified and validated miR-290 targets with high confidence. We 
further confirmed the expression variation of IRF2 in response to miRNAs’ depletion 
in ESC. Moreover, we revisited the involvement of nuclear factor kappa-B (NF-kB) 
pathway in the miRNA-dependent regulation in mESCs. Hence, our results provided 
new understanding of the role and mechanistic of miR-290-295 microRNAs 
involvement in ESC pluripotency and differentiation.  
In a similar fashion to ESC pluripotency and differentiation mechanisms, a global 
analysis-approach that compares and combines data from different epithelial to 
mesenchymal transition (EMT) models enabled us to construct a more detailed 
network of regulatory entities implicated in epithelial plasticity. The maintenance and 
plasticity of the epithelial cell phenotype are important events not only during normal 
embryonic development, but also to cancer progression and metastasis formation. 
Comparing this network between mouse and human, we identified a new transcription 
factor (TF) motif TFAP2A/C that is consistently involved in EMT. When applying 
the NMuMG cellular model of TGFβ-induced EMT, we found that the predicted 
activity of the TFAP2A/C is inversely correlated to the Tfap2a mRNA expression 
during the process. We have confirmed that TFAP2A directly binds to the promoter 
of Zeb2, a TF central to EMT. Thus, it regulates the expression of this gene. 
Furthermore, the TFAP2A overexpression in NMuMG cells modulates the cells’ 
epithelial phenotype and induces changes in cell adhesion and morphology. This 
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overexpression was followed by increased mRNA levels of EMT master regulator 
TFs, together with an elevated expression of genes involved in cellular adhesion. 
Therefore, we identified a potentially new role of TFAP2A transcription factor, which 
suggests that elements of its regulatory function during neural crest development 
might operate in mechanisms controlling epithelial plasticity in normal breast and 
tumor tissues.  
Overall, we characterized another facet of microRNAs’ function in pluripotency and 
differentiation in ESC, as well as a new aspect of the implication of TFAP2A in 
epithelial cell state integrity and plasticity. Therefore we contributed to expanding our 
insight of how are regulated at molecular level the cell identity homeostasis and the 
unfolding of cellular phenotypical plasticity. 
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Introduction 
 
Molecular Basis of Cellular Specialization 
 
The development of vertebrate organisms follows a strictly defined program that 
gives rise to a multitude of cell types and tissues from a single cell. A complex 
network of signaling cues, gene expression regulators and epigenetic factors define 
the fate of individual cells within the developing organism. Thus, even though all 
cells in an organism carry the same genetic information, they assume cell fates with 
little overlap in functionality. Terminally differentiated cells generally maintain their 
identity across various conditions and stimuli, but exogenously-driven changes in 
gene expression can reverse, or even drastically change cell fate. In the late eighties a 
pioneering study by Walter Gehring introduced the concept of a selector transcription 
factor, which governs a particular developmental decision (Schneuwly, Klemenz et al. 
1987). In an ingenious experiment, he showed that the exogenous expression of a 
transcription factor, Antennapedia, promotes the development of legs at the place 
where antennae would normally develop in the fly Drosophila melanogaster. In 
another pilot study the overexpression of the transcription factor Myoblast 
determination protein 1 (MYOD1) in fibroblasts resulted in their transdifferentiation 
into myoblasts. These studies strengthen the idea that single genes, also called 
“master regulators”, are at the top of ”regulatory hierarchies” that define precise 
cellular states (Davis, Weintraub et al. 1987). Although the mechanisms that induce 
the differentiation of particular cell types are generally well studied, how cell identity 
is maintained in response to perturbations is not entirely understood. For example, in 
the case of postmitotic neuronal cell types the factors that determine the fate of a 
neuronal cell type are the same responsible for its maintenance: in the absence of 
inductive signal, autoregulatory feedback processes that involve maintenance-
dedicated factors preserve the stability of the differentiated state (Deneris and Hobert 
2014). That the maintenance of cell identity is important for organism function is 
undisputed. Among the various pathologies that are associated with loss of defined 
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differentiated phenotypes, cancer is perhaps the prototype. Many parallels have been 
drawn between cancer and metastasis and pluripotency (Goding, Pei et al. 2014). The 
aim of the project described here was to identify transcriptional and post-
transcriptional regulators that can best explain gene expression changes that take 
place during two paradigmatic processes: embryonic development and epithelial-to-
mesenchymal transition. A better understanding of the molecular circuits that underlie 
the homeostasis and plasticity of cell identity in these circumstances will benefit the 
general understanding of the differentiation programs that operate both in 
development and during pathological conditions. 
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Chapter I. Functions of miR-290 microRNAs in 
embryonic stem cells 
 
Embryonic Stem Cells 
Discovery of Embryonic Stem Cells 
 
After fertilization, the ovum starts traveling through the female reproductive tract, 
taking approximately six days until it reaches the uterus (Figure 1) (Clift and Schuh 
2013). During this time a series of mitotic divisions that do not change the size of the 
embryo take place. In the end of this process, towards the sixteen-cell stage, the 
embryo has a berry-like shape and it is called morula, from the Latin mora, meaning 
mulberry (Alberts 2002). Up to the 8-cell stage, the cells are totipotent, meaning that 
they can divide and give rise to any of the differentiated cells in the entire organism; 
they are identical to each other and mutually replaceable, meaning that when single 
cells are removed, the remaining ones will compensate (Alberts 2002). 
Between the third and the forth cleavage (from the 8-cell to 16-cells stage), the 
previously poorly organized embryo will engage into a compaction process that will 
result in the separation of the cells to an outer and inner set.  
 
 
  
 
 
 
 
 
 
 
Figure 1.  First six days of human embryogenesis.  After fertilization of the oocyte, 
in approximately five to six days, the embryo divides, migrates and forms the 
blastocyst.  Adapted from Fundamentals of Anatomy & Physiology, 7e By Frederic 
H.Martini, Copyright Pearson Education, Published by Benjamin Cummings, 2005. 
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After the compaction, the inner and outer cells will commit to different fates. The 
cells that constitute the wall of the sphere will give rise to extra-embryonic tissues, 
namely the trophectoderm. The cells from the inner cell mass will give rise to all 
tissues and organs of the adult organism (Alberts 2002). An internal fluid-filled cavity 
is created and the embryo is called blastocyst (Figure 1). Following the compaction is 
the gastrulation phase, in which the single layered blastula transforms into a trilaminar 
gastrula, which is composed of three germ layers: ectoderm, mesoderm and 
endoderm. Cells derived from the inner cell mass, also called embryonic stem cells 
(ESCs), can be explanted from the embryo and cultured in vitro (Evans and Kaufman 
1981; Martin 1981). Although murine ESCs (mESCs) are extensively studied 
currently, the path to obtain these cells was quite long. 
In 1954, Stevens and Little described a spontaneous testicular teratoma in mice, a 
complex tumor formation that contains a range of differentiated cells and tissues 
(Stevens and Little 1954). They argued that teratomas are composed of both 
undifferentiated pluripotent embryonic cells, as well as different cells of various 
types. They further determined that the pluripotent cells, which they called embryonal 
carcinoma (EC) cells, are able to give rise both to differentiated cells as well as self-
renew (Stevens and Little 1954). Similarly, when early mouse embryos were grafted 
in adult animals, they generated teratomas (Solter, Skreb et al. 1970). Following these 
initial studies, much effort has been put into optimizing the growth conditions for 
embryonic cells in culture so that their properties and their differentiation in vitro can 
be studied (Evans 2011). In 1975, Minz and Illmensee generated a chimeric mouse by 
injecting EC cells in the mouse blastocyst. However, due to karyotypic abnormalities 
often present in the EC cells, the chimerism was never observed at the germ cells 
level (Mintz and Illmensee 1975).  EC cells were found to have highly similar 
properties to normal non-cancerous cells from the inner cell mass of the blastocyst, 
for instance they are able to form embryoid bodies (EB) in vitro (Martin and Evans 
1975).  This finding paved the way to the isolation and culturing of ESCs (Martin and 
Evans 1975; Evans 2011). The first ESCs from mouse were cultured in the beginning 
of the eighties. (Evans and Kaufman 1981; Martin 1981). However, it took much 
longer until human ESCs were obtained in 1998 (Thomson, Itskovitz-Eldor et al. 
1998).  
ESCs are pluripotent, meaning that they are able to form any of the tissues and organs 
of the entire organism, except those forming the placenta and certain parts of the 
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embryo (Figure 3). Furthermore they are able to differentiate into any of the three 
germ layers. In addition, as any stem cell, they are capable of self-renewal, and thus 
they can also produce additional stem cells (Evans 2011). In contrast to EC cells, 
when injected in the mouse blastocyst, mouse ESCs give rise to chimeric mice, 
including their germ-lines (Robertson, Bradley et al. 1986). As a consequence, the in 
vitro modified genetic material of ESCs can be used to generate fully mutant animal 
by germ-line transmission. This in turns allows the study of target genes functions 
(Evans 2011). Stem cells form a topic of great current interest. They enable basic 
research on understanding the development and function of human cells and are 
expected to have a prospectively important role for testing drugs safety and efficacy. 
In addition they are highly relevant for the future of regenerative medicine, as they 
represent a promising source of tissue and cells in replacement therapies (Evans 2011; 
van Berlo and Molkentin 2014)  
 
Pluripotency Maintenance in Cell Culture 
 
In the years following their discovery, mouse ESC were maintained in culture 
together with a feeder layer of embryonic cells that were treated such that could not 
divide anymore (Evans and Kaufman 1981; Martin 1981). Later studies found that the 
factor that feeder cells provided and was important for maintaining mESC 
pluripotency in vitro is LIF (Leukemia inhibitory factor). When combined with fetal 
calf serum (FCS), LIF bypasses the requirement for feeder cells (Martin and Evans 
1975; Smith, Heath et al. 1988; Williams, Hilton et al. 1988). When LIF is 
withdrawn, mESC still proliferate but their differentiation is induced, suggesting that 
LIF presence in culture media supports mESC’s self-renewal capacity (Smith 2001).  
LIF is a cytokine, member of the interleukin 6 (IL-6) family, and it interacts with its 
corresponding transmembrane receptor Leukemia inhibitory factor receptor (LIFR). 
Upon ligand binding, LIFR dimerizes with Interleukin 6 signal transducer 
IL6ST/gp130 receptor, which further transduces the signal. The effect of LIF on 
mESC pluripotency is subsequently mediated via Janus kinases (JAKs)-dependent 
activation of the transcription factor Signal transducer and activator of transcription 3 
(STAT3) (Niwa, Burdon et al. 1998; Smith 2001) (Figure 2). Furthermore STAT3 
activation alone is sufficient to sustain mESC pluripotency (Matsuda, Nakamura et al. 
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1999). Despite the critical role of LIF-gp130 in maintaining cell cultures of mESC, 
the developing embryo is not dependent on this signaling path prior to gastrulation. 
Instead, this pathway is important in a process named diapause, in which a lactating 
mouse female is fecundated and the embryo development is blocked at the blastocyst 
stage before implantation, until the mother’s hormone levels are reestablished 
(Nichols, Chambers et al. 2001; Smith 2001). To avoid the use of Fetal Calf Serum 
(FCS) which is heterogeneous in composition and therefore an important source of 
variability, the bone morphogenetic protein 4 (BMP4) can be added to the cell culture 
and thus allow the growth of mESC in chemically defined medium (Ying, Nichols et 
al. 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. LIF signaling maintains the expression of pluripotency genes. Binding 
of LIF to its cellular receptor, which is a homodimer of LIFR and gp130, triggers 
STAT3 phosphorylation and concomitant signal transduction to the nucleus, where 
the expression of pluripotency genes is activated. Adapted from (Arabadjiev 2012) 
 
The optimal culture conditions for human ESC (hESC) are surprisingly different than 
those for mESCs, and human ESCs differ from mouse ESC in their molecular profile, 
morphology and differentiation potential (Nichols and Smith 2009). Neither LIF 
addition, nor STAT3 activation, via gp130 receptor signaling, are sufficient for 
preserving hESC pluripotency in the absence of a feeder layer of mouse embryonic 
fibroblasts (MEF) (Humphrey, Beattie et al. 2004). MEFs can be replaced with 
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Matrigel® or similar secreted gelatinous protein mixtures, in the presence of MEF 
conditioned media (Xu, Inokuma et al. 2001). However, as Matrigel® is produced by 
Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, it has limitations and cannot be 
used when hESC are employed in clinical applications. Matrigel® like substances 
exhibit extensive lot-to-lot variability and can lead to xenogenic contamination (Villa-
Diaz, Ross et al. 2013). Therefore extensive effort is currently being directed towards 
development of feeder-free, chemically defined conditions for the establishment and 
expansion of human pluripotent stem cells (hPSC) (Ludwig, Levenstein et al. 2006; 
Chen, Gulbranson et al. 2011; Rodin, Antonsson et al. 2014). Furthermore, adhesion 
independent suspension culture methods are of high interest for large scale derivation 
and propagation of hESC (Steiner, Khaner et al. 2010).    
 
Pluripotency in Different Embryonic States 
 
The embryonic stem cells that are derived from the cells of the inner cell mass (ICM) 
and are the progenitors of the epiblast, define the naïve pluripotent state (Evans and 
Kaufman 1981; Martin 1981). Shortly after the blastocyst stage the ICM will separate 
into two cell types: the epiblast, from which the embryo proper is formed, and the 
primitive endoderm, which gives rise to extra-embryonic tissues (Najm, Chenoweth et 
al. 2011). In the pre-implantation epiblast of female embryos both X chromosomes 
are active. This property is specific to the naïve pluripotent state. Upon implantation, 
the epiblast is subject to a series of developmental signals that will result in its 
conversion into a layer of epithelium, in parallel with random inactivation in one of 
the X chromosomes in XX epiblasts. Subsequently, the cells of this epithelium are 
subject to location-driven specification. The cells that constitute the post-implantation 
epiblast maintain a high degree of plasticity and their fate can be reoriented at this 
stage (Nichols and Smith 2009).  However, in contrast to cells originating from the 
inner cell mass, post-implantation epiblast cells cannot give rise to chimeras when 
injected into blastocysts (Rossant 2008). Mouse pluripotent cells from the post-
implantation epiblast, EpiSCs, have been already isolated and can be cultured in the 
presence of Fibroblast growth factor (FGF) and Activin instead of LIF (Brons, 
Smithers et al. 2007; Tesar, Chenoweth et al. 2007). Consistent with their 
pluripotency, EpiSC are efficient in teratoma formation (Tesar, Chenoweth et al. 
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2007).  Furthermore, as expected from their origin, double X EpiSCs have one 
inactivated copy of X chromosome. EpiSCs represent the so-called primed pluripotent 
state (Nichols and Smith 2009). Through the exogenous expression of a single 
transcription factor, namely Kruppel-like factor 4 (KFL4), these cells can be 
reprogrammed to the naïve pluripotent state. The transition from mESC to EpiSC is 
achieved with growth factors cues (Guo, Yang et al. 2009). For ethical reasons hESC 
cannot be tested for their ability to form chimeras (Nichols and Smith 2009). 
However they are shown to be able to engraft into mouse blastocyst, and in certain 
cases they can undergo gastrulation and form human/mouse embryonic chimeras 
(James, Noggle et al. 2006). Although hESC have similar embryological origin as 
mESCs, they reassemble in many aspects EpiSC and are considered to be in primed 
rather than in ground pluripotent state (Mascetti and Pedersen 2014). It was recently 
demonstrated that human blastocyst inner cell mass derived cells, when kept in 
NHSM (naïve human stem cell medium), which contains LIF, a combination of other 
growth factors and small molecule inhibitors of core signaling pathways, display 
more similarities to mESC and are thought to preserve their ground state pluripotency. 
Furthermore, ICM-like hESCs significantly outperform the previously derived hESC 
cell lines in their ability to generate interspecies chimeras (Gafni, Weinberger et al. 
2013).  
 
ESC Differentiation 
 
When placed in relevant growth conditions, ESCs can give rise to cells of any of the 
three germ layers (Figure 3). In contrast to mESCs, hESCs can also give rise to a 
population of cells that shares many characteristics with trophoblasts, when 
stimulated with BMP4 (Xu, Chen et al. 2002).  
Different methods exist to promote the differentiation of ESC. The most widely used 
method is aggregation of ESC in suspension that results in the formation of a three-
dimensional (3D) structure known as embryoid body (EB). This strategy was initially 
developed for the culture of EC cells and can also be applied to ESC (Martin and 
Evans 1975). The differentiation of EBs resembles in many aspects the developmental 
program that the ICM cells of the embryo undergo. However, a major difference is 
that the EBs lack a correct axial organization and body plan, and do not have 
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appropriate organization of the three germ layers. A recent improvement of this 
technique combines the growth of the embryoid colony in a 3D fibrin gel with a 
consequent step of cell anchorage to a collagen coated two-dimensional (2D) support, 
which promotes the proper germ layer organization of EBs (Poh, Chen et al. 2014). 
Other approaches consist in co-culturing the ESC on stromal cells that will stimulate 
their differentiation or using a layer of extracellular matrix proteins (Keller 2005). A 
series of cell types originating from any of the three germ layers: the mesoderm, the 
endoderm and the ectoderm can be produced from ESC. The differentiation of 
mesodermal cells gives rise to hematopoietic, vascular, cardiac, skeletal muscle, 
osteogenic, adipogenic, and chondrogenic lineages (Keller 2005; Salani, Donadoni et 
al. 2012; Slukvin 2013; Barad, Schick et al. 2014). With respect to the endoderm, 
pluripotent stem cells (PCS) were used to obtain various cell types from the 
gastrointestinal and respiratory tract, as well as hepatocytes, pancreatic cells and 
thyroid follicular cells (Kadzik and Morrisey 2012; Cheng, Tiyaboonchai et al. 2013; 
Sewell and Lin 2014; Sinagoga and Wells 2015). Concerning ectoderm-derived 
lineages, protocols that establish neuroectoderm and epidermis commitment are well 
defined. The neural differentiation leads to the three major cell types present in the 
central nervous system: neurons, astrocytes and oligodendrocytes. Furthermore, 
engendering of specialized neuronal sub-types such as dopaminergic, cholinergic and 
glutaminergic neurons is also possible (Keller 2005). An exciting recent development 
is the generation of organ-like tissues, named “organoids” through 3D cell cultures 
methods (Shamir and Ewald 2014). Organoids are structurally similar to the model 
organs, can be composed of cells derived from different germ layers and are formed 
from various cell lineages. Eyecup, gut, brain, kidney, liver and lung are amongst the 
successfully produced organoids. These experimental models are instrumental for 
better understanding of organ development and function in healthy, or pathological 
conditions (Shamir and Ewald 2014; Dye, Hill et al. 2015). 
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Figure 3. Embryonic stem cells differentiation potential. Adapted by permission of 
Macmillian Publishers Ltd Nature Reviews Genetics (O'Connor and Crystal 2006), 
copyright 2006. Embryonic stem cells are explanted form the blastocyst. They can be 
maintained in cell culture for indefinitely long periods of time or can be differentiated 
into any of the three germ layer-derived cell types. 
 
Induced Pluripotency 
 
In 2006, a crucial discovery changed the landscape of molecular and cellular biology. 
By expressing a cocktail of four transcription factors: Octamer-binding protein 
4/OCT4, homeobox protein NANOG, transcription factor SOX2 and Myc proto-
oncogenic protein/MYC (OSKM), in mouse fibroblasts Takahashi and Yamanaka 
obtained cells that were in many aspects similar to embryonic stem cells (Takahashi 
and Yamanaka 2006). This finding opened new avenues in stem cell research. The 
rapidly developing technology of generating induced Pluripotent Stem Cells (iPSC) 
promises to offer an alternative solution for disease modeling, drug discovery and 
regenerative medicine (Yamanaka 2012). In 2007 the successful reprogramming of 
human fibroblasts to iPSCs allowed the generation of cells that reassembled but 
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circumvented the ethical issues associated with hESCs. Moreover iPSCs have the 
important advantage of a matched genetic background with the patient from which the 
fibroblasts were initially isolated. iPSCs provide a unique opportunity in disease 
modeling and drug discovery, as they allow for the generation of virtually any cell 
type from a given subject and the use of large number of genetically variable cell lines 
and tissues in drug screening assays (Park, Arora et al. 2008). 
 
Figure 4. Induced pluripotency stem cells technology. Terminally differentiated 
cells can be reprogrammed, using a combination of four reprogramming transcription 
factors. Adapted by permission of Macmillian Publishers Ltd Nature (Loh and Lim 
2013), copyrights 2013. 
 
Indeed, many disease-modeling studies followed. IPSCs derived from people 
suffering of amyotrophic lateral sclerosis (ALS) were used to better understand the 
mechanism of the disease and to test for potential drugs (Dimos, Rodolfa et al. 2008). 
ALS is a devastating neurodegenerative disorder and more than 100 mutations in 
dozens of genes are known to be in its origin. Motor neurons derived from iPSCs of 
patients with different forms of ALS presenting different set of mutations allowed the 
identification of potential general mechanism of the disease. With the application of 
the same methodology an anti-epileptic drug showed promising results and will be 
further studied in clinic (Dimos, Rodolfa et al. 2008; Kiskinis, Sandoe et al. 2014; 
Wainger, Kiskinis et al. 2014). IPSC-derived cardiac myocytes and hepatocytes can 
be used as an alternative to test drug toxic effects (Yamanaka 2009). Another major 
future application of the stem cell technology is in regenerative medicine. In 2007 
autologous iPSCs were used for the first time successfully in the treatment of sickle 
cell anemia in mice (Hanna, Wernig et al. 2007). Currently research is being directed 
towards making the iPSC technology useful in the treatment of macular degeneration, 
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spinal cord injuries, Parkinson’s disease, and platelet deficiency (Takayama, 
Nishimura et al. 2010; Kriks, Shim et al. 2011; Nori, Okada et al. 2011; Okamoto and 
Takahashi 2011). The research on regeneration of cardiac tissue progressed very 
quickly in the last decade. Myocardial infraction (MI) or advanced heart failure, leads 
to the destruction of cardiac tissue and important loss of cardiomyocytes, which are 
leading cause of death. ES and iPS cells based methods currently show the highest 
regenerative potential for therapeutic cardiac regeneration (van Berlo and Molkentin 
2014). Both strategies were tested in animal models and were demonstrated to be 
efficient (Kawamura, Miyagawa et al. 2012; Chong, Yang et al. 2014). However, 
prior to any of these approaches advancing towards the clinic, important safety 
questions related to the technology, namely the long term genetic stability of iPSC 
need to be addressed. Furthermore, proving that every cell in the treatment suspension 
is differentiated enough not to form cancer or teratoma remains challenging (van 
Berlo and Molkentin 2014). 
 
Regulation of pluripotency  
 
The stable pluripotent state results from a balance of signals promoting stemness and 
inhibiting differentiation (Smith 2001). Extracellular and intrinsic signaling are 
integrated by a network of molecules that involves complex interactions between 
transcription factors, RNA binding proteins, small and long non-coding RNAs and 
other regulators of gene expression (Young 2011). This tangled molecular circuitry is 
responsible for maintaining the epigenetic and transcriptional landscape of pluripotent 
stem cells (PSCs) in a ground state.  
 
Transcriptional Control of Pluripotency 
 
Transcription factors are proteins that interact directly or indirectly with DNA and 
thus activate or suppress the transcription of different genes. They can bind to 
elements that are either proximal to the promoter or distal, 100s of kb away (Young 
2011). 
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Core Pluripotency Factors 
 
Three transcription factors are known as the core pluripotency transcription factors 
that are responsible for maintaining stemness of PSC: OCT4, SOX2 and NANOG 
(Young 2011; Theunissen and Jaenisch 2014). 
Murine OCT4 is encoded by Pou5f1 gene and it belongs to the POU family of 
homeodomain transcription factors. Its expression during mouse development is 
restricted to the blastomere before compaction, the pre- and post- implantation 
epiblast and the primordial germ cells (Young 2011). In OCT4-deficient mouse 
embryos, the blastocyst forms, but the ICM cells are not pluripotent and rather 
committed to the trophoblast lineage (Nichols, Zevnik et al. 1998). The OCT4 levels 
regulate ESC’s fate. Increased OCT4 levels induce ESC differentiation towards 
primitive endoderm and mesoderm, while its repression leads to trophectoderm 
specification (Niwa, Miyazaki et al. 2000). OCT4 acts in concert with SOX2 to 
maintain pluripotency and induce mesendoderm determination. SOX2 is a member of 
Sox (SRY-related HMG (High Mobility Group) box) and it is considered as 
transcriptional partner of OCT4. Consistently, the SOX2 expression pattern in the 
early development is highly similar to that of OCT4. The SOX2 protein and mRNA 
are found in the epiblast and primordial germ cells. In contrast, however, to OCT4, 
SOX2 is equally expressed in the post-implantation extra-embryonic ectoderm that 
further develops to mature placenta (Avilion, Nicolis et al. 2003). A further 
confirmation of the synergy between SOX2 and OCT4 is the similarity in the 
phenotype of their knockout in mouse embryo, which in both cases results in a failure 
to establish a pluripotent ICM population (Avilion, Nicolis et al. 2003; Yeo and Ng 
2013). In mouse embryos, NANOG is expressed only in the parietal germ cells and 
the pluripotent cells populations that arise after compaction. Nanog is rapidly silenced 
upon the specification of these lineages. Homozygous Nanog-knockout mice lack 
defined epiblast cells population upon implantation (Chambers, Colby et al. 2003; 
Mitsui, Tokuzawa et al. 2003). In contrast Nanog-null homozygous mESC can self-
renew indefinitely, although with lower efficiency, and without committing into 
EpiSC (Chambers, Silva et al. 2007).  Despite the fact that NANOG is dispensable for 
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mESC pluripotency, it stabilizes their undifferentiated state(Chambers, Silva et al. 
2007).  
The core transcription factors exert their control over pluripotency in a cooperative 
manner. They act in concert to regulate the expression of their own genes and thus 
establish a positive auto-regulatory feedback loop. In addition, they co-regulate the 
genes involved in preserving pluripotency and at the same time contribute to the 
repression of those promoting differentiation (Young 2011).  
 
Extended Network of Transcription Factors. 
  
Though less important, other transcription factors were found to complement 
OCT4/SOX2/NANOG in the regulation of pluripotency. KFL4 and c-Myc/MYC are 
part of the Yamanaka’s cocktail of factors that reprogram fibroblasts to pluripotent 
stem cells similar to ESC and have important roles in ESC pluripotency maintenance 
(Takahashi and Yamanaka 2006). In addition, studies aiming to understand the 
regulators of pluripotency identified more transcription factors to be tightly involved 
in governing this state together with the core transcription factors. A non- exhaustive 
list includes REX1, TCF3, SMAD1, STAT3, ESRRB, ZFX, Ronin/THAP11, KLF2, 
KLF5, SALL4, PRDM14, TCL1, DAX1, NAC1, ZFP281 and others (Chia, Chan et 
al. 2010; Kim, Woo et al. 2010; Young 2011) (Table 1). Some of them, like 
PRDM14, are specific for hESC and are dispensable for mESC pluripotency (Chia, 
Chan et al. 2010). 
A recent systemic study of protein-protein interactions, as well as protein-DNA 
interaction of some of the pluripotency related factors in ESC, concluded that in their 
functional network, three regulatory cores exist (Kim, Woo et al. 2010). The first one 
is composed of the core pluripotency transcription factors and a number of other 
transcription factors, and it is responsible for activation of pluripotency related genes. 
The second one is focused around Polycomb Repressive Complex (PRC) and the 
genes that are part of its regulatory module are repressed in ESC. Finally, the third 
one is centered on MYC and forms a module of transcription factors that act together 
with it to positively regulate a subset of genes involved in PSC self-renewal and 
maintenance (Kim, Woo et al. 2010).  
 
Page 20 of 124
  
Transcription 
factors or 
cofactors 
          Gene function Reference 
      
OCT4 Core circuitry  (Nichols, Zevnik et al. 1998) 
SOX2 Core circuitry 
(Chambers and Smith 2004; 
Masui, Nakatake et al. 
2007)(Avilion, Nicolis et al. 
2003) 
NANOG Core circuitry 
(Chambers, Colby et al. 
2003; Mitsui, Tokuzawa et 
al. 2003)  
TCF3 
WNT signaling to core 
circuitry 
(Cole, Johnstone et al. 2008; 
Marson, Foreman et al. 
2008)  
STAT3 
LIF signaling to core 
circuitry 
(Niwa, Burdon et al. 1998)  
SMAD1 
BMP  signaling to core 
circuitry 
(Ying, Nichols et al. 2003)  
SMAD2/3 
TGFβ/Activin/Nodal 
signaling 
(Beattie, Lopez et al. 2005; 
James, Levine et al. 2005)  
MYC Proliferation 
(Cartwright, McLean et al. 
2005)  
ESRRB Steroid hormone receptor (Ivanova, Dobrin et al. 2006)  
SALL4 Embryonic regulator (Zhang, Tam et al. 2006)  
TBX3 Mediates LIF signaling (Ivanova, Dobrin et al. 2006)  
ZFX Self-renewal 
(Galan-Caridad, Harel et al. 
2007)  
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Ronin Metabolism  (Beattie, Lopez et al. 2005) 
KFL4 LIF signaling (Jiang, Chan et al. 2008)  
PRDM14 ESC identity  (Chia, Chan et al. 2010) 
Mediator Core circuitry 
(Hu, Kim et al. 2009; Kagey, 
Newman et al. 2010)  
Cohesin Core circuitry 
(Hu, Kim et al. 2009; Kagey, 
Newman et al. 2010)  
PAF1 complex 
Couples transcription with 
histone modification 
(Ding, Paszkowski-Rogacz et 
al. 2009)  
DAX1 OCT4 inhibitor 
(Niakan, Davis et al. 2006; 
Sun, Nakatake et al. 2009)  
CNOT3 MYC/ZFX cofactor (Hu, Kim et al. 2009)  
TRIM28 MYC/ZFX cofactor 
(Fazzio, Huff et al. 2008; Hu, 
Kim et al. 2009)  
 
Table 1.  Transcription factors and cofactors implicated in the regulation of 
pluripotency in ESC. (Young 2011). 
 
 
 
Function of MYC in Pluripotency Regulation 
 
Myc transcription factors belong to the family of basic helix-loop-helix (bHLH) is 
composed of three members, namely MYC/c-Myc, MYCN/n-Myc and MYCL/L-
Myc. They are well known oncogenes and are deregulated in many cancers (Luscher 
and Vervoorts 2012). Myc proteins bind to E-box elements in DNA and 
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heterodimerize with a protein named MAX. The interaction with MAX is critical for 
most MYC functions. MAX can also bind to some of the MAX dimerization proteins, 
Mxd/MAD, such as MXD1 MNT, and MGA, and thus MAD proteins antagonize 
MYC (Luscher and Vervoorts 2012).  Different mechanisms are suggested to explain 
how MYC can mechanistically activate gene expression.  In particular, those include 
promoter activation by recruitment of histone acetyl transferases (HATs) such as 
TIP60/KAT5 and GCN5/KAT2A, RNA polymerase II pause release mediated by p-
TEFb, and a recent model, in which MYC is rather amplifying the already existing 
expression of genes than initiating de novo transcription (Cole and Nikiforov 2006; 
Rahl, Lin et al. 2010; Lin, Loven et al. 2012; Nie, Hu et al. 2012). 
In mouse embryonic development, as well as in ESC, Myc deletion did not affect 
pluripotency (Sawai, Shimono et al. 1991; Stanton, Perkins et al 1992; Davis, Wims 
et al. 1993). However, when Myc and Mycn are simultaneously knocked out in ESC, 
the cells switch towards a differentiated state (Varlakhanova, Cotterman et al. 2010). 
Additionally, the overexpression of MYC in mESC replaces the need of LIF addition 
in culture media, which further underlines the importance of these transcription 
factors in supporting self-renewal and pluripotency (Cartwright, McLean et al. 2005).
  
Studies of transcription factors-DNA binding in ESC determined that gene targets 
occupied by core transcription factors differ from those regulated by MYC. Therefore 
it is suggested that MYC, together with other transcription factors, regulates gene 
expression in a regulatory module in the transcription factor network of pluripotency 
(Kim, Woo et al. 2010).  
 
 
Epigenetic Landscape of Pluripotency 
 
In the nucleus, the DNA is embedded together with proteins and RNA molecules in a 
structure called chromatin. The DNA is tightly packed in nucleosomes containing 147 
nucleotides wrapped around a core of histone proteins. The nucleosomes are further 
stacked in complex 3D organisations (Woodcock and Ghosh 2010). Post-translational 
modifications in histones recruit different factors, affect the way nucleosomes are 
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compacted, and can further influence higher-order chromatin structures (Tee and 
Reinberg 2014).   
Epigenetic regulation encompasses various mechanisms that act on the structure and 
accessibility of DNA to modify gene expression. They include DNA methylation, 
histone modification and chromatin remodelling (Tee and Reinberg 2014). Generally, 
in PSCs genes that are involved in commitment decisions are maintained in a silenced 
state, while still responsive to the appropriate signals (Han and Yoon 2012). 
 
Chromatin 
Regulators 
Gene function Reference 
      
Polycomb 
Silencing of lineage-
specific regulators 
(Boyer, Plath et al. 2006; 
Lee, Jenner et al. 2006)  
SETDB1 (ESET) 
Silencing of lineage-
specific regulators 
 (Bilodeau, Kagey et al. 
2009) 
esBAF Nucleosome mobilization (Ho, Ronan et al. 2009)  
CHD1 Nucleosome mobilization 
(Gaspar-Maia, Alajem et al. 
2009)  
CHD7 Nucleosome mobilization 
 (Schnetz, Handoko et al. 
2010) 
TIP60-p400 
 
 
 
Histone acetylation 
 
 
(Fazzio, Huff et al. 2008) 
   
 
Table 2. Chromatin regulators, implicated in the regulation of pluripotency in 
ESC. (Young 2011) 
The input from different signalling pathways can be integrated by changes in 
chromatin structure and in certain cases the signalling molecules directly interact with 
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the chromatin. In mESC JAK kinases, also involved in signalling downstream of LIF, 
can phosphorylate the tyrosine residue 41 of histone H3, and thus impede 
Heterochromatin protein 1α (HP-1α)/CBX5 interplay with chromatin to consequently 
affect the core pluripotency factors expression (Griffiths, Li et al. 2011; Ye and 
Blelloch 2014). In another study, a JNK effector of MAPK pathway was shown to 
phosphorylate histone H3 at serine (Ser3), in the course of ESC differentiation into 
neurons (Tiwari, Stadler et al. 2012). Moreover, a SWI/SNF-like ATP dependent 
chromatin remodelling complex, named esBAF, is essential for mESC maintenance 
and cooperates with LIF signalling by promoting genome-wide STAT3 binding (Ho, 
Ronan et al. 2009; Ho, Miller et al. 2011). A number of other chromatin regulators 
were found to be essential for ESC functionality and among those are 
cohesion/condensin complexes (Young 2011). In addition, histone modifying 
regulators, such as polycomb group protein (PcG) complexes, TIP60-p400 and 
SETDB1, are critical for pluripotency regulation (Table 2) (Young 2011).  
 
RNA Binding Proteins 
 
RNA binding proteins (RBP) participate in a large number of functions related to 
RNA processing, including splicing, poly-adenylation, nuclear export, translation, 
modification of RNA molecules, and degradation. Thus, it is nor surprising that RBPs 
are also associated with the pluripotency network, either promoting the 
undifferentiated state or differentiation along various lineages (Ye and Blelloch 
2014).  The role of different RBPs in pluripotency is reviewed in detail in (Ye and 
Blelloch 2014). An interesting example is that of Mettl3/MTA70 and 
Mettl14/MET14, two mammalian methyltransferases, which transfer the methyl 
group of S-adenosyl-L-methionine to produce N
6
-methyladenosylated RNA (m
6
A 
RNA) (Liu, Yue et al. 2014). When any of these two RBPs is depleted, mESC exhibit 
a reduction in m
6
A RNA methylation and impaired self-renewal (Wang, Li et al. 
2014). Transcripts enriched in this modification correspond to developmental 
regulators with particular chromatin state, where m
6
A incorporation has a 
destabilizing effect on the RNA. MBNL proteins were shown to block ES-cell-
specific alternative splicing and reprogramming and were shown to act in synergy 
with RBFOX2 to create a splicing program into iPSCs differentiation (Han, Irimia et 
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al. 2013; Venables, Lapasset et al. 2013). The Epithelial splicing regulatory protein 1, 
ESRP regulated the expression of pluripotency-associated regulators (Fagoonee, 
Bearzi et al. 2013). These results suggest that RBPs and importantly splicing factors 
are relevant for cell identity determination (Ye and Blelloch 2014). 
 
microRNAs 
 
MicroRNAs are small non-coding RNA of  approximately 22 nucleotides in length 
that play important roles in vertebrate development, as well as in diverse 
physiological and cellular processes (He and Hannon 2004; Bartel 2009; Mencia, 
Modamio-Hoybjor et al. 2009; de Pontual, Yao et al. 2011). In mammals, microRNAs 
are loaded into Ago proteins and in most of the cases the microRNA-guided Ago 
protein will bind to a region in the mRNA 3’UTR that can have as few as 6 
nucleotides complementarity to the 5` bases 2-7 of the microRNA, which is the so-
called “microRNA seed region”. Once the ribonucleoprotein RNA-induced silencing 
complex (RISC) complex, containing the microRNA loaded Ago, is localized on its 
mRNA target, the corresponding mRNA is destabilized, and the expression of the 
corresponding protein decreases (Lingel and Izaurralde 2004; Filipowicz, 
Bhattacharyya et al. 2008; Chekulaeva, Mathys et al. 2011) (Fabian, Sonenberg et al. 
2010).  
MicroRNAs are derived from either independently regulated genes that are 
transcribed by RNA polymerase II or from processing of introns of genes that produce 
protein-coding or non-coding RNAs (Lee, Kim et al. 2004; Borchert, Lanier et al. 
2006; Bortolin-Cavaille, Dance et al. 2009). Different type-III RNases are involved at 
different steps of miRNA biogenesis. Primary microRNA transcripts can be processed 
by Drosha-DGCR8 ribonuclease complex in the nucleus, or in the case of mirtons by 
the splicing machinery, and result in precursor microRNA (pre-microRNA) hairpins 
that are translocated into the cytoplasm by Exportin5 (Yi, Qin et al. 2003; Bohnsack, 
Czaplinski et al. 2004; Han, Lee et al. 2004; Ruby, Jan et al. 2007). In the cytoplasm, 
pre-microRNAs are further processed by the nuclease Dicer to give rise to double-
stranded RNA molecules with 5’ monophosphate and 3’ hydroxyl groups (Hutvagner, 
McLachlan et al. 2001). One of the two strands, named guide strand, is incorporated 
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into the RISC and targets it to complementary messenger RNA (mRNA) (Kai and 
Pasquinelli 2010). 
MicroRNAs (miRNAs) are critical for mammalian embryonic development, and this 
is exemplified by the lethality of Dicer and DGCR8 knockouts (Bernstein, Kim et al. 
2003; Wang, Medvid et al. 2007). In PSC, a set of microRNAs is specifically 
associated with the undifferentiated cellular state. The list of microRNAs specifically 
enriched in the pluripotent state includes the clusters of miR-17-92, miR-302-367, 
hsa-miR-371-373, and its mouse orthologue mmu-mir-290-295, the miR-200 family, 
as well as the miR-106 and miR-195 miRNAs. A particular case is the C19MC cluster 
of embryonic microRNAs, encoding the miR-520 family that is only represented in 
human and primates (Suh, Lee et al. 2004; Bar, Wyman et al. 2008; Laurent, Chen et 
al. 2008; Morin, O'Connor et al. 2008). Interestingly, individual microRNAs or 
clusters, such as miR-17, miR-106, hsa-miR-372/mmu-miR-290, miR-302, and miR-
520, have the same or very similar seed sequence that might differ in one nucleotide 
despite the fact that some of them have different evolutionary origin. As the seed 
sequence is critical for target recognition this observation suggests that there is 
important number of mRNA that are regulated by all of the above-mentioned 
microRNAs (Leonardo, Schultheisz et al. 2012). Some of the embryonic microRNAs, 
including miR-17-92, miR-106a-25, mmu-miR-290/ hsa-miR-372, miR-302-367, and 
miR-200, promote reprogramming, when expressed together with reprogramming 
factors (Leonardo, Schultheisz et al. 2012; Wang, Guo et al. 2013). Moreover, it has 
been reported that lentiviral expression of mmu-miR-302-367 or transient transfection 
of all three hsa-miR-200c, hsa-miR-302, and hsa-miR-363 are sufficient to reprogram 
respectively mouse or human fibroblast to iPSC (Anokye-Danso, Trivedi et al. 2011; 
Miyoshi, Ishii et al. 2011). Consistently, it has been argued that core pluripotency and 
OSKM reprogramming transcription factors promote the undifferentiated state partly 
by inducing the expression of microRNAs. For instance, OCT4, SOX2 and NANOG 
bind to the promoter of miR-106a-363, mmu-miR-290 and miR-302-367 in mESC 
(Marson, Levine et al. 2008). Myc is equally shown to transactivate the expression of 
miR-17-92 (O'Donnell, Wentzel et al. 2005). 
Another set of miRNAs that belong to the let-7 family are related to various 
differentiation pathways and can negatively affect pluripotency. For instance, they 
inhibit reprogramming by stimulating the expression of prodifferentiation factors 
(Worringer, Rand et al. 2014).  
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Embryonic specific miRNAs are known to functionally enforce ESC cell cycle and 
glucose metabolism, to regulate mesenchymal to epithelial transition (MET) during 
reprogramming, to control DNA methylation in ESC, to influence m
6
A modification 
of RNA and to affect PSC apoptosis (Miyoshi, Ishii et al. 2011; Leonardo, 
Schultheisz et al. 2012; Cao, Guo et al. 2015).  
ESCs have a particular cell cycle, with a shortened G1 phase. ESC depleted in 
components of miRNA biogenesis pathway, and therefore, deficient in miRNAs, 
exhibit a cell cycle defect, which can be partially reversed by the transfection of 
mmu-miR-290 family members in mouse or hsa-miR-372 and hsa-miR-195 in hESC 
(Wang, Baskerville et al. 2008; Qi, Yu et al. 2009).  MiRNAs from miR-290 family 
were shown to regulate self-renewal of mESC by regulating MYC, Lin28 and Sall4, 
while the let-7 family members controlled the same genes in an opposite manner 
(Melton, Judson et al. 2010). Surprisingly, a recent study of DGCR8-null mESC 
found that the mutant embryonic cells resemble ground state pluripotent stem cells 
cultured in 2i +LIF, a medium in presence of inhibitors of Extracellular regulated 
kinases ERK/MAPK and Glycogen synthase kinases GSK3, suggesting that 
microRNAs might not be critical for the ground state pluripotency (Kumar, Cahan et 
al. 2014). Furthermore, wild type ground state pluripotent stem cells express let-7 
family members together with miR-290-295, suggesting that the two miRNA families 
might act synergistically to maintain this state. However, miRNA depletion in mECS, 
led to higher heterogeneity in the stem cell population, in agreement with previous 
studies that suggest a role of miRNA in controlling the noise in gene expression 
(Kumar, Cahan et al. 2014). 
In mESCs, the miR-290-295 cluster miRNAs are among the most abundantly 
expressed (Houbaviy, Murray et al. 2003; Leung, Young et al. 2011). Moreover, 
homozygous deletion of this cluster in mice results in partially penetrant embryonic 
lethality and compromised fertility in females. Nevertheless, surviving male miR-290-
295
-/-
 mice are phenotypically normal (Medeiros, Dennis et al. 2011). This 
observation can probably be explained by the expression of microRNAs with same or 
similar seed that might compensate in certain cases the absence of miR-290-295. 
Alternatively, the fact that microRNAs deficient DGCR8-null mESCs do not impede 
the ground state pluripotent stem cells state might also be related to the partial 
penetrance of the miR-290-295 knock-out phenotype (Kumar, Cahan et al. 2014).  
Page 28 of 124
  
The important role of miRNAs in maintenance and differentiation of PSC is well 
accepted (Leonardo, Schultheisz et al. 2012). However, the targets and the mechanism 
of miR-290-295 cluster function in ESCs are not well understood (Leonardo, 
Schultheisz et al. 2012). To fill this gap, we have carried out an extensive analysis of 
data sets derived from mESCs that either expressed or were deficient in expression of 
miR-290-295 cluster miRNAs. We aimed to identify reproducible, high confidence 
and direct transcription factor targets of the miRNAs that propagate and perhaps 
amplify the effects of these miRNAs in the pluripotency network. Indeed, an initial 
computational analysis of these data carried by another PhD student in the group 
pinpointed a number of transcription factors that appeared to be involved in 
differentiation processes and to be directly regulated by the miR-290-295 cluster. We 
have followed up these results, constructing and testing luciferase reporters in a 
mouse cell line. In collaboration with other group members we have confirmed the 
expression variation of IRF2 in response to miRNAs depletion in ESC and we have 
validated the involvement of nuclear factor kappa-B (NF-kB) pathway in the miRNA-
dependent regulation in mESCs. Overall, this study complements the current 
knowledge on the manner miR-290-295 regulates pluripotency, and proposes a new 
insight into its involvement in cell cycle, innate immune response, and chromatin 
modification in mESC.  
  
Page 29 of 124
  
 
 
 
Results  
 
 
Manuscript published under the following title: 
 
“Embryonic stem cell-specific microRNAs contribute to pluripotency by 
inhibiting regulators of multiple differentiation pathways.” 
 
Gruber AJ, Grandy WA, Balwierz PJ, Dimitrova YA, Pachkov M, Ciaudo C, 
Nimwegen Ev, Zavolan M. 
 
Nucleic Acids Res. 2014 Aug;42(14):9313-26. doi: 10.1093/nar/gku544. 
Epub 2014 Jul 16 
 
By Permission of Oxford University Press 
Page 30 of 124
Published online 16 July 2014 Nucleic Acids Research, 2014, Vol. 42, No. 14 9313–9326
doi: 10.1093/nar/gku544
Embryonic stem cell-specific microRNAs contribute to
pluripotency by inhibiting regulators of multiple
differentiation pathways
Andreas J. Gruber1, William A. Grandy1, Piotr J. Balwierz1, Yoana A. Dimitrova1,
Mikhail Pachkov1, Constance Ciaudo2, Erik van Nimwegen1 and Mihaela Zavolan1,*
1Biozentrum, University of Basel, Klingelberstrasse 50-70, CH-4056 Basel, Switzerland and 2ETH Zu¨rich,
Otto-Stern-Weg 7, CH-8093 Zu¨rich, Switzerland
Received April 17, 2013; Accepted June 5, 2014
ABSTRACT
The findings that microRNAs (miRNAs) are essential
for early development in many species and that em-
bryonic miRNAs can reprogram somatic cells into
induced pluripotent stem cells suggest that these
miRNAs act directly on transcriptional and chromatin
regulators of pluripotency. To elucidate the transcrip-
tion regulatory networks immediately downstream of
embryonic miRNAs, we extended the motif activity
response analysis approach that infers the regula-
tory impact of both transcription factors (TFs) and
miRNAs from genome-wide expression states. Ap-
plying this approach to multiple experimental data
sets generated from mouse embryonic stem cells
(ESCs) that did or did not express miRNAs of the
ESC-specific miR-290-295 cluster, we identified mul-
tiple TFs that are direct miRNA targets, some of
which are known to be active during cell differentia-
tion. Our results provide new insights into the tran-
scription regulatory network downstream of ESC-
specific miRNAs, indicating that these miRNAs act
on cell cycle and chromatin regulators at several lev-
els and downregulate TFs that are involved in the
innate immune response.
INTRODUCTION
Embryonic stem cells (ESCs) originate from the inner cell
mass of mammalian blastocysts. Due to their ability to self-
renew as well as differentiate into various specialized cell
types, they hold the promise of medical applications, such
as stem cell therapy and tissue engineering. Therefore, the
regulatory mechanisms behind pluripotency, stem cell fate
and renewal are of great interest.
MiRNAs are short (∼22 nt long), single-stranded RNAs
that post-transcriptionally regulate the expression of target
genes (1). Computational and high-throughput studies sug-
gest that a single miRNA can regulate hundreds of target
genes (2,3) and that the majority of humanmRNAs are reg-
ulated by miRNAs (4). Several studies found that the ex-
pression of ESC-specific miRNAs is required for initiation
of stem cell differentiation and normal embryonic develop-
ment (5–7). The ESC-specificmiR-290-295 cluster accounts
for ∼50% of the miRNA population of mouse ESCs (8–11)
and its expression is downregulated relatively rapidly dur-
ing differentiation (9,12). Interestingly, three of the seven
miRNAs that are co-expressed from the miR-290-295 clus-
ter, namely, miR-291a-3p, miR-294 and miR-295, are suffi-
cient to force a G1→S transition (13) and promote induced
pluripotency (14). All of these miRNAs, as well as those of
another ESC-specific miRNA cluster, miR-302-367 (12,15),
have the same sequence ‘AAGUGCU’ at positions 2-8 (also
called the ‘seed’) which defines a family of miRNAs with
related targets (4).
In contrast to the miR-290-295 cluster, miR-302-367 is
also present in human and has been used to reprogram fi-
broblasts into induced pluripotent stem cells (iPSCs) (16).
The reprogramming of differentiated cells into pluripotent
stem cells by the ESC-specific miRNAs entails large gene
expression and phenotypic changes that are likely to be due
to regulatory cascades that involve several regulators. To
identify transcriptional regulators that are immediate targets
of the AAGUGCU seed family miRNAs, we analyzed data
obtained in several previous studies that aimed to uncover
the function of the miR-290-295 cluster.
These data consist of microarray-based measurements
of mRNA expression in ESCs that were either deficient
in miRNAs or expressed subsets of ESC-specific miR-
NAs (Supplementary Table S1). Sinkkonen et al. (17) an-
alyzed mRNA expression of ESCs that express miRNAs
(Dicer+/ −), ESCs that do not express miRNAs (Dicer−/ −)
as well as Dicer−/ − ESCs transfected with the miR-290-
295 cluster miRNAs (miR-290, miR-291a-3p, miR-292-
3p, miR-293, miR-294 and miR-295 mimics). The study
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showed that the expression profile of ESCs can be restored
to a large extent in Dicer−/ − ESCs through transfection of
miR-290-295 cluster miRNAs, and that these miRNAs are
important for appropriate de novoDNAmethylation in dif-
ferentiating ESCs. Hanina et al. (18) profiled mRNA ex-
pression in Dicer−/ − ESCs as well as in Dicer−/ − ESCs
transfectedwithmiR-294. Combining these expression data
with a biochemical approach to isolateArgonaute 2 (Ago2)-
bound mRNAs, the study identified miR-294 targets in
ESCs. It further concluded that miR-294 regulates a subset
of genes that are also targeted by the Myc transcriptional
regulator and that some of the effects of miR-294 expres-
sion may be due to the indirect upregulation of pluripo-
tency factors, such as Lin28. Employing mRNA expression
profiling of Dgcr8−/ − ESCs, as well as miR-294-transfected
Dgcr8−/ − ESCs,Melton et al. (19) showed that self-renewal
and differentiation of ESCs is regulated in an antagonis-
tic manner by miR-294 and let-7. Finally, Zheng et al.
(11) profiledmRNAexpression ofmiRNA expressing ESCs
and Dicer−/ − ESCs and uncovered a pro-survival, anti-
apoptotic function of the miR-290-295 cluster of miRNAs.
Altogether, these studies provide five separate experimen-
tal data sets that can be used to investigate the function of
AAGUGCU seed family miRNAs in ESCs. They all deter-
mined mRNA expression profiles of ESCs with impaired
miRNA expression (due to knockout of either Dgcr8 or
Dicer components of the miRNA biogenesis pathway), as
well as of ESCs that expressedmiRNAs of the AAGUGCU
seed family. The latter were either ES cells which expressed
the full complement ofmiRNAs, ormiRNA-deficient ESCs
that were transfected with either miRNAs of the miR-290-
295 cluster, or onlymiR-294. Although it has been observed
that these studies resulted in sets of miRNA targets that are
only partially overlapping (10), a meta-analysis that com-
bines these data sets to identify the pathways that are most
reproducibly targeted by the AAGUGCUmiRNAs has not
been performed.
In our study, we aimed to infer transcriptional regu-
lators that are directly and consistently targeted by the
AAGUGCU family of miRNAs, the pathways that these
regulators control and the interactions that they have with
each other. Toward this end, we modeled genome-wide
mRNA expression in terms of computationally predicted
target sites of both transcription factors (TFs) and miR-
NAs. This approach allowed us to identify a number of tran-
scriptional regulators whose activity is consistently altered
by miRNAs of the AAGUGCU seed family and that could
contribute to the maintenance of pluripotency. Through re-
porter assays we validated these regulators as targets of
AAGUGCU seed family miRNAs. Employing Dicer−/ −
mouse ES cells we showed that the expression of the IRF2
TF is strongly upregulated in the absence of miRNAs and
that the nuclear concentration of the RelA component of
the nuclear factor kappa-B (NF-B) pathway upon stimula-
tion with tumor necrosis factor  (TNF-) is also increased.
Our results give new insights into the functions of miRNAs
in the regulatory circuitry of ESCs.
MATERIALS AND METHODS
Experimental data sets
Supplementary Table S1 summarizes the data sets that
we obtained from the Gene Expression Omnibus (GEO)
database of the National Center for Biotechnology Infor-
mation (NCBI) and that we have used in our study. Each
data set covers at least two distinct experimental conditions,
with three replicates per condition. The first condition of
every data set corresponds to an ESC line deficient in ma-
ture miRNAs due to Dicer- or Dgcr8-knockout. The sec-
ond condition corresponds to either an ESC line expressing
the entire complement of embryonically expressedmiRNAs
or the knockout cell line transfected with miR-294 or with
mimics of themiR-290 clustermiRNAs (mir-290,mir-291a-
3p, mir-292-3p, mir-293, mir-294 and mir-295).
Microarray analysis
Computational analysis of Illumina MouseWG-6 v2.0 Ex-
pression BeadChips from Hanina et al. (2010). We down-
loaded the processed data from the GEO database of NCBI
(accession no. GSE20048). Probe-to-gene associations were
made by mapping the probe sequences (provided by the au-
thors) to the set ofmouse transcript sequences (downloaded
2011-02-19 from the UCSC Genome Bioinformatics web
site).
We computed average gene expression levels as weighted
averages of the signals of all probes that perfectly matched
to at least one transcript of the gene. Whenever a probe
mapped to multiple genes, a weight of 1/n was assigned to
each of the n genes that the probematched. For a given repli-
cate experiment, the log2 expression fold change of each
gene was then determined by subtracting the log2-average
expression of the gene in the first condition (control) from
the log2-average expression in the second condition (treat-
ment).
Computational analysis of Affymetrix Mouse Genome 430
2.0 chips from Sinkkonen et al. (2008) and Zheng et al.
(2011). We downloaded the data from the GEO database
(accessions GSE8503, GSE7141 and GSE30012) and an-
alyzed the CEL files with the R software (http://www.R-
project.org) using the BioConductor affy package (20). We
used the GCRMA algorithm (21) for background correc-
tion and theMClust R package (22) to fit a two-component
Gaussian mixture model to the log2-probe intensities and
classify probes as expressed or not expressed. A probe was
considered for further analysis if it was consistently clas-
sified as expressed in all three replicates of at least one
of the two experimental conditions. The remaining probes
were quantile normalized across all conditions and repli-
cates of a particular experiment. Probe-to-gene associa-
tions were made by mapping probe sequences (provided
on the Affymetrix web site, http://www.affymetrix.com)
to mouse transcript sequences (as used by motif activ-
ity response analysis (MARA), downloaded from UCSC
Genome Bioinformatics web site as described above). We
then computed log2-gene expression fold changes as de-
scribed for Illumina Expression BeadChips (see above).
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Computational analysis of Affymetrix Mouse Gene 1.0 ST
chips from Melton et al. (2010). We downloaded the data
from the GEO database (accession no. GSE18840) and
analyzed the CEL files with the R Bioconductor oligo
package (23). We used the Robust Multi-array Average
(RMA) algorithm (24) for background adjustment. The rest
of the analysis, including the classification of probes into
expressed/not expressed, the quantile normalization, and
the calculation of log2 gene expression fold changes, was
carried out as described above.
Proportions of AAGUGCU miRNA seed family targets
among genes that are consistently downregulated in multiple
experiments. For each gene and each experiment, we cal-
culated the standard error in its log2 fold change across the
replicates. A gene was considered significantly downregu-
lated when it was down-regulated more than 1.96 standard-
errors. We then determined the intersection set of signif-
icantly downregulated genes for every possible subset of
the experiments S={MeltonDGCR8KOVs294, Sinkkonen-
DicerKOVs290, SinkkonenDicerKOVsWT}. Subsequently,
for every obtained intersection set, the proportion of
AAGUGCU miRNA seed family targets (TargetScan ag-
gregate PCT score predictions (4)) was determined and plot-
ted against the size of the corresponding intersection set.
Combined MARA of TFs and miRNAs. We carried out
the MARA (25) separately for each experimental data set.
MARA relates the expression level E driven by individ-
ual promoters (measured by microarrays) to the number of
binding sites N that various regulators have in the promot-
ers using a simple linear model
Eps = c˜s + cp +
∑
m
NpmAms, (1)
where cp is a term reflecting the basal expression of pro-
moter p, c˜s reflects the mean expression in sample s, and
Ams is the (unknown) activity of binding motif m in sample
s (where with ‘sample’ we refer to any individual replicate of
any condition of a data set, see section ‘Experimental data
sets’ above). That is, using the predicted site-countsNpm and
the measured expression levels Eps we used an approxima-
tion (1) to infer the activitiesAms of all motifs across all sam-
ples by ridge regression. In our analyses, we considered a
curated set of 189 TF binding motifs (for detailed informa-
tion about the motifs and the corresponding TFs see Sup-
plementary Table S7). Furthermore, we included the bind-
ing sites in the 3’UTRs of mRNAs of 85 miRNA families
by incorporating aggregate PCT scores as provided by Tar-
getScan (4) (predictions downloaded on the 27th of March
2012 from the TargetScan web site, http://www.targetscan.
org). miRNAs are grouped into families by their seed se-
quences and in particular theAAGUGCU seed family corre-
sponds to the followingmiRNAs:mmu-miR-291a-3p,mmu-
miR-294, mmu-miR-295, mmu-miR-302a, mmu-miR-302b
and mmu-miR-302d. An aggregate PCT score was assigned
to a promoter by averaging the aggregatePCT scores of tran-
scripts associated with this promoter.
For a given motif m, MARA provides for each sample s
motif activities A∗ms and associated errors ms. More specif-
ically, marginalizing over all other motifs, the likelihood
P(D|Ams) of the expression data D given the activity of a
given motif is proportional to a Gaussian
P(D|Ams) ∝ exp
[
−1
2
(Ams − A∗ms)2
σ 2ms
]
. (2)
Given that all analysed experiments were performed in
multiple replicates we were interested in averaging motif ac-
tivities across replicates and we used the following Bayesian
approach. For each motifm separately, we assumed that the
activities across a group g of replicates belonging to a spe-
cific condition of an experiment (see section ‘Experimental
data sets’ above) are normally distributed around some (un-
known) mean A¯mg with (unknown) variance σ 2mg
P(Ams |A¯mg, σmg) = 1√
2πσmg
exp
[
−1
2
(
Ams − A¯mg
)2
σ 2mg
]
.(3)
By combining the prior from Equation (3) with the likeli-
hood from Equation (2) for each replicate sample s ∈ g and
integrating out the (unobserved) true activities Ams in each
of the replicates, we obtained the probability of the form
P(D|A¯mg, σmg)
=
∏
s∈g
1√
2π (σ 2mg + σ 2ms)
exp
[
− (A
∗
ms − A¯mg)2
2(σ 2mg + σ 2ms)
]
. (4)
Formally, we would next integrate out the unknown stan-
dard deviation of activities in the group mg of this likeli-
hood. Unfortunately, this integral cannot be performed an-
alytically. We thus approximated the integral by the value
of the integrand at its maximum, i.e. we numerically found
the value of mg that maximizes expression (4). Assum-
ing an uniform prior over mean activity A¯mg, we find that
P(A¯mg|D) is again a Gaussian with mean
A¯∗mg =
∑
s∈g
A∗ms
(σ ∗mg)2+(σms )2∑
s∈g
1
(σ ∗mg)2+(σms )2
, (5)
and error
σ¯ ∗mg =
√√√√ 1∑
s∈g
1
(σ ∗mg)2+(σms )2
. (6)
where σ ∗mg is the maximum likelihood estimate of Expres-
sion (4). We call the quantities defined in (5) and (6) aver-
aged activities and averaged errors, respectively.
To identify motifs that consistently change in their activi-
ties across experiments, we wanted to further average motif
activities across these experiments. However, because of the
inherent differences in the scale of expression variation in
the different experiments, the motif activities also varied in
scale across the experiments. Thus, before averaging we first
standardized the motif activities across the two conditions
a and b. That is, for a given experiment we defined a scale L
L =
√(
A¯∗bmg
)2 + (A¯∗amg)2
2
, (7)
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and rescaled the activities
A˜∗mg =
A¯∗mg
L
(8)
and their errors
σ˜ ∗mg =
σ¯ ∗mg
L
. (9)
These condition-specific, averaged and rescaled activities
(A˜∗mg) and errors (σ˜
∗
mg) from the different experiments were
then combined into two groups, i.e. the group of a condi-
tions and the group of b conditions, and for each group we
again averaged the activities exactly as described above for
the replicates.
To rank the activity changes between two different exper-
imental conditions (presence/absence of miRNAs) we de-
termined a z-value for every motifm by dividing the change
in averaged activities between the two different conditions
a and b by the averaged errors as follows
z = A˜
∗b
mg − A˜∗amg√(
σ ∗bmg
)2 + (σ ∗amg)2 . (10)
Consequently, from the results of Equation (10) we ob-
tained a global z-value-based ranking of the motifs.
Motif–motif interaction network. To uncover which TFs
were targeted by a particular motif m, we focused only on
those TF genes, whose promoters were consistently (in all
experiments) predicted by MARA to be targets of motif m.
MARA computes a target score S for each potential target
promoter ofmotifm.S corresponds to the log-likelihood ra-
tio of the data D assuming the promoter is indeed a target,
and assuming the promoter is independent of the regulator,
i.e.
S= log
[
P(D|target)
P(D|nottarget)
]
. (11)
Assuming a uniform prior of 1/2 that the promoter is in-
deed a target, the posterior probability p that the promoter
is a target given the data is
p = 1
1+ 1es
. (12)
To obtain a combined probability pc that a gene is a tar-
get of a particular motif across N different experiments the
probability product was calculated by multiplying the prob-
abilities pn obtained in individual experiments n, i.e.
pc =
N∏
n=1
pn. (13)
Evaluating miR-294 targets with luciferase assays
Cloning, cell culture and luciferase assay. We polymerase
chain reaction (PCR)-amplified 3′UTR fragments of the
putative target genes from Normal Murine Mammary
Gland (NMuMG) genomic DNA and cloned them into
pGEM-T Easy vector (Promega; A1360). We used site-
directed mutagenesis and the QuickChange II kit (Strata-
gene; 200524-5) to generate deletion mutant constructs
that differed in a few nucleotides in the miR-294 seed-
matching region from the wild-type construct. All con-
structs, wild-type and mutated, were verified by sequenc-
ing and then subcloned into the empty psiCHECK-2 vec-
tor (Promega; C8021) at XhoI - NotI restriction sites. The
sequences of the primers used for cloning and mutagenesis
can be found in Supplementary Tables S9 and S10, respec-
tively.NMuMGcells were reverse-transfectedwith Lipofec-
tamine2000 reagent (Invitrogen; 11668019), and the corre-
sponding psiCHECK-2 constructs in the presence of 50nM
Syn-mmu-miR-294-3p mimic (QIAGEN; MSY0000372),
or 50 nM of non-targeting negative control siRNA (Mi-
crosynth). Between 36 and 48 h post-transfection cells were
collected and both Renilla and firefly luciferase activities
were measured using Dual Glo Luciferase Assay System
(Promega; E2940).
For each gene, expression was measured for both con-
structs in 3 separate experiments, and each experiment con-
tained 3 technical replicates.
Analysis of the luciferase data. We denote by wir the loga-
rithm (base 2) of the expression level of the luciferase con-
struct containing the wild-type 3′UTR in experiment i repli-
cate r and by mir the analogous expression for the mutant
construct. For each gene the data thus consist of 9 values
w and 9 values m. We took into account two sources of
variability, namely, true expression variability across exper-
iments and ‘measurement noise’ between replicates.We first
describe the measurement noise. Assuming the true expres-
sion of the wild type was wi, we assumed that the proba-
bility to measure expression level wir (in a given replicate r)
follows a Gaussian distribution with a certain variance  i
P(wir |wi , τi ) = 1
τi
√
2π
exp
[
−1
2
(
wir − wi
τi
)2]
, (14)
thus allowing for the possibility that each experiment i has a
different level of noise  i between replicates. The probability
of the wild-type data of experiment i, assuming that  i is
given, is simply the product of expressions P(wir|wi,  i) over
the three replicates r = 1 through 3. Using 〈wi〉 and var(wi)
to denote the mean and variance of the measurement across
the replicates, we can rewrite this as
P({wir }|wi , τi )
∝ 1
τ 3i
exp
[
−3
2
(
wi − 〈wi 〉
τi
)2
− 3
2
var(wi )
τ 2i
]
. (15)
Integrating over the unknown variable  i from 0 to infinity
with a scale prior P( i)∝1/ i we obtain
P({wir }|wi ) ∝
(
1+ (wi − 〈wi 〉)
2
var(wi )
)3/2
. (16)
Approximating this Student’s t distribution by a Gaussian,
that is, approximating the probability of the data in experi-
ment i by a Gaussian with mean 〈wi〉 and variance var(wi),
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we have
P({wir }|wi ) ≈
√
3
var(wi )
exp
[
−3(wi − 〈wi 〉)
2
2var(wi )
]
. (17)
Since the variability between replicates is much smaller than
the variability across experiments, this approximation will
have a negligible effect on the final outcome.
For the true variability between experiments, we denote
by w the ‘true’ average expression of the wild-type con-
struct. We assume that the deviation of the level wi in ex-
periment i from the meanw follows a Gaussian distribution
with variance σ . We thus have
P(wi |w, σ ) = 1
σ
√
2π
exp
[
−1
2
(
wi − w
σ
)2]
. (18)
To obtain the probability of the data given w we multiply
P({wir}|wi) by P(wi|w, σ ) and integrate over the unknown
expression level wi. We then obtain
P({wir }|w, σ )
∝ 1√
σ 2 + var(wi )/3
exp
[
− (〈wi 〉 − w)
2
2(σ 2 + var(wi )/3)
]
. (19)
The interpretation of this formula is straightforward. The
deviation between the mean 〈wi〉 of the observations in ex-
periment i, and the average level w is Gaussian-distributed
with a variance that is the sumof the variability σ 2 across ex-
periments, and the variability var(wi)/3 associated with es-
timating wi from the 3 replicate measurements due to mea-
surement noise.
For the measurements of the mutant construct in experi-
ment i we obtain an analogous equation
P({mir }|m, σ˜ )
∝ 1√
σ˜ 2 + var(mi )/3
exp
[
− (〈mi 〉 −m)
2
2(σ˜ 2 + var(mi )/3)
]
, (20)
where we have introduced the variability σ˜ of the true ex-
pression of the mutant construct across replicates. What we
are interested in is the difference w −m in log-expression of
the wild-type and mutant construct. To this end, we define
μ = w −m and y= (m+w)/2 and integrate over y. We then
obtain
P({wir }, {mir }|μ, σ, σ˜ ) ∝
1√
σ 2 + σ˜ 2 + var(wi )/3+ var(mi )/3
exp
[
− (〈wi 〉 − 〈mi 〉 − μ)
2
2(σ 2 + σ˜ 2 + var(wi )/3+ var(mi )/3)
]
. (21)
This is again a Gaussian with mean 〈wi〉 − 〈mi〉 and a vari-
ance that is the sum of all variances σ 2, σ˜ 2, var(wi)/3 and
var(mi)/3.
Clearly, although both σ 2 and σ˜ 2 are unknown, the only
variable that enters in our equations is their sum. We thus
simplify the notation by defining this sum as
γ 2 = σ 2 + σ˜ 2. (22)
Similarly, we redefine the variance associated with mea-
surement noise as
t2i = var(wi )/3+ var(mi )/3, (23)
which leads to
P({wir }, {mir }|μ, γ )
∝ 1√
γ 2 + t2i
exp
[
− (〈wi 〉 − 〈mi 〉 − μ)
2
2(γ 2 + t2i )
]
. (24)
We now combine the data from the different experiments
and remove the final unknown variable γ . The probability
of all data given the variable of interestμ and unknown vari-
ability parameter γ is simply the product
P(D|μ, γ ) =
3∏
i=1
P({wir }, {mir }|μ, γ ). (25)
To obtain the probability of the dataD given μ we multiply
this expression with a scale prior for γ , i.e. P(γ )= 1/γ , and
integrate over γ
P(D|μ) =
∫ ∞
0
P(D|μ, γ )dγ
γ
. (26)
We performed the integration numerically with Mathemat-
ica to obtain P(D|μ), and used Bayes’ theorem to compute
the posterior distribution of the parameter , P(μ|D) as
P(D|μ)/ ∫∞−∞ P(D|μ)dμ. Finally, we determined the 5 per-
centile, the 25 percentile, the median, the 75 percentile and
the 95 percentile of this distribution again with the Mathe-
matica software.
Mouse ESC (mESC) culture
The generation of Dicer(DCR)flox/flox and DCR−/ − mouse
ES cell lines has been described elsewhere (26). The cells
were routinely screened for both pluripotency and differen-
tiation markers (see Supplementary Figure S4). Both mES
cell lines were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco; 41966-029) supplemented with
15% of a special batch of fetal bovine serum tested for opti-
mal growth of mESCs. In addition, the DMEM contained
1000U/ml of a homegrown recombinant LIF (a kind gift of
Thomas Grentzinger), 0.1mM 2-mercaptoethanol (Milli-
pore; ES-007-E), 1x L-Glutamine (Gibco; 25030-024), 1x
Sodium Pyruvate (Gibco; 11360) and 1x Minimum Essen-
tial Medium, Non-Essential Amino Acids (MEM, NEAA)
(Gibco; 11140-35). The cells were grown on gelatin-coated
(Sigma; G1393) dishes. Themediumwas changed daily, and
the cells were subcultured every 2–3 days. To induce NF-B
signaling, mESCs were treated with 20 ng/ml TNF- (Cell
Signaling Technology; 5178) for 24 h.
Quantitative reverse transcriptase-PCR (qRT-PCR)
Total RNA was extracted from mESCs using Tri Reagent
(Sigma; T9424) following the supplier’s protocol. Con-
taminating DNA was removed using the RQ1 RNase-
Free DNase kit (Promega; M6101). The resulting DNA-
free RNA was then purified using the RNeasy MinElute
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Cleanup kit (Qiagen; 74204) and quantified using Nan-
odrop. Superscript III (Invitrogen; 18080) was then used
to create cDNA following the manufacturer’s recommenda-
tions. The cDNA was finally purified using QIAquick PCR
Purification kit (Qiagen; 74204), quantified using Nan-
odrop and diluted to 8 ng/l. Each qRT-PCR reaction was
run using 2 l of the purified cDNA in triplicate (n= 3) us-
ing Power SYBRGreen PCRMaster Mix (Applied Biosys-
tems; 4367659) on a StepOne Plus RT-PCR System (Ap-
plied Biosystems). The following primer pairs were used in
this study:
 Mouse IRF2 Fwd: 5′-CTG GGCGAT CCA TAC AGG
AAA-3′
 Mouse IRF2 Rev: 5′-CTC AAT GTC GGG CAGGGA
AT-3′
 Mouse E2F5 Fwd: 5′-GTTGTGGCTACAGCAAAG
CA-3′
 Mouse E2F5 Rev: 5′-GGC CAA CAG TGT ATC ACC
ATG A-3′
 Mouse c-Myc Fwd: 5′-GTT GGA AAC CCC GCA
GAC AG-3′
 Mouse c-Myc Rev: 5′-ATAGGGCTG TACGGAGTC
GT-3′
 Mouse GAPDH Fwd: 5′-CAT CAC TGC CAC CCA
GAA GAC TG-3′
 Mouse GAPDH Rev: 5′-ATG CCA GTG AGC TTC
CCG TTC AG-3′
qRT-PCR data were normalized using glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) expression and evalu-
ated using the 2−Ct method (27). Significant changes in
gene expression were identified based on Student’s t-test.
Western blots
To extract total proteins from mESCs, radioimmunopre-
cipitation assay buffer supplemented with 1x Complete,
ethylenediaminetetraacetic acid (EDTA)-free protease in-
hibitor cocktail (Roche; 11873580001) was used to lyze cell
pellets. Cytosolic and nuclear protein fractions were en-
riched using a series of lysis buffers as follows:
 Lysis Buffer 1 (LB1): 50 mM Hepes-KOH, pH 7.5; 140
mMNaCl; 1mMEDTA, pH8.0; 10%v/vGlycerol; 0.5%
v/v NP-40; 0.25% v/v Triton X-100.
 Lysis Buffer 2 (LB2): 10 mM Tris-HCl, pH 8.0; 200 mM
NaCl; 1mM EDTA, pH 8.0; 0.5 mM EGTA, pH 8.0.
 Lysis Buffer 3 (LB3): 10mM Tris-HCl, pH 8.0; 100
mM NaCl; 1 mM EDTA, pH 8.0; 0.5 mM EGTA,
pH 8.0; 0.1% v/v Na-Deoxycholate; 30% v/v N-
Lauroylsarcosine.
All lysis buffers were supplemented with the protease in-
hibitor cocktail immediately before use. The cytosolic frac-
tionwas extracted by lyzing the cell pellets in LB1 that leaves
the nuclear membrane intact. The nuclei were then pelleted
(1,350 x g; 4◦C; 5 min), washed with LB2, pelleted once
more and finally lyzed with LB3 to release the nuclear con-
tents. All protein lysates were quantified using the BCAPro-
tein Assay kit (Pierce; 23227). The following antibodies (di-
lution 1:1000) were used in this study:
 Anti-IRF2 (Center) rabbit IgG (Abgent; AP11225c)
 Anti-NF-B p65 (D14E12) XP rabbit IgG (Cell Signal-
ing Technology; 8242)
 Anti-GAPDH (6C5) mouse IgG (Santa Cruz Biotech-
nology; sc-32233)
 Anti-Histone H3 (C-16) goat IgG (Santa Cruz Biotech-
nology; sc-8654)
 HRP-conjugated Polyclonal swine Anti-Rabbit (Dako;
P0217)
 HRP-conjugated Polyclonal rabbit Anti-Mouse (Dako;
P0260)
 HRP-conjugated Polyclonal rabbit Anti-Goat (Dako;
P0449)
Western blot signals were visualized with the enhanced
chemiluminescence blotting detection reagents (GEHealth-
care; RPN2106). Cytosolic enrichment was confirmed via a
postive GAPDH signal, while nuclear enrichment was con-
firmed by Histone H3. Western blot quantifications were
performed using the ImageJ software by quantifying the
pixels of each band and normalizing against a housekeeper,
such as Histone H3.
RESULTS
General relationship between data sets
A common, though perhaps naive expectation is that com-
bining data from experiments that have been independently
performed in different labs, with different experimental pro-
cedures, allows one to identify essential properties of the
system that are invariant with respect to details of the ex-
perimental approach. In our case, in any given experiment,
confounding effects may have led to some genes being spu-
riously identified as targets of AAGUGCU miRNAs (false
positives), and true targets of AAGUGCU miRNAs be-
ing missed (false negatives). For example, because it is un-
clear whether the miRNA processing enzymes solely func-
tion in this pathway, it is important to analyze data from
ESCs in which the miRNA biogenesis has been impaired
at different levels (Dicer in the studies of Sinkkonen et al.
(17) and Hanina et al. (18) and Dgcr8 in the study of
Melton et al. (19)). Furthermore, although ESCs express-
ing the full complement of miRNAs provide the most phys-
iological reference point for the function of the miR-290-
295 cluster miRNAs in normal, unstressed cells, the effect
of these miRNAs in these cells is confounded by the ef-
fects of other co-expressed miRNAs. Similarly, if the pro-
filed cell population was heterogeneous with respect to the
pluripotency/differentiation status, the let-7 miRNAs may
have masked the effect of miR-294, because these miRNAs
have antagonistic effects (19).
Requiring targets to show consistent downregulation
across multiple data sets can reduce the number of false
positive miR-294 targets. On the other hand, requiring per-
fect consistency across a large number of experiments is
likely to lead to too many false negatives, simply because
different experiments have different levels of accuracy or
confounding effects. Thus, we first investigated the relation-
ship of gene-level expression changes between ESCs that
did or did not express embryonic miRNAs in all pairs of
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Figure 1. Overview of the mRNA expression data sets––(a) Data sources.
(b) Matrix of scatter plots (below diagonal) and Pearson’s correlation co-
efficients (above diagonal) of per-gene log2 fold changes in pairs of exper-
iments. The names of the individual data sets are shown on the diagonal.
(c) Proportion of predicted targets of the AAGUGCU seed family of miR-
NAs (TargetScan aggregate PCT score based predictions (4)) among genes
that are consistently downregulated in all three (orange), pairs (green) or
individual data sets (blue) (indicated by the labels, key given in the ‘Abbr.’
column of the table in panel (a)), plotted against the number of genes that
are consistently downregulated in all of the considered data sets.
experiments. Although pairwise Pearson’s correlation co-
efficients were as low as 0.11 (Supplementary Figure S1),
three of the five experimental data sets (Figure 1a), cover-
ing all described conditions (expression of miR-294, miR-
290-295 cluster miRNAs or the entire complement of em-
bryonically expressedmiRNAs in amiRNA-deficient back-
ground) gave reasonably high pairwise correlation coeffi-
cients (Figure 1b). We therefore focused our discussion on
these data sets, and for completeness, we present the re-
sults of a similar analysis of all five data sets in the Sup-
plementary material (Supplementary Figure S2 and Tables
S5 and S6). Of the ∼4000–5000 genes that were downreg-
ulated in a single experiment, a little less than 2000 genes
were downregulated in all three experiments. Importantly,
the proportion of predicted AAGUGCU seed family tar-
gets among downregulated genes increased when intersect-
ing an increasing number of data sets (Figure 1c), indicating
that the approach of a combined analysis of these data sets
does have the potential to reveal important regulators that
are immediately downstream of the AAGUGCU family of
miRNAs. 252 of the genes downregulated in all three exper-
iments were predicted AAGUGCU seed family targets (4)
(Supplementary Table S2).
The transcriptional network regulated by the miRNAs of the
AAGUGCU seed family in ESCs
As mentioned in the Introduction, the main aim of our
study was to identify transcriptional regulators that are tar-
geted by the AAGUGCU seed family and at the same
time can account for the largest fraction of gene expres-
sion changes that are observed in cells that do or do not
express the miRNAs. We therefore built on the MARA ap-
proach (28) that we recently made available in the form of
an easy-to-use web application (25). In contrast to standard
transcriptome analyses that strive to find genes (including
transcription regulators) whose expression changes signif-
icantly between conditions, MARA aims to infer changes
of the regulatory impact (also referred to as ‘activity’) of
binding motifs. This is achieved by modeling gene expres-
sion as a linear function of the number of regulatory mo-
tif binding sites occurring in the promoter (for TFs) and
3′UTR (for miRNAs) of the gene and the unknown ac-
tivity of each motif. The change in activity of a specific
binding motif (e.g. of the Irf2 TF) in a specific condition
(e.g. transfection of miR-294) is inferred from the expres-
sion changes of all (predicted) targets of this motif (deter-
mined by transcriptome profiling), taking into account the
occurrences of sites for other regulators in these targets.
For example, a decrease in Irf2 activity is inferred when
the predicted Irf2 targets consistently show a decrease in
expression that cannot be explained by the occurrence of
binding sites for other regulatory motifs in the promoters
or 3′UTRs of these targets. This means that MARA can
uncover gene expression changes that are due not only to
changes in the mRNA expression level of a regulator, but
also to changes in the active form (e.g. for TFs through post-
translationalmodifications, such as phosphorylation) of the
regulator. MARAwas initially developed for the character-
ization of transcription regulatory networks (28), and we
have recently extended it to also model miRNA-dependent
changes in mRNA stability (25). For this study we further
extended theMARA approach to identify regulators whose
activity not only changes most significantly between sam-
ples but also reproducibly across multiple data sets. Our ap-
proach is described in detail in the Materials and Methods
section.
To verify that MARA can indeed uncover the key reg-
ulator in these experiments, namely, the miRNAs of the
AAGUGCU seed family, we first applied MARA taking
into account all TFs and miRNA seed families (see Sup-
plementary Table S4). In subsequent analyses, however, we
performed the MARA analysis with only the AAGUGCU
seed family motif added to the full complement of TF mo-
tifs. This was because when all miRNAs are included in the
analysis, MARAwill also infer non-zero activities for other
miRNAs, e.g. those with significantly overlapping sets of
targets (29).
MARA quantifies the extent to which the activity of each
motif varies across conditions by a z-statistic, that roughly
corresponds to the ratio between the average deviation of
the motif activity from zero and the standard deviation of
themotif activity (seeMaterials andMethods). Supplemen-
tary Table S3 shows all motifs ranked by their absolute z-
values.
MARAalso predicts which promoters or 3′UTRs are tar-
geted by each motif, quantifying the confidence in each pre-
dicted motif-target interaction by a posterior probability
(see Materials and Methods). We used these probabilities
to construct a regulatory network of motif–motif interac-
tions (Figure 2) that provides a synthetic view of the regu-
latory impact of the AAGUGCU seed family of miRNAs
on the transcriptional network of pluripotent stem cells. An
arrowwas drawn frommotifA to motifBwhenever motifA
was predicted by MARA to regulate a TF b whose binding
specificity is represented by motif B. Only motif-TF inter-
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Figure 2. The transcriptional network inferred to be affected by the miR-
NAs of the AAGUGCU seed family (represented by miR-294)––A di-
rected edge was drawn from a motif A to a motif B if A was consistently
(across data sets) predicted to regulate a TF b whose sequence specificity
is represented by motif B. The thickness of the edge is proportional to the
product of the probabilities that A targets b. For the clarity of the figure,
only motifs with absolute z-values >5 and only edges with a target prob-
ability product >0.3 are shown. The intensity of the color of a box repre-
senting a motif is proportional to the significance of the motif (the corre-
sponding z-values can be found in Supplementary Table S3). Red indicates
an increase and green a decrease in activity, corresponding to increased and
decreased expression, respectively, of the tagets of the motif when the miR-
NAs are expressed. The full motif names as well as the corresponding TFs
are listed in Supplementary Table S7.
actions that were predicted in all data sets and that involved
motifs with high significance (|z-value| > 5) are shown.
The motif corresponding to the AAGUGCU seed family
(represented by the dark green ‘miR-294’ motif in Figure 2)
is by far themost significantly changingmotif (see also Sup-
plementary Table S3). Its negative change in activity upon
miRNA expression is consistent with the destabilizing effect
of the miRNA on its targets.
The motif with the second most significant change in ac-
tivity, ‘IRF1,2,7’, is bound by the interferon regulatory fac-
tors. MARA predicts that this motif is directly targeted by
miR-294, in line with previous suggestions that the inter-
feron regulatory factors are targets of the miR-290 cluster
miRNAs (18). We present a more detailed analysis of this
motif in the next section.
A second motif whose activity decreases significantly
upon miRNA expression is ‘FOX{I1,J2}’ (Figure 3a). Of
the TFs associated with this motif, Foxj2 is predicted within
all data sets to be directly regulated by miR-294 (Figure 2).
Consistently, Foxj2 is downregulated upon miRNA expres-
sion on the mRNA level (Figure 3b). In order to validate
that Foxj2 is a direct target of the miRNAs, as predicted by
both ElMMo (30) and TargetScan (Figure 3b), we cloned
the 3′UTR of Foxj2 downstream of a luciferase reporter
and co-transfected this construct together with miR-294 in
the murine mammary gland cell line NMuMG. For com-
parison, we generated a construct in which the presumed
miRNA-294 target site was mutated and we performed sim-
ilar co-transfection experiments. The results of this experi-
ment clearly show that Foxj2 is indeed a functional target
of miR-294 (Figure 3c). We carried out similar transfection
experiments with control siRNAs, that do not target the re-
porter, and a standard analysis of these data is presented in
Supplementary Figure S3. Little is known about the func-
tion of Foxj2 in cell fate. It appears to be expressed very
early in development (31), but its overexpression has a neg-
Figure 3. Foxj2 is a direct target of miR-294––(a) The ‘FOX{I1,J2}’ mo-
tif shows a negative change in activity in the presence of miR-294. (b)
Foxj2 mRNA log2 fold changes (±1.96*SEM; n = 3) in the Melton
et al. Dgcr8−/ − versus miR-294 transfection (yellow), Sinkkonen et al.
Dicer−/ − versus miR-290-295 cluster transfection (dark brown) and
Dicer−/ − versus Dicer+/ − (light brown) data sets, as well as the predic-
tion scores for these genes as targets of miR-294 as given by ElMMo (30)
(dark red) and TargetScan (aggregate PCT) (4) (light red). (c) A luciferase
reporter construct carrying the 3′UTRof Foxj2 is downregulated upon co-
transfectionwithmiR-294 relative to a construct carrying theFoxj2 3′UTR
but with a mutated miR-294 target site (n = 9).
ative effect on embryogenesis (32). Our results suggest that
the AAGUGCU seed family of miRNAs contributes to the
maintenance of an adequate expression of Foxj2 in pluripo-
tent stem cells. The third most significant changing motif,
basic-helix-loop-helix (referred to as ‘bHLH..’ in Figure 2),
can be bound by many TFs (reviewed in (33)), some of
which are predicted direct targets of miR-294.
To further elucidate the transcription regulatory network
downstream of the AAGUGCU seed family of miRNAs,
we analyzed in-depth the TFs whose associated motif had
the most significant activity change (|z-value| > 5) and that
were consistently predicted byMARA to be direct targets of
the miR-294 seed family miRNAs across the multiple data
sets (Table 1).
We found that the majority of these direct target TFs fall
into three categories that have previously been associated
with pluripotency: NF-B-related interferon response fac-
tors that control NF-B signalling, cell cycle regulators and
epigenetic regulators.
AAGUGCU seed family miRNAs modulate Irf2-dependent
transcription
The ‘IRF1,2,7’ motif shows the second strongest activity
change upon changes in miR-294 expression (Figure 4a
and Supplementary Table S3). Of the individual factors
associated with this motif, Irf2 is the one that was con-
sistently predicted by our analysis to be a direct target
of the AAGUGCU seed family miRNAs across data sets
(Table 1), consistent with the predictions of both ElMMo
and TargetScan (Figure 4b). Irf2 was downregulated at
the mRNA level across all analyzed data sets (Figure 4b).
Consistently, we found that Irf2 is strongly downregulated
in DCRflox/flox compared to DCR−/ − ESCs, both at the
mRNA level (Figure 4c) as well as at the protein level (Fig-
ure 4d). To validate Irf2 as a direct target of miR-294, we
conducted luciferase assays as described above for Foxj2.
Our results demonstrate that Irf2 is indeed targeted bymiR-
294 (Figure 4e). Although relatively little is known about
the function of this factor in ESCs, a recent study showed
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Table 1 TFs consistently predicted by MARA to be direct targets of miR-294 and whose absolute motif activity z-value is >5
Name Motif
Motif
Abbreviation
Activity
z-value
Irf2 IRF1,2,7.p3 IRF1,2,7 -16.29
Mxd3 bHLH family.p2 bHLH.. 13.00
Clock bHLH family.p2 bHLH.. 13.00
Arnt2 ARNT ARNT2 BHLHB2 MAX MYC USF1.p2 ARNT.. 11.60
Arnt2 AHR ARNT ARNT2.p2 AHR.. 8.39
BAF170
DMAP1 NCOR{1,2} SMARC.p2 ..SMARC -6.98
E2f5 E2F1..5.p2 E2F1..5 6.62
Foxj2 FOX{I1,J2}.p2 FOXI1,J2 -5.62
Figure 4. miR-294 targets the Irf2 TF and modulates ‘IRF1,2,7’ and
‘NFKB1 REL RELA’ activities––(a) The activity of the ‘IRF1,2,7’ motif
is strongly decreased in the presence of miR-294. (b) The expression of Irf2
is downregulatedwithin all analysed data sets (±1.96*SEM; n= 3) and Irf2
is predicted by ElMMo and TargetScan to be a direct target of miR-294
(color scheme as in Figure 3). Low levels of Irf2 mRNA (c) and protein (d)
in DCRflox/flox ES cells compared to miRNA deficient DCR−/ − ESCs are
observed with qRT-PCR and western blot, respectively. qRT-PCR exper-
iments were run in triplicate (± SEM; n = 3). (e) The luciferase reporter
construct carrying the Irf2 3′UTR shows a strong response to miR-294 co-
transfection compared to a similar construct but with amutated Irf2 target
site (n= 9). (f) Sequence logo of the ‘NFKB1 REL RELA’motif that is as-
sociated with the canonical NF-B pathway and that exhibits a significant
decrease in activity in the presence of miR-294. (g)Western blots of RelA,
GAPDH and Histone H3 in nuclear and cytoplasmic fractions in ESCs
that do and do not express miRNAs. The densitometric quantification in-
dicates an increased level of nuclear RelA in the DCR−/ − ESCs compared
toDCRflox/flox ESCs (± SEM; n= 3). (h) Proposedmodel of the inhibitory
effect of miR-290-295 cluster miRNAs on the canonical NF-B pathway
in pluripotent stem cells. Regulatory motifs are denoted by colored rectan-
gles and individual genes by ovals. See text for the evidence of individual
interactions.
that Irf2 overexpression causes differentiation of ESCs (34).
The strong impact of AAGUGCU miRNAs on Irf2 lev-
els and the relatively large impact of the ‘IRF1,2,7’ motif
on gene expression suggest that this regulatory connection
plays an important role in maintaining ESC pluripotency.
Like the ‘IRF1,2,7’ motif, the ‘NFKB1 REL RELA’
motif also exhibits a significantly lower activity when
the embryonic miRNAs are expressed (Figure 4f). West-
ern blot confirms that after stimulation with TNF-,
DCRflox/flox ESCs have lower levels of nuclear NF-B
pathway-associated marker RelA compared with miRNA-
deficient DCR−/ − ES cells (Figure 4g). This observation is
consistent with a decreased activity of the canonical NF-B
signalling pathway in the presence of the miRNAs, which
has been shown to be important for maintaining ESCs in
a pluripotent state yet poised to undergo differentiation
(35,36). Indeed, the Nanog pluripotency factor directly in-
teracts with components of the NF-B complex, inhibiting
its transcriptional activity (35). Combining our results with
recent reports that link the expression of the miR-290-295
cluster to signalling through the canonical NF-B pathway
and the latter to Irf2, the following model of the involve-
ment of the miR-290-295 cluster in the regulation of NF-
B signalling emerges. Expression of the RelA component
of theNF-B complex is repressed post-transcriptionally by
the miR-290-295 cluster members miR-291b-5p and miR-
293 both of which do not belong to the AAGUGCU seed
family of miRNAs (36). In humans, RelA recruitment to
the nucleus, which is a pre-requisite for NF-B complex-
dependent transcription, appears to depend on IRF2 (37),
whose knockdown interferes with transcriptional activation
via NF-B (37). Here we found that in mouse, IRF2 expres-
sion is also repressed by other members of the miR-290-295
cluster, namely, the AAGUGCU family of miRNAs. Thus,
the miRNAs of the miR-290-295 cluster may act in con-
cert to inhibit the canonical NF-B signalling in ESCs (Fig-
ure 4h).
miRNAs of the AAGUGCU seed family impact the cell cycle
at multiple levels
AAGUGCU seed family members of the miR-290-295
cluster were previously shown to accelerate the G1→S
transition and promote proliferation of ESCs by target-
ing the cyclin E-Cdk2 regulatory pathway (13). Consis-
tently, we found that these miRNAs increase the activ-
ity of transcription regulatory motifs associated with ac-
tivation of the cell cycle (Figure 5a), in particular, the
‘ARNT ARNT2 BHLHB2 MAX MYC USF1’ motif that
is bound byMyc. This TF was previously found to increase
uponmiR-294 transfection (19). How themiRNAs, with in-
trinsically repressive function, increase the Myc activity on
its targets is unknown. Our analysis suggests a few hypothe-
ses.
Specifically, luciferase assays show that three cell cycle-
associated TFs, namely, Mxd3 (also known as Mad3), E2f5
and Arnt2 are not only predicted but also experimentally
confirmed direct targets of the AAGUGCU seed family
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Figure 5. miR-294 impacts cell cycle regulation at multiple levels––(a) MARA analysis reveals that miR-294 induces positive activity changes
of multiple motifs involved in cell cycle regulation. Shown are the sequence logos of these motifs: the Myc- and Arnt2-associated motif
‘ARNT ARNT2 BHLHB2 MAX MYC USF1’, the putative Myc-regulating ‘E2F1..5′ motif and the Mxd3-associated ‘bHLH-family’ motif. (b) log2
mRNA fold changes (±1.96*SEM; n= 3) of Myc, Arnt2, E2f5 and Mxd3 (color scheme as in Figure 3) in the analyzed data sets. (c) Luciferase constructs
carrying the 3′UTR of Arnt2, E2f5 or Mxd3, respectively, are downregulated upon co-transfection with miR-294 relative to constructs carrying the same
3′UTRs but with mutated miR-294 binding sites (n = 9). (d) qRT-PCR shows decreased expression of Myc and increased expression of E2f5 in DCR−/ −
ESCs relative to DCRflox/flox ESCs. qRT-PCR experiments were run in triplicate (±SEM; n = 3). (e) Proposed model of miR-294-dependent regulation of
the Myc-Max/Mxd-Max network. Shapes scheme is as in Figure 4. Green or red shapes represent negative or positive changes (in motif activities or gene
expression fold changes), respectively. Dashed lines indicate indirect and solid lines direct regulatory links between motifs/genes.
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miRNAs (Figure 5b and c and Table 1). Mxd3 is one of the
so-called ‘Mad’ partners of the Max protein (reviewed in
(38)). In contrast toMyc, which forms a heterodimeric com-
plex with Max in proliferating cells (39), the Mad factors
Mad1,Mad3 (i.e.Mxd3) andMad4 are primarily expressed
and form complexes with Max in differentiating, growth-
arrested cells (40). Mxd3 was further shown to specifically
regulate the S-phase (41).
Second, we found that E2f5, one of the TFs associated
with the ‘E2F1..5′ motif, was consistently downregulated at
the mRNA level in all analyzed data sets (Figure 5b) and lu-
ciferase assays further confirm that E2f5 is a target of miR-
294 (Figure 5c), albeit with a small response to the miRNA.
Consistently, E2f5 expression is increased inDCR−/ − ESCs
compared toDCRflox/flox ESCs (Figure 5d). The positive ac-
tivity change of the E2F1..5 motif in the presence of the
miRNAs (Figure 5a) suggests that this TF acts predomi-
nantly as repressor (as proposed before, reviewed in (42)).
Notably, Myc is among the predicted targets of E2F1..5,
providing an indirect path to the upregulation ofMyc upon
the presence of the miRNAs (Figure 5b and d).
Finally, Arnt2, a TF associated with the
‘ARNT ARNT2 BHLHB2 MAX MYC USF1’ motif,
but also with the ‘AHR ARNT ARNT2’ motif that corre-
sponds to the complex of Arnt2 and Ahr, is also a predicted
direct target of the AAGUGCU seed family which we
validated in a luciferase assay (Figure 5c). This TF forms
heterodimers with the aryl-hydrocarbon receptor (AHR)
(43) and appears to be involved in the differentiation of
ESCs into endothelial cells under hypoxic conditions (44),
but otherwise little is known about its function. Given
that Arnt2 and Myc (45) share the same binding motif,
an interesting hypothesis is that Arnt2 competes with
Myc for binding to targets and that its downregulation
by AAGUGCU miRNAs allows Myc to act at promoters
which would otherwise be bound by Arnt2. This hypothesis
is again consistent with a positive Myc activity in ESCs, in
which these miRNAs are expressed.
The model that we propose based on these results is that
miRNAs of the AAGUGCU family regulate the cell cycle
and the G→S transition through multiple pathways that
come together in the increased expression of the crucialMyc
regulator (Figure 5e). The miRNAs are able to downregu-
late the Mxd3 antagonist of Myc, the E2f5 repressor which
would in turn result in the increased expression of E2f5 tar-
gets includingMyc, and can downregulateArnt2whichmay
compete with Myc for binding to regulatory sites.
miRNAs of the AAGUGCU seed family control multiple epi-
genetic regulators
As TFs, epigenetic regulators are also enriched among the
targets of miRNAs (46). A role for the miR-290-295 cluster
in epigenetic regulationwas already proposed by Sinkkonen
et al. (17), who found that expression of retinoblastoma-like
2 (Rbl-2) protein, a known repressor of the de novomethyl-
transferases, is controlled by these miRNAs. Through our
analysis we found that the AAGUGCU miRNAs directly
target the epigenetic regulator BAF170 (Smarcc2), a com-
ponent of ATP-dependent, BAF (BRG1-associated factor)
complexes (also known as SWI/SNF complexes) that re-
Figure 6. The BAF170 (Smarcc2) component of the dBAF chromatin re-
modeling complex is a direct target of miR-294––(a) MARA analysis re-
veals a negative activity change of the ‘DMAP1 NCOR{1,2} SMARC’
motif in the presence of miR-294. (b) Expression of BAF170 (Smarcc2) is
consistently downregulated in the presence of miR-294 in all considered
experimental data sets (±1.96*SEM; n = 3; color scheme as in Figure 3).
(c) A luciferase construct carrying the BAF170 3′UTR is downregulated
upon co-transfection with miR-294 relative to a construct carrying a mu-
tated 3′UTR (n = 9). (d) Model of the possible involvement of miR-294
in the maintenance of the ESC-specific chromatin remodeling complex es-
BAF. The miRNA-induced reduction in BAF170 levels may contribute to
themaintenance of appropriate levels of esBAF complexes in ESCs thereby
maintaining self-renewal and proliferation (48). Color, shapes and lines
scheme is as in Figure 5.
model the nucleosome structure and thereby regulate gene
expression (reviewed in (47)). The activity of the BAF170
motif changed significantly upon AAGUGCU miRNA ex-
pression in miRNA-deficient ESCs (Figure 6a, Table 1),
accompanied by consistent downregulation of BAF170
mRNA (Figure 6b). Comparing constructs with and with-
out the putative miR-294 binding site in the BAF170
3′UTR in a luciferase assay we found that BAF170 is sig-
nificantly downregulated by miR-294 (Figure 6c), indicat-
ing that BAF170 is indeed a direct target of miR-294.
Recently, it was shown that BAF170 is downregu-
lated during miR-302-367-based reprogramming and that
BAF170 knockdown increases the number of iPSC colonies
in somatic cell reprogramming (49). As miRNAs of the
miR-302-367 cluster share the seed sequence with miR-294,
it is likely that miR-294 has similar effects on BAF170 ex-
pression and pluripotency.
The model that emerges from these studies is that the
AAGUGCU family of miRNAs may play a role in the re-
modeling of BAF complexes. In ESCs, the BAF complex
(esBAF), which contains a BAF155 subunit, shares a large
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proportion of target genes with the pluripotency-associated
TFs Oct4, Sox2 and Nanog (50) and is required for the
self-renewal and maintenance of pluripotency in mESCs
(48). Consistently, overexpression of esBAF components
was found to promote reprogramming (51). In differenti-
ated cells, however, the so-called differentiated cell BAF
complex (dBAF) (52), contains the BAF170 and not the
BAF155 subunit (48). The fact that induced BAF170 ex-
pression in ESCs decreases the level of BAF155 protein
suggested that BAF170 can displace BAF155 from esBAF,
thereby increasing its degradation rate (48). By preventing
expression of BAF components that are specific to differ-
entiated cells and that antagonize embryonic state-specific
BAF (Figure 6d), the AAGUGCU family of miRNAs may
promote an ESC-specific epigenetic state.
DISCUSSION
It has been established that ESC-specific miRNAs that
share an AAGUGCU seed region are among the regula-
tory factors that are necessary to maintain a pluripotent
ESC state. Strikingly, overexpression of a cluster of ESC-
specific miRNAs was found sufficient for inducing repro-
gramming of differentiated cells into iPSCs. This suggests
that the miRNAs can set into motion an entire regulatory
cascade that leads to cell reprogramming. Several studies
determined the gene expression profiles of ESCs that did
and did not express AAGUGCU family miRNAs. An in-
sight emerging from these studies was that miR-290-295
miRNAs regulate the cell cycle and apoptosis, either di-
rectly or indirectly.
To better understand how the direct regulatory factor tar-
gets of these miRNAs contribute to pluripotency, we made
use of a recently developed method, called MARA, that
models gene expression in terms of computationally pre-
dicted regulatory sites. The approach originates in regres-
sion models that were first proposed by Bussemaker et al.
(53) for inferring regulatory elements from gene expression
data. However, MARA’s goal is different. It uses predicted
regulatory sites in combination with a linear model to infer
from gene expression data the activities of transcriptional
regulators. The first application of MARA (28) to the re-
construction of the core transcriptional regulatory network
of a differentiating human cell line, demonstrated that the
method can successfully infer key regulatory interactions ab
initio. Notably, it was found that MARA accurately infers
the activities of the key regulatory motifs, in spite of com-
putational predictions of regulatory sites being error-prone,
and of gene expression likely being a much more complex
function of the regulatory sites. The power of the method
stems from the fact that motif activities are inferred from
the statistics of expression of hundreds to thousands of pu-
tative target genes of each regulatory motif. Here we have
used an extended version of the MARA model, which also
includes predicted miRNA binding sites, to infer both tran-
scriptional and post-transcriptional regulators of mRNA
expression levels. A similar approach was recently applied
by Setty et al. (54) to reconstruct the regulatory networks
in glioblastoma.
The TF targets of the AAGUGCU miRNAs that we
identified with the extended MARA model had the follow-
ing properties:
(i) The activity of their corresponding motif changed sig-
nificantly upon expression of the AAGUGCU miR-
NAs, meaning that the predicted targets of these
regulators showed, on average, consistent expression
changes.
(ii) Their expressionwas consistently downregulated at the
mRNA level upon expression of theAAGUGCUmiR-
NAs.
(iii) They were predicted as direct targets of the
AAGUGCU family of miRNAs by miRNA tar-
get prediction programs.
(iv) They were consistently (i.e. within every analyzed data
set) predicted by MARA to be directly regulated by
the AAGUGCU seed family of miRNAs on the basis
of the dependence of their expression changes on the
presence of the miRNA binding sites in their 3′UTRs.
(v) They could be confirmed as AAGUGCUmiRNA tar-
gets with luciferase assays.
Altogether, these lines of evidence firmly establish
these transcriptional regulators as direct targets of the
AAGUGCU seed family miRNAs, forming the first layer
downstream of this miRNAs in the regulatory network of
pluripotency.
First, our analysis suggests that AAGUGCU miRNAs
target the cell cycle, and in particular the G1→S transition,
through multiple pathways. By targeting the repressive cell
cycle regulator E2f5, the miRNAs might directly promote
the G1→S transition. In addition, the miRNAs seem to in-
crease the activity of the proliferation-associated TF Myc
through multiple indirect routes, including shifting the bal-
ance between Myc and its antagonist Mxd3 within tran-
scription regulatory complexes that act onMyc target genes.
Second, we found that the AAGUGCU miRNAs may af-
fect the balance between chromatin remodeling complexes
that are active in ESCs and in differentiated cells, a func-
tion probably important for keeping specific genomic re-
gions from being silenced through heterochromatin forma-
tion. Third, we found that the AAGUGCU miRNAs di-
rectly target the interferon regulatory factor Irf2, whose ex-
pression is strongly increased in DCR−/ − cells, consistent
with a significant change in the regulatory impact that we
inferred for this factor. Finally, our analysis uncovers a few
transriptional regulators that have previously not been con-
nected to the transcriptional network of pluripotent stem
cells, including Foxj2, whose expression is strongly affected
by the miRNAs and the Clock (circadian locomotor output
cycles kaput) TF. Interestingly, circadian oscillations are not
present in mouse ES cells, but are switched on during differ-
entiation, and then disappear again upon reprogramming
of differentiated cells into iPSCs (55). It is thus tempting to
speculate that circadian oscillations in ESCsmay be actively
suppressed by theAAGUGCUmiRNAs and that downreg-
ulation of these miRNAs during development may be nec-
essary for the establishment of circadian rhythms. However,
the response of the 3′UTR of Clock in luciferase assays was
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very variable in our hands, and we were not able to unam-
biguously validate it as a direct target of miR-294.
As mentioned before, the AAGUGCU seed motif is not
unique tomiRNAs of themouse-specificmiR-290-295 clus-
ter. It also occurs in the miR-302 family of miRNAs that
is present in human and in a shifted version (at positions
3–9 instead of 2–8) it occurs in the miR-17/20a miRNAs
of the oncogenic miR-17-92 cluster. Although miR-19 has
been reported to be the key oncogenic component of this
cluster (56), the strong effects that AAGUGCU miRNAs
exert on the cell cycle raise the question of whether miR-
17 and miR-20a may not play a role similar to miR-294 in
malignant cells.
In summary, our analysis demonstrates that combining
accurate predictions of regulatory elements with analysis
of transcriptome-wide mRNA expression changes in re-
sponse to specific manipulations is a general and power-
ful approach to uncovering key regulators within gene ex-
pression networks. In the future, incorporation of measure-
ments of miRNA expression as well as of predictions of TF
binding sites in miRNA genes will enable identification of
feedback loops between miRNAs and TFs that are known
to operate in many systems.
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Chapter II. Implication of TFAP2A in Epithelial 
Plasticity in Breast Cancer and Development 
 
Epithelial Plasticity 
 
Epithelial to mesenchymal transitions (EMT) describes a transition that epithelial 
cells undergo, progressively losing their epithelial characteristics, and acquiring a new 
mesenchymal phenotype. Elizabeth Hay and colleagues observed and documented 
such changes for the first time, in the primitive streak formation of chicken embryo 
(Trelstad, Hay et al. 1967). The process is reversible, the term mesenchymal to 
epithelial transition (MET) being used to describe the opposite process (Lamouille, 
Xu et al. 2014). Incomplete EMT may also exist (Bryant and Mostov 2008). 
The epithelial organization is evolutionary older than Metazoa. Simple, non- 
cadherin-based, and polarized epithelial structures are already found in the fruiting 
body formed by the unicellular Dictyostelium discoideum (Dickinson, Nelson et al. 
2011). In multicellular organisms the epithelial tissue fulfills the function of creating a 
barrier between two different media, frequently segregating internal from external 
environments (Rodriguez-Boulan and Macara 2014). Characteristic of epithelial 
organization is the close contact in between adjacent cells, but also their apico-basal 
polarity, stabilized by adherens junctions, desmosomes and tight junctions (Bryant 
and Mostov 2008).  The epithelium is separated from neighboring tissues by basal 
lamina, an assembly of extracellular proteins and glycoproteins (Thiery, Acloque et 
al. 2009).  In contrast, the connective tissue surrounding epithelia is formed from 
unconfined mesenchymal or stromal cells, embedded in a 3D extracellular matrix 
(Thiery, Acloque et al. 2009).   
A number of specific events occur during EMT, including the disassembly of 
epithelial junctions, loss of apico-basal cell polarity, cell morphological changes, 
cytoskeleton rearrangements, and increased cell motility (Spano, Heck et al. 2012). 
EMT is a critical process during embryonic development; it also participates in 
normal and pathological mechanisms such as wound healing, fibrosis and tumor 
metastasis. Moreover, ECS differentiation and reprogramming of somatic cells to 
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iPSC, involve respectively EMT and MET steps (Goding, Pei et al. 2014). In addition, 
EMT is also suggested to associate to the origin of cancer stem cells (Mani, Guo et al. 
2008) 
All of these processes, which involve complete transition or partial modification of 
epithelial phenotype, are collectively referred to as epithelial plasticity.  
 
Epithelial Plasticity During Embryonic Development 
 
EMT is fundamental process that is part of the embryonic development in vertebrates. 
The majority of adult organs and tissues are formed in result of a sequence of 
successive EMT and MET transitions. The mesenchymal cells formed from the 
primary EMT can undergo the reverse process that is MET, and thus form transient 
epithelial structures. For instance, the heart is formed after three consecutive rounds 
of EMT and MET (Thiery, Acloque et al. 2009). The successive cycles of conversion 
in between the epithelial and mesenchymal cell state, involved in embryonic cells 
differentiation and organogenesis, are named primary, secondary and tertiary EMT, 
respectively (Thiery, Acloque et al. 2009).  
The first EMT event described in early embryogenesis is the formation of the 
primitive endoderm from ICM cells that later contributes to extra-embryonic tissues 
(Figure 5) (Thiery, Acloque et al. 2009).  Another example of profoundly investigated 
EMT process is in the course of gastrulation, which leads to the segregation of three 
germ layers (Figure 5) (Nakaya and Sheng 2008). The EMT conversion is involved in 
the formation of a structure of cells that arises from the epiblast, and constitutes the 
primitive streak. Cells from the epiblast migrate towards the internal part of the 
embryo along the primitive streak to form the definitive endoderm and later the 
mesoderm layers of the embryo (Arnold and Robertson 2009; Thiery, Acloque et al. 
2009).   
The neural crest cells (NCC) population arises from the ectoderm, surrounded by the 
neural plate and prospective epidermis. NCCs gain extensive migratory capacity and 
separate from the neuroepithelium through a complete or partial EMT, the process is 
referred as delamination (Figure 5). Afterwards they migrate in the embryo and due to 
their multipotent nature are at the origin of a variety of cell types, including certain 
neurons, glial cells, constituents of the peripheral nervous system, cardiac structures, 
Page 46 of 124
  
endocrine cells, smooth muscle and others (Thiery, Acloque et al. 2009; Theveneau 
and Mayor 2012).  
 
Figure 5.  Primary EMT during Embryonic Development. Primary EMT starts 
before implantation of the embryo with the formation of the parietal endoderm. Next, 
after implantation, the mesodermal progenitors also undergo EMT during 
gastrulation. The neural crest delamination is a later event, following the 
embryogenesis. Reprinted from (Thiery, Acloque et al. 2009) with permission from 
Elsevier. 
 
Epithelial Plasticity During Cancer Progression 
 
The activation of invasion and metastasis is considered a hallmark in human tumors 
and it is a major contributor to cancer related mortality (Hanahan and Weinberg 2011; 
Slattum and Rosenblatt 2014) (Bill and Christofori 2015). The metastasis formation is 
considered as a multistep mechanism. It starts with tumor cells, invading the 
surrounding tissues, followed by their extravasation into neighboring blood and 
lymph vessels. After transit in the circulatory system, the cells undergo extravasation 
towards the parenchyma of distant tissues, which then they colonize (Fidler 2003; 
Hanahan and Weinberg 2011; Bill and Christofori 2015). EMT is related to increased 
migration and invasiveness, and it is thought to be involved in cancer malignancies, 
where epithelial tumor cells escape the initial tumor site, by invading nearby stroma 
and reaching the circulatory system (Bill and Christofori 2015). Furthermore, 
cooperation between cancer cells and platelets in blood vessels might contribute to 
lung metastasis by induction of EMT in the tumor cells (Labelle, Begum et al. 2011). 
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On the other hand MET is suggested to be important for the colonization step, which 
involves the metastatic outgrowth in the secondary cancer site (Brabletz 2012). 
Moreover, it has been proposed that EMT may play a role beyond metastatic 
formation, regulating processes like tumor initiation and drug resistance, by 
promoting the cancer stem cells phenotype (Mani, Guo et al. 2008; De Craene and 
Berx 2013; Plaks, Kong et al. 2015).  
It is well established that certain cancer cell lines undergo EMT in vitro upon 
exogenous expression of EMT master regulators or stimulation with different factors, 
such as TGFβ. However, the clinical relevance of EMT in tumor formation and 
progression is still debated mainly because the evidence of EMT in the tumor are to 
certain extent speculative (De Craene and Berx 2013; Bill and Christofori 2015). In 
support of the involvement of EMT, the loss or down regulation of E-cadherin 
(CDH1), an epithelial adherens junction protein and hallmark of the transition, in 
carcinoma cells is frequently related to a malignancy progression (Cavallaro and 
Christofori 2004; Yilmaz and Christofori 2010). Nevertheless, the link between EMT 
and metastasis remains controversial in the lobular breast carcinoma, which is due to 
an inactivating mutation of CDH1, but has also well delineated epithelial features 
(Lombaerts, van Wezel et al. 2006). Aggressive breast cancer cell lines and tumors 
subtypes, such as basal B and claudin-low, were related with an EMT transcriptomic 
signature (Neve, Chin et al. 2006; Herschkowitz, Simin et al. 2007; Hennessy, 
Gonzalez-Angulo et al. 2009). Despite the fact that an EMT transcriptomic signature 
does not correlate with survival and it is not informative of poor outcome, specific 
regulators of EMT such as SOX4, PRRX1 and LXH2 do show such relationships 
(Ocana, Corcoles et al. 2012; Tiwari, Tiwari et al. 2013; Kuzmanov, Hopfer et al. 
2014; Bill and Christofori 2015). It is not clear, however, if those tumors undergo 
EMT, at what stage they do and if this is essential for metastasis formation (Bill and 
Christofori 2015). 
 
Gene Regulatory Networks Involved in EMT 
 
A number of transcription factors were shown to be master regulators of EMT and to 
be able to induce it in different contexts. Among those are snail family zinc finger 1 
and 2 (SNAI1 and 2), twist family bHLH transcription factor 1 and 2 (TWIST1 and 
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2), zinc-finger E-box binding homeobox 1 and 2 (ZEB1 and 2) (Table 3) (Lamouille, 
Xu et al. 2014).  Beyond these transcription master regulators, epithelial plasticity is 
regulated at a number of distinct levels, including splicing and miRNA-dependent 
silencing, by interconnected regulatory networks (Figure 6) (De Craene and Berx 
2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. EMT is controlled by interconnected regulatory networks. ZEB, SNAI1 
and TWIST1 are key EMT-inducing transcription factors and have a central role in 
the regulatory network. miRNAs form negative feedback loops with these 
transcription factors. Adapted by permission of Macmillian Publishers Ltd Nature 
Reviews Cancer (De Craene and Berx 2013), copyright 2013 
 
EMT is associated with important changes in genes expression and large number of 
genes is affected (Lamouille, Xu et al. 2014). Among the epithelium-specific genes, 
changes are observed in those encoding epithelial tight junction and desmosome 
complexes, including claudins, occludin, desmoplakin and plakophilin, respectively 
(Lamouille, Xu et al. 2014).  E-cadherin deserves a particular attention as its down-
regulation is considered a hallmark of the transition (Yilmaz and Christofori 2010). 
Furthermore, the down-regulation of E-cadherin is often coupled with the up-
regulation of N-cadherin, and therefore, mesenchymal adherens junctions replace the 
epithelial adherens junctions, in a phenomenon known as “cadherin switch” 
(Wheelock, Shintani et al. 2008; Yilmaz and Christofori 2010). Other adhesion 
Epithelia Mesenchyme 
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molecules are unregulated upon EMT, for instance neural cell adhesion molecule 
(NCAM) expression increases during the transition and it participates in focal 
adhesion assembly and cell migration (Lehembre, Yilmaz et al. 2008). In additions, 
the expression of genes involved in the formation of cytoskeleton, such as cytokeratin 
and vimentin is modified (Lamouille, Xu et al. 2014).  
EMT is also coupled with changes in the way cells interact with components of the 
extracellular matrix (ECM) (Lamouille, Xu et al. 2014).  Fibronectin (FN1) is found 
in the stromal ECM of breast tumors (Christensen 1992).  Its expression is 
upregulated during the transition and its interactions with mammary epithelial cells 
promote EMT (Park and Schwarzbauer 2014). In the course of the transition cells 
down-regulate epithelial integrins and up-regulate those that enforce EMT and 
invasion (Yilmaz and Christofori 2009). For example, in Madin-Darby canine kidney 
(MDCK) cells the expression of SNAI1 induced up-regulation of αvβ3 integrin, 
recognized for its role in cancer invasion (Haraguchi, Okubo et al. 2008; Yilmaz and 
Christofori 2009).  
 
Transcription Level Regulation of Epithelial Plasticity 
 
Firstly, the SNAI1 transcription factor was identified to regulate EMT by interacting 
with CDH1 promoter and thus repressing its expression (Batlle, Sancho et al. 2000; 
Cano, Perez-Moreno et al. 2000). Consequently, a number of other transcription 
factors including SNAI2, ZEB1, ZEB2, E47, Kruppel-like factor 8 (KLF8) and 
Brachyury were reported to directly repress E-cadherin expression together with other 
epithelial junction proteins and thus promote an EMT phenotype. Another 
continuously growing set of transcription factors, such as SOX4, paired mesoderm 
homeobox 1 (PRRX1), TWIST1, some of the Forkhead box protein, for instance C2 
(FOXC2), high mobility group A2 (HMGA2), goosecoid, E2-2 (TCF4), certain 
GATA proteins and SIX1 were equally described to control the process without 
directly regulating E-cadherin promoter (Tiwari, Gheldof et al. 2012; De Craene and 
Berx 2013; Lamouille, Xu et al. 2014). A non-exhaustive list of transcription factors 
implicated in EMT is presented in Table 3. It is important to note that despite the 
multitude of transcription factors controlling the transition like ZEB, SNAIL and 
TWIST, have been described to be consistently involved in EMT (Peinado, Olmeda et 
al. 2007; De Craene and Berx 2013). Their expression or activity is activated in the 
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early steps of the process. Furthermore, the EMT inducing transcription factors exert 
their action on same or related pathways and are frequently part of interconnected 
regulatory network (Taube, Herschkowitz et al. 2010; De Craene and Berx 2013). 
They repress epithelial genes, while also activating the mesenchymal ones. In many 
cases they act in synergy and they regulate mutually their expression (De Craene and 
Berx 2013). Often transcription factors outside ZEB, SNAIL and TWIST would 
rather ease EMT and/or feed to those core factors (Table 3) (De Craene and Berx 
2013). 
 
Transcription 
Factor 
     Function in EMT Reference 
    
SNAI1 and 2 
Zinc-finger protein, 
transcriptional repressor 
(Batlle, Sancho et al. 2000; 
Cano, Perez-Moreno et al. 
2000; De Craene, van Roy et 
al. 2005) 
ZEB1 and 2 
Zinc-finger protein, 
transcriptional repressor 
(Tiwari, Gheldof et al. 2012) 
KLF8 
Zinc-finger protein, 
transcriptional repressor and 
activator 
(Wang, Zheng et al. 2007; 
Lahiri and Zhao 2012) 
Brachyury Transcriptional activator 
(Fernando, Litzinger et al. 
2010) 
TWIST1 and 2 bHLH factors (Peinado, Olmeda et al. 2007) 
FOXD3 Neural crest specifier (Dottori, Gross et al. 2001) 
FOXQ1  
Repressed expression of the 
core EMT regulator e-
cadherin 
(Zhang, Meng et al. 2011) 
FOXO3A  Notch regulator Gopinath et al.(2014 
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FOXC2 Transcriptional activator (Mani, Yang et al. 2007) 
Goosecoid Homeobox protein (Hartwell, Muir et al. 2006) 
E2-2/TCF4 Class I bHLH factor (Peinado, Olmeda et al. 2007) 
SIX1 Homeobox protein 
(McCoy, Iwanaga et al. 2009; 
Micalizzi, Christensen et al. 
2009) 
PRRX1 Homeobox protein (Ocana, Corcoles et al. 2012) 
GATA4 and 6 
 
Downregulation of 
junctional dE-Cadherin 
(Campbell, Whissell et al. 
2011) 
HMGA2  
Co-regulates SNAI1 
expression 
(Thuault, Tan et al. 2008) 
SOX9  
Co-regulates SNAI2 
expression 
(Sakai, Suzuki et al. 2006) 
CBFA–KAP1  Transcriptional activator (Venkov, Link et al. 2007) 
ZNF703 /Zeppo1  Represses E-Cadherin (Slorach, Chou et al. 2011) 
PRX1  Regulates BMP2 and TGFβ 
(Makrodouli, Oikonomou et al. 
2011) 
SOX4 Controls EZH2 expression (Tiwari, Tiwari et al. 2013) 
E47/TCF3 bHLH factor (Peinado, Olmeda et al. 2007) 
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Table 3.  Transcription factors and cofactors implicated in the regulation of 
EMT. Adapted by permission of Macmillian Publishers Ltd Nature Reviews Cancer 
(De Craene and Berx 2013), copyright 2013 
SNAIL Transcription Factors 
 
In mammals two out of three SNAIL proteins, namely SNAI1 and SNAI2, are 
involved in EMT.  Mouse Snai1 gene is expressed in the prospective mesoderm as 
well as at the edge of the neural plate (Cano, Perez-Moreno et al. 2000). During 
embryonic development SNAIL gene family are essential for gastrulation, left-right 
patterning and affect neural crest delamination (Alberga, Boulay et al. 1991; Nieto, 
Sargent et al. 1994; Carver, Jiang et al. 2001; Murray and Gridley 2006). In the adult, 
SNAI1 presence is restrained to mesenchymal cells of lung, dermis and cartilage as 
well to wound-healing activated fibroblasts and mesenchymal stem cells (Franci, 
Takkunen et al. 2006; Batlle, Alba-Castellon et al. 2013).  SNAIL is also expressed in 
human and mouse invasive tumors and it represses E-cadherin expression. (Batlle, 
Sancho et al. 2000; Cano, Perez-Moreno et al. 2000).  
SNAIL transcription factors are conserved in metazoans and possess a particular 
domain organization (Barrallo-Gimeno and Nieto 2005). At their C-terminus they 
contain from two to six zinc-fingers, which confers them the capacity to specifically 
recognize the DNA E Box element (CTGGTG) (Nieto 2002). The N-terminus 
sequence of SNAIL proteins is more divergent (Nieto 2002). Traditionally SNAIL 
transcription factors are considered as transcriptional repressors, but they have been 
also demonstrated to activate certain target genes (Barrallo-Gimeno and Nieto 2005; 
Lamouille, Xu et al. 2014). In order to repress the expression of E-cadherin, SNAI1 
interacts with distinct proteins and complexes that control histone modifications 
(Lamouille, Xu et al. 2014). Among those are Polycomb repressive complex (PRC2), 
SIN3A and histone deacetylases HDAC1, 2 and 3, and lysine specific demethylase 1 
(LSD1) (Lamouille, Xu et al. 2014). It was also demonstrated that SNAI1 cooperates 
with ETS1 and SMAD3-SMAD4 complexes to govern the expression of EMT 
associated genes. SNAI2, on its side, recruits different repressor complex together 
with HDAC1/3 and C-terminal binding protein (CTBP) to promote EMT in a similar 
manner (Tiwari, Gheldof et al. 2012). 
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A variety of signaling pathways regulate SNAIL expression. The list of those that can 
activate SNAI1 activity and expression includes receptor tyrosine kinases (RTK), 
tumor growth factor (TGF), WNT, Notch, integrins, phosphatidylinositol 3 kinase 
(PI3K)-AKT, mitogen activated protein kinase (MAPK) and nuclear factor kB 
(NFkB) signaling (De Craene, van Roy et al. 2005; Tiwari, Gheldof et al. 2012; 
Lamouille, Xu et al. 2014). Most of those pathways are known to regulate SNAI1 at 
transcription level (De Craene, van Roy et al. 2005). However, the activity and 
stability of the transcription factor are also controlled by post-translational 
modifications. Glycogen synthase kinase 3b (GSK3β) can phosphorylate SNAI1 at 
Ser97 or Ser101 and protein kinase D1 (PKD1) at Ser11, which in both cases 
promotes its translocation to the cytoplasm (Zhou, Deng et al. 2004; Yook, Li et al. 
2006; Du, Zhang et al. 2010). Additionally, GSK3β phosphorylates SNAI1 at Ser108, 
Ser112, Ser116 and Ser120 in its turn can stimulate the SNAI1 ubiquitin-mediated 
degradation (Zhou, Deng et al. 2004; Yook, Li et al. 2006). WNT, PI3K-AKT, NFkB 
and Notch signaling interfere with GSK3β phosphorylation of SNAI1 and thus lead to 
increased stability and activity of the transcription factor (Yook, Li et al. 2006; 
Lamouille, Xu et al. 2014). On the other hand, phosphorylation of SNAI1 at Ser246 
and Thr203, respectively by PAK1 or large tumor suppressor 2 (LATS2), can 
stimulate the nuclear retention of the protein and therefore its activity (Yang, Rayala 
et al. 2005; Zhang, Rodriguez-Aznar et al. 2012). Finally Lox and lysyl oxidase-like 2 
and 3 (LOXL2/3) stabilize SNAI1 protein (Tiwari, Gheldof et al. 2012). 
 
ZEB Transcription Factors 
 
The ZEB family consists of two transcription factors ZEB1 and ZEB2, which have 
overlapping functions, but not always overlapping expression patterns (Peinado, 
Olmeda et al. 2007). Both ZEB proteins induce EMT and cell migration (Tiwari, 
Gheldof et al. 2012). They are expressed in human fetal and adult tissues, including 
central nervous systems, heart, skeletal muscle and hematopoietic cells (Funahashi, 
Sekido et al. 1993; Genetta, Ruezinsky et al. 1994; Sekido, Murai et al. 1994; Postigo 
and Dean 2000). In addition, knockout of mouse Zeb1 resulted in severe T-cell 
developmental impairment and various skeletal abnormalities, while knockout of 
Zeb2 is embryonically lethal with delamination arrest and lack of TFAP2A positive 
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migrating neural crest cells (Higashi, Moribe et al. 1997; Takagi, Moribe et al. 1998; 
Van de Putte, Maruhashi et al. 2003). 
ZEB1 and ZEB2 share important structural similarities (Postigo and Dean 2000). 
They possess two clusters of zinc-finger domains at both the C-terminal and N-
terminal ends, and a homeodomain in the central part (Peinado, Olmeda et al. 2007).  
They recognize bipartite E Box DNA elements (CACCT and CACCTG) via their 
zinc-finger clusters and present similar sequence specificities (Postigo and Dean 
2000; Peinado, Olmeda et al. 2007).  
ZEB1 and ZEB2 form repressive complexes with SMAD proteins, CTBP or via 
BRG1 protein with Switch/Sucrose nonfermentable (SWI/SNF) complex (Tiwari, 
Gheldof et al. 2012; Lamouille, Xu et al. 2014). ZEB1 can also function as an 
activator by interacting with p300/CBP via PCAF and p300, and is potentially 
involved in histone demethylation via binding of LSD1 (Lamouille, Xu et al. 2014).  
Signaling cascades downstream of TGFβ, WNT and RAS-MAPK pathways induce 
the expression of ZEB proteins (Peinado, Olmeda et al. 2007; Tiwari, Gheldof et al. 
2012; Lamouille, Xu et al. 2014). Furthermore SNAI1 and TWIST1 were 
demonstrated to directly activate ZEB1 promoter (Dave, Guaita-Esteruelas et al. 
2011).  Both of the ZEB factors participate in a regulatory loop with miR-200 family 
of microRNAs, which antagonizes TGFβ-induced EMT (Gregory, Bert et al. 2008; 
Korpal, Lee et al. 2008; Park, Gaur et al. 2008). PRC2 inhibits the activity of ZEB2 at 
post-translational level by sumoylation (Tiwari, Gheldof et al. 2012).  
 
bHLH Transcription Factors 
 
Helix-loop-helix (HLH) proteins have a common structural organization consists of 
two amphipatic α-helices and middle loop linker involved in dimerization (Peinado, 
Olmeda et al. 2007). In certain HLH proteins supplementary basic domain exists 
therefore named bHLH, while others such as the Id proteins have no additional 
structural elements (Massari and Murre 2000). They can form hetero- or homo-dimers 
and in the case of bHLH recognize an E Box DNA consensus sequence (CANNTG) 
(Massari and Murre 2000). With respect to EMT, a number of HLH proteins are 
implicated, including TCF3, TCF4, TCF12, TWIST1,2 and the Id proteins (Peinado, 
Olmeda et al. 2007). TCF3, with its two isoforms E12 and E47, and TWIST 1 and 2 
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directly regulate E-cadherin expression and are essential inducers of EMT (Tiwari, 
Gheldof et al. 2012).  The Id proteins are devoided from DNA binding domain but 
can still dimerize with other HLH factors.  In this way they inhibit their action and 
therefore EMT (Kondo, Cubillo et al. 2004). Upon TGFβ1 induced EMT, Id1 protein 
is downregulated and the decrease of its expression correlates with that of E-cadherin, 
while expression of Id2 and Id3 can inhibit the transition (Tiwari, Gheldof et al. 
2012). 
 
microRNA Regulation of EMT 
 
Non-coding RNAs and in particular microRNAs are critical modulators of 
developmental processes (Stefani and Slack 2008). Their abnormal expression is 
related to pathological conditions such as cancer (Nicoloso, Spizzo et al. 2009). In the 
recent years a large number of microRNAs that are involved in EMT, cancer 
progression and metastasis formation were identified (Nicoloso, Spizzo et al. 2009). 
For instance, miR-200 family members form a double-negative feedback loop with 
ZEB transcription factors (Figure 7). Five different microRNAs (miR-200a, miR-
200b, miR-429, miR-200c, miR-141), encoded in two separate clusters are part of 
miR-200 family (Altuvia, Landgraf et al. 2005; Bracken, Gregory et al. 2008). The 
microRNA seed is critical for target recognition, and the members of the microRNA 
family comprise highly similar and conserved seed sequences. Therefore, this 
suggests that they also share important number of target genes (Lewis, Shih et al. 
2003; Lewis, Burge et al. 2005). In the case of miR-200 family two seed sequences 
with a single nucleotide difference do exist: AAUACU, contained in miR-200bc/429, 
and AACACU found in miR-200a/141 (Feng, Wang et al. 2014). In the 3’UTR of 
ZEB1 and ZEB2 miR-200 family members have between 5 and 8 binding sites that 
allow a tight control over the transcription factors (Gregory, Bert et al. 2008; Park, 
Gaur et al. 2008). On the other hand ZEB represses the expression of the microRNA 
clusters by directly interacting with their promoters (Bracken, Gregory et al. 2008; 
Burk, Schubert et al. 2008). In this manner elevated miR-200 levels safeguard the 
epithelial state, whereas upon the transition ZEB increases and blocks the expression 
of miR-200 (Gregory, Bert et al. 2008). Ectopic expression of miR-200 in the 
mesenchymal cell state is sufficient to revert the process (Gregory, Bert et al. 2008). 
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Furthermore low levels of miR-200 family members are associated with aggressive 
tumor progression, metastasis formation, cancer stem cell stemness potential and 
chemoresistance (Feng, Wang et al. 2014). Additional targets of miR-200 family, 
such as SUZ12 and BMI, also contribute to the microRNAs anti-metastatic potential 
and their role in promoting the epithelial cellular state (Wellner, Schubert et al. 2009; 
Iliopoulos, Lindahl-Allen et al. 2010). Other microRNAs-TF interactions have also 
been described in the context of EMT. For example, several microRNAs, including 
miR-29b, miR-30a and miR-34 family members directly target SNAI1, while miR-1 
and miR-200b repress SNAI2 (De Craene and Berx 2013; Lamouille, Xu et al. 2014).  
SNAIL transcription factors might control the expression of miR-200, miR-1 and 
miR-34 thus establishing a double-negative feedback regulation similar to the one 
described between ZEB TFs and miR-200 family members (Figure 7) (De Craene and 
Berx 2013). Downregulation of miR-335 is a hallmark of EMT and tumor 
progression, and it is mechanistically explained by the microRNA control over SOX4 
and tenascin-C mRNAs (Tavazoie, Alarcon et al. 2008; Tiwari, Gheldof et al. 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. MicroRNAs-transcription factors feedback loops in EMT. TGFβ and 
other growth factors or extracellular stimuli induce EMT promoting transcription 
factors from the ZEB and SNAIL families, which on their turn activate EMT 
phenotypical changes, stemness and drug resistance. miR-200 and miR-34 family 
members form a double negative feedback loop with the EMT promoting TFs. ZEB 
and SNAIL block the transcription of the microRNAs, while miR-200 and miR-34 
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negatively regulate the expression of the TFs. In addition, p53 can induce the 
expression of both miRNA families, thus promoting the epithelial state. Adapted by 
permission of Macmillian Publishers Ltd Nature Reviews Cancer (Brabletz 2012), 
copyright 2012. 
Apart from regulating the expression of master TFs microRNAs can also modulate 
EMT by controlling genes characteristic either of the epithelial or mesenchymal cell 
state (Lamouille, Xu et al. 2014). In mammary carcinomas miR-9 levels can be 
elevated and confer mesenchymal and invasive features to the tumors by targeting E-
cadherin gene (Ma, Young et al. 2010).  Another interesting example of a microRNA 
that promotes EMT and metastasis is miR-22. In mouse xenograft models it triggers 
EMT and stimulates metastasis formation, whereas in patients it correlates with poor 
clinical outcome. It is suggested that it indirectly contributes to the silencing of tumor 
suppressor miR-200 by targeting an enzyme, Ten eleven translocation (TET), 
involved in the miR-200 promoter demethylation (Song, Ito et al. 2013).   
 
Splicing Factors in EMT 
 
Alternative splicing is a regulatory mechanism of gene expression that leads to the 
formation of different proteins from a single gene and it is involved in cancer 
formation and EMT (Tiwari, Gheldof et al. 2012). The RNA binding proteins, ESRP1 
and ESRP2 promote the epithelial state by inducing the splicing of epithelial-specific 
isoforms of certain EMT associated genes such as CD44, FGFR2 and CTNND1 
(Warzecha, Sato et al. 2009; Warzecha, Jiang et al. 2010; Brown, Reinke et al. 2011). 
On the contrary RBFOX2 can regulate both epithelial and mesenchymal splicing and 
stimulate tissues invasiveness (Braeutigam, Rago et al. 2014).  CELF, MBNL and 
hnRNP splicing factors were also associated with EMT (Shapiro, Cheng et al. 2011). 
 
TFAP2A Transcription Factor 
 
Transcription factor TFAP2A (also named AP-2α) belongs to the AP-2 family of 
transcription factors(Hilger-Eversheim, Moser et al. 2000; Eckert, Buhl et al. 2005). 
In 1987, Mitchell et al. were the first to discover and further designate TFAP2A as 
binding partner of the SV40 enhancer elements in HeLa cells (Mitchell, Wang et al. 
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1987). In human and mice there are five AP-2 transcription factors that share 
significant sequence similarity between 56 and 78 %, which are TFAP2A, TFAP2B, 
TFAP2C, TFAP2D and TFAP2E, or AP-2α, AP-2β, AP-2γ, AP-2δ and AP-2ε, 
respectively (Eckert, Buhl et al. 2005). They present a specific domain structural 
organization featuring an N-terminal prolin and glutamine rich trans-activation 
domains, a central basic region and very well conserved helix-loop-helix C-terminal 
region, involved in DNA binding and dimerization.(Williams and Tjian 1991) The 
protein can function as a hetero-or homo- dimer(Eckert, Buhl et al. 2005).  In mice, 
Tfap2a gene is composed from 7 exons and it is expressed as four different isoforms; 
the first three (1a,1b and 1c) differ in the first exon and the forth isoform lacks the 2
nd
 
exon due to alternative splicing event(Meier, Koedood et al. 1995; Eckert, Buhl et al. 
2005). 
SELEX (Systemic Evolution of Ligand by EXponential Evolution) based, in vitro 
binding site enrichment assays, have determined that TFAP2A binds to a palindromic 
motif GCCN3GGC and its variations GCCN4GGC, GCCN3/4GGG (Mohibullah, 
Donner et al. 1999). In more recent chip-seq experiments it was shown that human 
AP-2γ and AP-2α have consensus binding site of respectively SCCTSRGGS and 
SCCYSRGGS (S = G or C, R = A or G and Y = C or T)(Woodfield, Chen et al. 2010; 
Rada-Iglesias, Bajpai et al. 2012) (Bogachek, Chen et al. 2014) . 
 
Mode of Action and Control 
 
AP-2 family of proteins canonically functions as transcriptional regulators in the 
nucleus, where it regulates the expression of certain targets (Eckert, Buhl et al. 2005). 
They were shown to activate genes involved in apoptosis, cell growth, proliferation 
and differentiation (CDKN1A, TGFA, ESR1, ERBB2/HER-2/neu, FOXA1)(Bosher, 
Williams et al. 1995; Wang, Shin et al. 1997; Zeng, Somasundaram et al. 1997; 
Woodfield, Chen et al. 2010). In addition, it was shown that they can also repress the 
expression of many genes, including MYC, cyclin-D2, c/EBP- α /CEBPA, 
MCAM/MUC18.(Gaubatz, Imhof et al. 1995; Jean, Gershenwald et al. 1998; Jiang, 
Tang et al. 1998; Yu, Hitchler et al. 2009)  In the promoter region of cyclin-D2, the 
TFAP2A binding site is found in close vicinity to MYC responsive E-Box element, 
therefore creating a mutually exclusive interaction (Hilger-Eversheim, Moser et al. 
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2000). Apart from its function as transcription factor, it has been demonstrated that 
TFAP2A participates in WNT signaling pathway by forming complex with 
adenomatous polyposis coli protein (APC) and -catenin, disrupting the interaction 
between -catenin and the transcription factors TCF and thereby blocking its effector 
function (Aqeilan, Palamarchuk et al. 2004). The activity of TFAP2A can be 
regulated by protein-protein interactions or by post-translational modifications 
(PTMs) (Eckert, Buhl et al. 2005). For instance TFAP2A binding to the PC4 
transcription factor reduces its transcriptional self-interference and stimulates its 
transactivation potential (Zhong, Wang et al. 2003). TFAP2A can be sumoylated, 
inducing its degradation and suppressing its activity (Eloranta and Hurst 2002; 
Berlato, Chan et al. 2011). Equivalently, a phosphorylation by PKA at Ser239 of 
TFAP2A regulates its transactivation potential and oxidation of conserved cystein 
residues in TFAP2A DNA binding domain shifts its capacity to interact with DNA 
(Huang and Domann 1998; Garcia, Campillos et al. 1999; Grether-Beck, Felsner et al. 
2003). It has been also proposed that TFAP2C sub-cellular localization can be 
regulated by an interaction of with WWOX  that sequesters the transcription factor in 
the cytoplasm (Aqeilan, Palamarchuk et al. 2004). In addition, the different isoforms 
of TFAP2A were shown to differ in activity suggesting that TFAP2A activity can be 
further regulated at gene level by alternative splicing and/or alternative promoter 
usage (Buettner, Kannan et al. 1993; Berlato, Chan et al. 2011).  
 
AP-2 Transcription Factors in Development and Cancer 
 
In the developing embryo, AP-2 transcription factors are implicated in trophectoderm 
development, neural crest formation, as well as in the differentiation of numerous 
tissues and cell types (Eckert, Buhl et al. 2005). TFAP2A expression in the mouse 
embryo becomes apparent at day 8 in the lateral head mesenchyme and shortly after 
that in the neural tube and the primitive mesenchyme. The expression of -, - and -
variants follows the same pattern between day 8-10. After day 11 on and in later 
stages they start to be expressed in different tissues(Moser, Ruschoff et al. 1997). The 
knockout of Tfap2a in mice results in a range of cranio-facial deformations 
originating from neural tube closure defect, as well as sensory organs and cranial 
ganglions abnormalities (Schorle, Meier et al. 1996; Zhang, Hagopian-Donaldson et 
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al. 1996). In humans, mutations in TFAP2A are linked to another developmental 
defect, namely the Branchio-Oculo-Facial Syndrome (BOFS) (Milunsky, Maher et al. 
2008). Within the normal adult mammary tissue, TFAP2A is expressed in virgin and 
pregnant mice mammary gland. It is detected at the terminal end buds and also in the 
ductal epithelium, predominantly in the luminal cell population (Zhang, Brewer et al. 
2003). Targeted overexpression of TFAP2A and TFAP2C in the mouse mammary 
gland results in lactation deficiency, increased proliferation and apoptosis, reduced 
alveolar budding and differentiation (Jager, Werling et al. 2003; Zhang, Brewer et al. 
2003). Knockout of TFAP2C, a TFAP2A paralogue, in mouse mammary luminal 
cells, results in an increased number of terminal end buds with reduced distal 
migration (Cyr, Kulak et al. 2014).  
Aberrant expression of TFAP2A has been observed in various cancers. In human 
nasopharyngeal carcinoma it is overexpressed and it is involved in tumorigenesis by 
targeting the HIF-1α/VEGF/PEDF pathway (Shi, Xie et al. 2014). On the contrary, 
reduced TFAP2A expression was reported to be associated with poor prognosis in 
gastric adenocarcinoma (Wang, Lv et al. 2011). The loss of TFAP2A is connected 
with the acquisition of the malignant phenotype in melanoma through regulation of 
cell adhesion molecules (ALCAM) (Melnikova and Bar-Eli 2008). In breast cancer, 
TFAP2A expression was found to be less organized than in normal mammary gland 
and it is associated with HER2/ ErbB-2 and ERα expression (Pellikainen, 
Naukkarinen et al. 2004). More recently TFAP2A and TFAP2C activation by loss of 
sumoylation in breast cancer was associated with the luminal breast cancer phenotype 
and it was suggested to interfere with EMT (Bogachek, Chen et al. 2014; Cyr, Kulak 
et al. 2014). 
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TFAP2A is a component of the ZEB1/2
network that regulates TGFB1-induced
epithelial to mesenchymal transition
Yoana Dimitrova1, Andreas J. Gruber1, Nitish Mittal1, Souvik Ghosh1, Beatrice Dimitriades1, Daniel Mathow3,
William Aaron Grandy1, Gerhard Christofori2 and Mihaela Zavolan1*
Abstract
Background: The transition between epithelial and mesenchymal phenotypes (EMT) occurs in a variety of contexts.
It is critical for mammalian development and it is also involved in tumor initiation and progression. Master
transcription factor (TF) regulators of this process are conserved between mouse and human.
Methods: From a computational analysis of a variety of high-throughput sequencing data sets we initially inferred
that TFAP2A is connected to the core EMT network in both species. We then analysed publicly available human
breast cancer data for TFAP2A expression and also studied the expression (by mRNA sequencing), activity (by
monitoring the expression of its predicted targets), and binding (by electrophoretic mobility shift assay and
chromatin immunoprecipitation) of this factor in a mouse mammary gland EMT model system (NMuMG) cell line.
Results: We found that upon induction of EMT, the activity of TFAP2A, reflected in the expression level of its
predicted targets, is up-regulated in a variety of systems, both murine and human, while TFAP2A’s expression is
increased in more “stem-like” cancers. We provide strong evidence for the direct interaction between the TFAP2A
TF and the ZEB2 promoter and we demonstrate that this interaction affects ZEB2 expression. Overexpression of
TFAP2A from an exogenous construct perturbs EMT, however, in a manner similar to the downregulation of
endogenous TFAP2A that takes place during EMT.
Conclusions: Our study reveals that TFAP2A is a conserved component of the core network that regulates EMT,
acting as a repressor of many genes, including ZEB2.
Reviewers: This article has been reviewed by Dr. Martijn Huynen and Dr. Nicola Aceto.
Keywords: Epithelial-to-mesenchymal transition, EMT, Transcription regulatory network, TFAP2A, ZEB2, TGFb1,
NMuMG
Background
The epithelial to mesenchymal transition (EMT) is de-
fined as the process in which cells that display predom-
inantly epithelial features transition to a state in which
they exhibit mesenchymal characteristics. EMT has well-
established and important roles in different stages of em-
bryonic development: it is observed during gastrulation, in
the generation of the primitive mesoderm, during neural
crest (NC) formation, and in the development of many
organs such as heart valves, skeletal muscle, and the palate
[1]. EMT-like phenomena were also described in adult or-
ganisms, as part of normal developmental changes, as well
as during pathological processes [2]. For example, during
breast development, an EMT-like program referred to as
epithelial plasticity is thought to be part of branching
morphogenesis, which leads to the formation of the com-
plex ductal tree [3]. Recent findings suggest that an EMT
program may increase the “stemness” potential of epithe-
lial cells [4].
The mammary gland epithelium is composed of an
internal luminal layer, and an external, basal layer of
myoepithelial cells. Recent studies suggest that these
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different cell types derive from a common stem cell,
through a process that involves epithelial plasticity [5, 6].
Whereas this process is very well coordinated in normal
development, its dysregulation in cancer leads to out-
comes that are difficult to predict [3]. While the majority
of experimental results indicate that manipulating EMT
also affects cancer metastasis, recent reports on cancer
cells circulating in the blood stream or resulting from
genetic lineage tracing have questioned a critical role of
EMT in the formation of metastases, but have demon-
strated a role in chemotherapy resistance [7–9]. In
breast cancer, it is believed that EMT affects the basal
epithelial phenotype and is responsible for an increased
metastatic potential [10].
The TFAP2A transcription factor (TF) is expressed
early in embryogenesis, where it contributes to cell fate
determination in the formation of the neural crest and
the epidermis. The knockout of Tfap2a in mouse is
lethal due to neural crest formation defects [11]. In
humans, mutations in TFAP2A have been linked to the
developmental defects in the Branchio-Oculo-Facial
Syndrome (BOFS) [12].
TFAP2A is a member of the AP-2 family of TFs, which
in humans and mice is composed of five members,
TFAP2A, TFAP2B, TFAP2C, TFAP2D and TFAP2E, or
AP-2α, AP-2β, AP-2γ, AP-2δ and AP-2ε, respectively.
These proteins share important sequence similarities
and have a specific structural organization with a proline
and glutamine-rich trans-activation domain located at
the N-terminus, a central region with positively-charged
amino acids, and a highly conserved helix-loop-helix
region at the C-terminus. The last two domains are in-
volved in DNA binding and dimerization, the proteins
being able to form hetero- or homo-dimers [13]. The
TFAP2A gene is composed of seven exons. In mice, four
different isoforms have been described [14]. Systemic
Evolution of Ligand by EXponential enrichment (SELEX)-
based, in vitro assays, have determined that AP-2α binds
to the palindromic motif GCCN3GGC and to some
close variants, GCCN4GGC, GCCN3/4GGG [15]. More
recent ChIP-seq experiments inferred SCCTSRGGS and
SCCYSRGGS (S =G or C, R = A or G and Y =C or T) as
the consensus sites for human AP-2γ and AP-2α, respect-
ively [16].
In the adult mammary gland, TFAP2A is expressed
in virgin and pregnant mice. Its mRNA and protein
are detected at the terminal end buds and also in the
ductal epithelium, predominantly in the luminal cell
population [17]. Targeted overexpression of TFAP2A
and TFAP2C in the mouse mammary gland results in
lactation deficiency, increased proliferation and apop-
tosis, reduced alveolar budding and differentiation
[17, 18]. Knockout of the TFAP2C paralog of TFAP2A in
mouse mammary luminal cells results in an increased
number of terminal end buds with reduced distal migra-
tion [19].
Aberrant expression of TFAP2A has been observed in
various cancers. It is overexpressed in human nasopha-
ryngeal carcinoma and is involved in tumorigenesis by
targeting the HIF-1α/VEGF/PEDF pathway [20]. In
contrast, reduced AP-2α expression was reported to be
associated with poor prognosis in gastric adenocarcin-
oma [21]. The loss of TFAP2A is connected with the ac-
quisition of the malignant phenotype in melanoma
through regulation of cell adhesion molecules (ALCAM)
[22]. TFAP2A expression was found to be less organized
in breast cancer compared to normal mammary gland
and it is associated with HER2/ErbB-2 and ERα expres-
sion [23].
To define conserved EMT regulatory networks, we
started by analyzing seven mouse and human datasets
obtained from EMT systems, altogether containing
thirty-six mRNA sequencing samples. We found that
TFAP2A is one of the factors that contribute most
significantly to mRNA-level expression changes that
take place during embryonic stem cell (ESC) differen-
tiation to mesoderm or to NC cells, during normal
mammary gland development, and most importantly,
in breast cancer models. To investigate TFAP2A’s in-
volvement in EMT we used mouse mammary gland
epithelial cell line NMuMG, a well-known model of
EMT [24]. We demonstrate, for the first time, that
the expression and activity of Tfap2a are modulated
during TGFβ1-induced transdifferentiation of these
cells. We further show that TFAP2A directly binds to
the Zeb2 promoter, modulating its transcriptional out-
put. TFAP2A overexpression in NMuMG cells results
in increased levels of EMT-inducing TFs, and pro-
motes an EMT-like phenotype. Our study sheds a
new light on the role of TFAP2A in processes that
involve EMT, including breast cancer, and it contrib-
utes to a deeper understanding of the molecular and
cellular mechanism of cancer development and
metastasis.
Methods
Expression vectors and constructs
Mouse TFAP2A cDNA was kindly provided by Prof.
Qingjie [25]. The TFAP2A-FLAG fusion was subcloned
into pDONR201 plasmid, using a Gateway® BP Clonase®
II Enzyme mix (#11789-020, Life Technologies) and it
was further subcloned into pCLX vector, using Gateway®
LR Clonase® II Enzyme mix (#11791-020, Life
Technologies).
Cell culture
We used a subclone of NMuMG cells that was gener-
ated as previously described (NMuMG/E9) [24]. Cells
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were cultured in Dulbecco's modified Eagle's medium
(DMEM #D5671, Sigma Aldrich) with high glucose and
L-glutamine, supplemented with 10% fetal bovine serum
(#f-7524, Sigma-Aldrich) and where indicated were
treated with 2 ng/ml TGFβ1 (#240-B, R&D Systems).
Transient transfection was done using Lipofecta-
mine2000 (#11668-019, Life Technologies) according to
the manufacturer's instructions. For time course experi-
ments, cells were grown in six well plates for up to
14 days and treated with 2 ng/mL TGFβ1. In addition,
NMuMG pCLX-TFAP2A or NMuMG pCLX-GFP
cells induced with 2 μg/mL of doxycycline for 6 days,
and further treated or not treated with TGFβ1 for
72 hours were used to study the effect of TFAP2A
overexpression.
Lentiviral infection
Stable populations of NMuMG cells expressing the
blasticidine-resistant marker together with TFAP2A-
FLAG under a doxycycline-inducible promoter were ob-
tained with the pCLX expression system [26]. Lentiviral
particles were produced in HEK293-LV cells using the
helper vectors pMDL, pREV and the envelope-encoding
vector pVSV. For infection, viral supernatants were added
to target cells in the presence of polybrene (#TR-1003-G,
Millipore) (1 μg/ml). Cells were further incubated at 37 °C
under 5% CO2 in a tissue culture incubator for 72 h, prior
to selection with blasticidine at 10 μg/ml (#15205-25 mg,
Sigma-Aldrich).
Light microscopy and immunofluorescence
Cells were treated with doxycycline or TGFβ1 for the
indicated times, and were grown on gelatin coated glass
coverslips. Cells were fixed with 4% paraformaldehyde in
1x PBS for 15 min (Fig. 2a, b). They were later perme-
abilized and blocked for 30 min with 0.1% Triton X-100
(#T8787, Sigma-Aldrich), 10% goat serum (#16210072,
Gibco®, Life Technologies), and 1% BSA (#A9647, Sigma-
Aldrich) in PBS (#20012-019, Gibco®, Life Technologies).
Afterwards, the coverslips were incubated with the indi-
cated primary antibodies overnight at 4 °C, and then with
Alexa Fluor 488,647 conjugated secondary antibodies,
(Molecular Probes, Life Technologies), for one hour at
room temperature. Where appropriate, Acti-stain™ 555
(#PHDH1, Cytoskeleton) diluted 1:200 was added together
with secondary antibody stain. The coverslips were
mounted with VECTASHIELD™ DAPI Mounting Media
(Vector Laboratories) on microscope slides and imaged
with a confocal microscope (Zeiss LSM 700 Inverted).
Quantitative real-time reverse transcription PCR
Total RNA was extracted with TRI Reagent® (#T9424,
Sigma-Aldrich) and further purified with Direct-zol™
RNA MiniPrep kit (#R2050, Zymo Research). Reverse
transcription was performed with SuperScript® III
Reverse Transcriptase (#18080-044, Life Technologies)
according to the manufacturer’s instructions. For qPCR,
8 ng of cDNA was used in a reaction with Power SYBR®
Green PCR Master Mix (#4367659, Applied Biosystems).
Gene expression changes are normalized to the expres-
sion of the house-keeping genes Gapdh and Rplp0.
mRNA sequencing
For the mRNA-seq library preparation, a well of a 6-well
plate of NMuMG cells was used, either treated with
growth factor and/or doxycycline, or with control re-
agents for the indicated times. mRNA-seq libraries were
prepared as already described [27].
Chromatin immunoprecipitation (ChIP), sequencing
library preparation and data analysis
The ChIP protocol was adapted from [28]. Cells were
crosslinked in fixing buffer (50 mM HEPES pH 7.5,
1 mM EDTA pH 8.0, 0.5 mM EGTA pH 8.0, 100 mM
NaCl, 1% formaldehyde) for 10 min with continuous
rocking at room temperature (RT), and then quenched
with 125 mM glycine for 5 min. Cells were washed three
times with cold PBS and collected by scrapping. Nuclei
were isolated, and lysed to obtain crosslinked chromatin.
Simultaneously, the antibody was coupled with protein
G magnetic beads (#88848, Pierce™) by incubating 100 μl
of protein G beads with 10 μg of TFAP2A-specific anti-
body (Novus) and 10 μg of rabbit IgG (#PP64, Millipore)
as a negative control, for minimum 1 h at RT with
continuous rotation. A probe sonicator was then used in
cold conditions to reduce heating, for six cycles of 30 s
pulse-on at amplitude value of 60 and 1 min and 15 s
pulse-off to obtain chromatin fragments of 100–500 bp
followed by centrifugation at 20,000 g for 10 min at 4 °C
to get rid of nuclear debris. Further, 3% chromatin was
kept as input control from each sample and an equal
amount (around 750–1000 μg) of chromatin was incu-
bated with magnetic beads-coupled antibody at 4 °C
overnight with continuous rotation. Immuno-complexes
were washed with 1 mL of wash buffers as described in
the original protocol. Samples of washed immuno-
complexes along with the input were further treated
with RNase and then with proteinase K followed by
overnight reverse crosslinking at 65 °C with continuous
shaking at 1400 rpm in a thermoblock with heating lid.
DNA was purified using Agencourt AMPure XP
(#A63880, Beckman Coulter) beads as detailed in the
reference. The enrichment of specific target genes was
quantified by qRT-PCR, comparing the TFAP2A-ChIP
with the IgG negative control.
Libraries of ChIPed and input DNA were prepared ac-
cording to the instruction manual of NEBNext® ChIP-
Seq Library Prep Reagent Set for Illumina. In brief, end
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repair of input and ChIPed DNA was done by incubat-
ing with T4 DNA Polymerase Klenow fragment and T4
PNK enzyme at 20 °C for 30 min. The reaction was puri-
fied using Ampure beads according to the instruction
manual. An A nucleotide overhang at the 3’ end was
produced by treating the end repaired DNA with dATP
and Klenow Fragment (3´→ 5´ exo−) at 37 °C for
20 min followed by DNA purification. Double stranded
DNA adapters were ligated to dA overhang DNA by T4
DNA ligase reaction at 37 °C for 30 min followed by
DNA purification and size selection as described in the
instruction manual. Size selected DNA was PCR-
amplified for 16 cycles using NEBNext® High-Fidelity 2X
PCR Master Mix with Illumina universal forward primer
and indexed reverse primer, that enabled multiplexing of
samples for sequencing. Amplified DNA was finally
purified and sequenced on an Illumina Hiseq2500 in-
strument. The obtained sequencing reads were mapped
to the genome and visualized within the clipz genome
browser (www.clipz.unibas.ch).
Antibodies and reagents
We used primary antibodies against the following pro-
teins: TFAP2A (#sc-12726, Santa Cruz Biotechnology) for
Western Blot (WB) and TFAP2A (#NBP1-95386, Novus
Biologicals, Bio-Techne) for immunofluorescence and
immunoprecipitation, actin (#sc-1615, Santa Cruz
Biotechnology), E-cadherin (#610181, BD Transduction
Laboratories), N-cadherin (#610921, BD Transduction La-
boratories), Fibronectin (#F3648, Sigma-Aldrich), GAPDH
(#sc-32233, Santa Cruz Biotechnology), vimentin (#v2258,
Sigma-Aldrich). Recombinant human TGFβ1 was ob-
tained from R&D Systems.
Electrophoretic Mobility Shift Assay (EMSA)
TnT® T7 Quick Coupled Transcription/Translation
System (#L1171, Promega) was used to express in vitro
translated TFAP2A from the pcDNA3-TFAP2A
construct. Double-stranded oligonucleotide probes were
end-labeled with 32P and purified on autoseq G-50
columns (#27-5340-01, Amersham). Binding reactions
containing probe, TFAP2A protein, poly (dI-dC) (#81349,
Sigma-Aldrich) non-specific competitor in gel retention
buffer (25 mM HEPES pH 7.9, 1 mM EDTA, 5 mM DTT,
150 mM NaCl, 10% Glycerol) and electrophoresis were
carried out as described previously [29].
Combined motif activity response analysis
The datasets used in the following analysis are listed in
Additional file 1: Table S1. We applied the ISMARA tool
to each dataset as previously described [30]. Briefly, the
Motif Activity Response Analysis (MARA) infers the
activity of regulatory motifs from the number of binding
sites of each motif m in each promoter p (Nm,p) and the
genome-wide expression driven by these promoters p in
samples s (Ep,s):
Ep;s ¼ ~cs þ cp þ
X
m
Nm;pAm;s
where ~cs represents the mean expression in sample s, cp
is the basal expression of promoter p, and Am;s is the
(unknown) activity of motif m in sample s. To identify
motifs that consistently change in activity across datasets
we used a computational strategy as previously described
[31]. In brief, first we obtained the average activities over
the replicates of each condition in every dataset. Next, be-
cause the range of gene expression levels and consequently
the motif activities varied across datasets, we re-centered
and then standardized the averaged motif activities A

m;g
and corresponding errors σ m;g , belonging to a specific con-
dition g. To standardize the activities in a given dataset
with the epithelial-like condition labeled as a and the
mesenchymal-like condition by b we defined a scaling fac-
tor S ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
A
b
m;g
 2
þ Aam;gð Þ2
2
r
, and then rescaled the activities
~A

m;g ¼
A

m;g
S and the corresponding errors ~σ

m;g ¼
σ m;g
S .
Subsequently, we separated the condition-specific, aver-
aged and rescaled activities ( ~A

m;g ) and errors ( ~σ

m;g ) ob-
tained from different datasets into two groups, depending
on whether they originated from epithelial-like cells (a) or
mesenchymal-like cells (b). We averaged activities belong-
ing to the same group as done for sample replicates before
(see above and [31]). Finally, to rank motif activity changes
during EMT we calculated for every motif m a z-score by
dividing the change in averaged activities by the averaged
errors:
z ¼ A
b
m;g−A
a
m;gﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðσbm;gÞ2 þ ðσam;gÞ2
q
Constructing motif-motif interaction networks
ISMARA predicts potential targets for each motif
m by calculating a target score R as the logarithm of
the ratio of two likelihoods: the likelihood of the
data D assuming that a promoter p is a target of the
motif, and the likelihood of the data assuming that it
is not:
R ¼ log P Djtarget promoterð Þ
P Djnot target promoterð Þ
 
The posterior probability p that a promoter is a target
given the data and assuming a uniform prior of 0.5 is
given by p ¼ 11þ 1
eR
. To construct motif-motif interactions,
we focused on those transcription regulators, whose
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regulatory regions were consistently (within all datasets)
predicted by ISMARA to be targeted by motifs of other
regulators. We obtained a combined probability pcomb
that a regulator is a target of a particular motif m across
I different datasets by calculating the probability product
of the probabilities obtained from individual datasets:
pcomb ¼
YI
i¼1
pi
GOBO analysis
The top 100 target genes of the TFAP2 {A,C}.p2 motif as
derived by applying ISMARA to the Neve et al. data set
[32] were analyzed with the Gene Expression-Based
Outcome for Breast Cancer Online (GOBO) tool [33].
For each gene only the promoter with the highest
ISMARA target score was considered for the analysis.
Estimating gene expression log2 fold changes from mRNA
sequencing data
For each sample s the expression values driven by each
promoter of a gene g (determined by ISMARA, see above)
were summed up to estimate the expression of gene g in
sample s. Log2 gene expression fold changes were then
calculated for TGFβ1-treated pCLX-GFP (pCLX-GFP +
TGF-beta), pCLX-TFAP2A (pCLX-TFAP2A), and for
TGFβ1-treated pCLX-TFAP2A (pCLX-TFAP2A+ TGF-
beta) cell lines relative to the pCLX-GFP (pCLX-GFP)
control cells.
Results
TFAP2A/C motif activity increases upon EMT in both
mouse and human systems
Aiming to identify major regulators of EMTand to further
construct a conserved network of their interactions, we
used the Motif Activity Response Analysis (MARA) ap-
proach, which combines high-throughput measurements
of mRNA expression with computational prediction of
regulatory elements [30]. The published ISMARA tool
[30] allows not only the automated analysis of individual
data sets, but also the inference of motifs that most gener-
ally explain gene expression changes across multiple
experiments.
The results from the combined MARA analysis of
different EMT mRNA expression datasets from breast
epithelial cell lines of mouse and human, and from the
differentiation of human pluripotent stem cells into NC
cell and mesoderm (Additional file 1: Table S1) are
shown in Fig. 1 [34–40]. How much a given motif
contributes to the observed gene expression changes is
quantified in terms of a combined z-score, which in our
case represents the significance of the motif activity
change between the epithelial and mesenchymal cell
types (denoted by the intensity of the color in Fig. 1a
and b and listed in Additional file 1: Tables S2 and S3).
Based on the genome-wide computational prediction of
binding sites for transcription regulators we can further
infer motif interaction networks. In Fig. 1, an arrow is
drawn between two motifs A and B when any of the reg-
ulators that recognizes motif B is a predicted target of
motif A. The motif interaction networks derived from
mouse and human EMT models suggest that only a
small fraction of the TFs has a highly conserved and sig-
nificant role in both species. The core transcriptional
network of EMT, containing the TFs Zeb1, Zeb2 and
Snai1, is conserved, as expected. The motifs that corres-
pond to these factors have negative activity changes dur-
ing EMT (represented by the blue color on the scheme)
which indicates that the expression of their targets
decreases, as expected from their known repressive func-
tion during the process [41]. The TFAP2A/C motif is
also a conserved component of both mouse and human
EMT networks. Its target genes are upregulated during
EMT (reflected by the red color in the figure) and thus
the motif itself is predicted to have a highly significant
positive change in activity. Furthermore, in both human
and mouse systems, the TFAP2A/C motif is predicted to
target both Zeb1 and Zeb2 TFs (Fig. 1a and b).
TFAP2A expression and activity changes in EMT and
breast cancer
We made use of the murine mammary gland cell line
NMuMG to further investigate the role of the AP-2 fam-
ily members TFAP2A and TFAP2C in EMT. Upon in-
duction with TGFβ1, NMuMG cells undergo EMT,
which manifests itself through E-cadherin downregula-
tion, formation of actin stress fibers and an elongated,
mesenchymal-like cell shape (Fig. 2a, b and [36]).
mRNA-seq revealed that of the five members of the AP-
2 family, only Tfap2a is expressed in this system, with
reads covering all its exons (Additional file 1: Figure S1).
Immunofluorescence staining of endogenous TFAP2A
demonstrated that the protein has a predominantly
nuclear localization (Fig. 2a, b). 48 h after the TGFβ1
stimulation we observed that Tfap2a mRNA levels
decreased moderately and further declined during the
14 days time course, while the common EMT markers
such as E-cadherin, Fibronectin and Vimentin followed
the expected trend (Fig. 2c).
We next generated mRNA-seq data from a 14 days
time course of NMuMG cells stimulated with 2 ng/mL
TGFβ1. Applying ISMARA to these data revealed the
dynamics of TFAP2A activity during the entire length of
the time course (Fig. 2d). As the paralogous TFAP2A
and TFAP2C bind similar sequences, we therefore refer
to their shared binding motif as TAFP2 {A,C}. In con-
trast to its mRNA expression (Fig. 2c), the TFAP2A
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transcriptional activity, reflected in the behavior of its
targets, increases during EMT (Figs. 1 and 2d). This in-
dicates that TFAP2A probably acts as a repressor in this
context. Despite the fact that Tfap2a transcript levels
and the TAFP2{A,C} motif activity exhibit a clear nega-
tive correlation, we observed the highest increase in ac-
tivity in the first 6 h of treatment, while the changes in
Tfap2a mRNA were delayed until a later time point.
This may indicate that Tfap2a is regulated at the protein
level. Considering that a rapid reduction of the active
form of a regulator (here within 6 h) can only be
achieved by post-translational mechanisms such as phos-
phorylation and/or targeted protein decay, the delayed
response at the mRNA level appears coherent [42, 43].
Consistent with the changes observed at mRNA level,
TFAP2A protein levels tend to decrease in the first 72 h
after the TGFβ1 treatment (Fig. 2e and f).
To gain further insight into the relationship between
TFAP2A expression and activity, we examined the
mRNA expression data that was previously generated
from human breast cancer cell lines [32]. The Neve et al.
data set contained 51 samples that were separated in three
categories according to their transcriptomic signature.
Using the GOBO online tool we found that TFAP2A ex-
pression is reduced in the basal B breast cancer cell lines
(Fig. 3a), which have a higher expression of the mesenchy-
mal markers compared to the basal A type cell lines
(Additional file 1: Figure S6). This is consistent with our
observations in the mouse cell line [33]. We also analyzed
the Neve et al. dataset [32] in ISMARA to identify the
most significant TFAP2{A,C} targets, based on their
ISMARA-provided z-score. Using the top 100 TFA-
P2{A,C} targets as input for the GOBO tool, we found that
their expression is significantly increased in the basal B
sub-type (Fig. 3b). Thus, we found a strikingly consistent
negative correlation between TFAP2A mRNA and the
expression of its transcriptional targets in the Neve et al.
dataset, as well as in the data that we obtained in the
NMuMG model. Remarkably, in a large panel of breast
tumor datasets originating from more than 1500 patients,
the expression of TFAP2A mRNA is also downregulated
in the basal sub-type cancer category (Fig. 3c) [33]. More
generally, using mRNA expression data from The Cancer
Genome Atlas, we found that the expression of TFAP2A
is positively correlated with that of epithelial markers and
negatively correlated with that of mesenchymal markers,
in normal breast tissue samples as well as in samples from
breast tumors (Additional file 1: Figure S7).
TFAP2A binds directly to the Zeb2 promoter region
In addition to the significant activity change of the TFA-
P2{A,C} motif activity in human and mouse EMT
systems (Fig. 1a and b), the interaction of the TFA-
P2{A,C} and ZEB1,2 motifs was also conserved in the
Mouse
Human
Fig. 1 The transcriptional networks inferred from different EMT systems. Motif–motif interaction networks derived from mouse (a) and human (b)
datasets. An arrow was drawn from a motif A to a motif B if motif A was consistently (across datasets from the corresponding species) predicted
to regulate a transcriptional regulator b that is known to bind motif B. The probability product that A targets b is reflected by the thickness of the
line. For readability, only motifs with an absolute z-score > 2.0 and having at least one interaction with another such motif (with a target probability
product > 0.35 for human and > 0.15 for mouse) are depicted. The color intensity of the nodes representing motifs is proportional to the significance
of the motif given by its z-score. Red indicates increased and green indicates decreased activity upon EMT
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EMT networks of both species. Our analysis predicted
that TFAP2{A,C} controls the expression of ZEB1 and
ZEB2 genes in both systems. The Zeb2 target has a
higher score than Zeb1 in NMuMG cells (target scores
from the initial ISMARA analysis were 0.7 for ZEB1 and
0.51 for ZEB2 in human, and 0.18 and 0.52, respectively
in mouse). To validate the interaction between
TFAP2A and the Zeb2 promoter we performed an
Electrophoretic Mobility Shift Assay (EMSA). From
the SwissRegulon database of transcription factor
binding sites that were predicted based on evolutionary
conservation (www.swissregulon.ch), we found that the re-
gion around the second exon of the Zeb2 gene, in which
the ATG start codon resides, contains seven clusters of
consensus binding sites for TFAP2{A,C} with a relatively
high posterior probability. The corresponding region is
represented in Fig. 4a. Two transcription start sites (TSS),
annotated in the SwissRegulon, based on cap analysis of
gene expression (CAGE) data [44], are in close proximity
to the TFAP2{A,C} binding sites, in the intronic region
between the first and the second exon (Fig. 4a) [44]. To
confirm that the TFAP2A TF binds to the predicted sites,
we carried out EMSA with radiolabeled oligonucleotides,
each spanning one of the predicted binding sites (Fig. 4a
and b). In the presence of the broad competitor poly-dI-
dC, most of the probes give a shift upon addition of
TFAP2A. The addition of an excessive amount of cold
probes containing the same binding sites (Wt), results in a
reduction of the shifted radiolabelled oligonucleotides, in-
dicating competition for specific binding. This is further
Fig. 2 TFAP2A expression and activity profile in the NMuMG EMT model. a-b NMuMG cells were treated with 2 ng/mL of TGFβ1 for 72 h and
were stained for TFAP2A and F-Actin (a) and TFAP2A and E-cadherin (b). The merged panels represent colocalization of the imaged markers with
the nucleus which was stained with DAPI and compared to controls. Scale bar represents 50 μm. c NMuMG cells were treated for 14 days with
2 ng/mL of TGFβ1. Quantitative RT-PCR of Tfap2a during the time course of this treatment indicates that Tfap2a mRNA levels are reduced upon
EMT. The EMT markers E-cadherin (Cdh1), Fibronectin (Fn1), Occludin (Ocln), and Vimentin (Vim) follow the expected trend. d Two mRNA-seq
samples from independent wells were prepared from a time course of NMuMG cells treated for 14 days with 2 ng/mL of TGFβ1, and the data
was consequently analyzed with ISMARA [30]. The figure depicts the dynamics of TFAP2A/C transcriptional activity during the time course. The
sequence logo of the TFAP2A/C binding motif is also indicated. e-f Lysates from NMuMG/E9 cells treated with 2 ng/mL of TGFβ1 for 72 h were
probed for TFAP2A, GAPDH and Lamin B expression by WB and their levels compared with the expression levels of Actin and also to the
Ponceau-stained membrane (e). The bar plot represents the densitometric quantification of the TFAP2A protein levels upon treatment compared
to the control (f) ** indicates a p-value < 0.01 in the paired t-test (P = 0.0014)
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demonstrated by the fact that only few probes, indicated
with red arrows, restored their shift in the presence of
cold competitors that contained mutated versions of
TFAP2A binding sites (M) (Fig. 4b).
To validate this regulatory interaction in NMuMG cells
we have generated a stable cell line in which the overex-
pression of TFAP2A can be induced with doxycycline (see
Methods; Additional file 1: Figure S2). As a control we
established a similar cell line using an expression construct
in which the TFAP2A coding region (CDR) was replaced
by green fluorescent protein (GFP) CDR. Using an anti-
body that recognizes the endogenous TF we further con-
firmed that TFAP2A binds to the Zeb2 promoter region by
TFAP2A-chromatin immunoprecipitation (ChIP) followed
by quantitative PCR: the Zeb2 promoter was significantly
enriched in the TFAP2A-ChIP from cell lines expressing
either exogenously-encoded TFAP2A (p = 0.005). Cells ex-
pressing only endogenous TFAP2A also showed an enrich-
ment of the the Zeb2, albeit not to the same level of
significance (p = 0.06) (Fig. 4c).
Visualization of ChIP-seq data that we also obtained in
this system, with the CLIPZ genome browser (www.clip-
z.unibas.ch) [45], confirms the presence of a peak in the
predicted binding region that is only present in the
TFAP2A-ChIP sample, but not in the Input controls
(Fig. 4d) or the IgG (not shown). Overall, these results
confirm that TFAP2A directly interacts with the Zeb2
promoter, both in vitro as well as in the NMuMG cell line.
TFAP2A overexpression in NMuMG modulates epithelial
plasticity
Finally, we used the above-mentioned cell lines to investi-
gate the consequences of perturbed TFAP2A expression.
Induced expression of TFAP2A, but not GFP, in untreated
NMuMG cells led to morphological changes visible in
phase contrast microscopy (Fig. 5a); compared to GFP-
expressing cells, TFAP2A-expressing cells lose their epi-
thelial polygonal cell shape and disperse on the plate.
Consistently, qRT-PCR showed that adhesion-related
genes were specifically deregulated upon TFAP2A induc-
tion (Additional file 1: Figure S3a and S3b). As expected,
the treatment of GFP-expressing cells with TGFβ1 for
3 days leads to the induction of EMT markers Snai1, Zeb2
and Vim. The expression of endogenous Tfap2a decreases
upon the treatment of GFP-expressing NMuMG cells with
TGFβ1. However, the induction of TFAP2A expression in
the absence of TGFβ1 treatment appears to promote the
expression of core EMT TFs such as Snai1, and Zeb2
(Fig. 5b and Additional file 1: Figure S3c), without
affecting the expression of E-cadherin at the mRNA level
(Additional file 1: Figure S3a).
To better understand the effect of TFAP2A overexpres-
sion, we carried out transcriptional profiling of these four
cell populations, namely untreated and TGFβ1-treated
GFP-expressing cells, and untreated and TGFβ1-treated
(for 72 h) TFAP2A overexpressing cells. The Tfap2a
expression is increased upon doxycycline induction
(Fig. 5b), but it decreases upon TGFβ1 treatment of GFP-
expressing control cells (as we have observed before).
Notably, the MARA analysis of these data reveals an
increased activity of the TFAP2{A, C} motif in TGFβ1-
induced, GFP-expressing cells, as we have initially
observed in wild-type NMuMG cells, but also in
TFAP2A-overexpressing cells treated with the growth fac-
tor when compared to GFP-expressing cells (Fig. 5c). The
TGFβ1 treatment of TFAP2A-overexpressing cells further
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Fig. 3 TFAP2A expression and activity in breast cancers. Box plots of TFAP2A gene expression (a) and expression levels of the top 100 ISMARA-
inferred TFAP2A targets (b) in a panel of breast cancer cell lines grouped in the basal A (red), basal B (grey) and luminal (blue) subgroups based
on the annotation from Neve et al. [32]. c Box plot of TFAP2A gene expression for tumor samples stratified according to PAM50 subtypes [57]. All
plots were generated with the GOBO online tool [33]
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increases the TFAP2A activity. Thus, the exogenously in-
troduced TFAP2A has an opposite transcriptional activity
relative to the endogenous form.
The activity of the SNAI1 motif decreases upon
TGFβ1 treatment while its mRNA level increases, as
expected from its known repressive activity in mesenchy-
mal cells [41] (compare Fig. 5b and c). However, the >4-
fold increase in Snai1 mRNA that occurred upon TFAP2A
overexpression was followed only by a small decrease in
SNAI1 motif activity. Interestingly, the TGFβ1-induced
decrease of SNAI1 activity is less pronounced when the
TGFβ1 treatment is carried out in TFAP2A-overexpress-
ing cells (Fig. 5b and c). These results indicate that overex-
pression of TFAP2A perturbs the course of TGFβ1-
induced EMT in NMuMG cells.
Discussion
Metastasis is the leading cause of death among breast can-
cer patients and a deeper understanding of the process is
necessary for the development of treatment strategies [46].
The development of malignancy has been related to epi-
thelial plasticity, and unsurprisingly, regulatory modules
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Fig. 4 TFAP2A binds directly to the Zeb2 promoter region. a Sketch of the region around the second exon of mouse Zeb2, showing the two
transcription start sites found in SwissRegulon [44]. The blue filled box indicates the non-coding untranslated region (UTR) in exon 2, while the
white filled box designates the start of the coding region (CDS). The predicted TFAP2A binding sites from SwissRegulon are marked with red arrows,
and the probes that were used in (b) are indicated with green lines below the gene structure. Predicted transcription start sites (TSS) are also indicated.
b Radiography of TFAP2A Electrophoretic Mobility Shift Assay (EMSA) with radiolabeled oligonucleotides, each spanning one of the predicted binding
sites. The presence or absence of TFAP2A protein in the assay is indicated by a + or – sign, respectively. Cold competitors were used at 200-fold excess
over the radiolabelled probes. Wt corresponds to unlabeled probe; M indicates a double-stranded oligonucleotide with a mutated TFAP2A binding site.
Red arrows indicate the predicted TFAP2A binding probes that behave as expected from specific binding of TFAP2A. c TFAP2A ChIP was performed in
NMuMG cells stably transduced with pCLX-TFAP2A (denoted as TFAP2A-OE (blue)) or with pCLX-GFP (denoted as TFAP2A-GFP (green)) viral vectors and
further treated with 2 μg/mL doxycycline. Quantitative PCR data shows the enrichment of Zeb2 promoter relative to a non-transcribed genomic region
in TFAP2A-ChIP normalized to IgG control (red). Two independent experiments were performed for each condition and shown are means and stand-
ard deviations. The one-tail paired t-test indicates that TFAP2A is significantly enriched at the Zeb2 (** for p < 0.01). d ChIP-seq libraries from TFAP2A
ChIP or input chromatin were generated and the coverage of the genomic region spanning the second exon of Zeb2 by reads is shown in a mouse
genome browser (www.clipz.unibas.ch and [45]). The results of two independent experiments are presented. The TFAP2A ChIP-seq the Zeb2 promoter
region previously assessed by qPCR is enriched with respect to the input control sample. Mapping, annotation and visualization of deep-sequencing
data was done with the ClipZ server [45]
Dimitrova et al. Biology Direct  (2017) 12:8 Page 9 of 17
Page 71 of 124
and networks that are involved in normal human develop-
ment are hijacked during tumorigenic processes [41].
Although the regulatory network behind EMT has been in-
tensely studied, by integrating data from multiple systems,
recently developed computational methods can continue
to provide new insights. In this study we have compared
data from both developmental processes and cancer
models of epithelial plasticity aiming to identify key regula-
tors that are evolutionarily conserved. We found only a
small number of motifs that have a significant activity
change upon EMT in both human and mouse systems. Of
these, SNAI1..3 and ZEB1..2 correspond to TFs that form
the core EMT network [35]. We did not explicitly recover
motifs for GSC, TWIST and FOXC2/SLUG. However, only
the last factor has a specific motif represented in ISMARA.
Motifs for miR-200 and the TGFβ1-related TGFI1 were
only identified from the human samples. A novel insight
derived from our analysis was that the motif corresponding
to the TFAP2A and/or TFAP2C TFs also has a significant
contribution to the expression changes that occur upon
EMT in both species (Fig. 1a and b). The mechanistic link
between TFAP2A/C and EMT was so far unknown, al-
though TFAP2A was previously found important for neural
crest formation and implicated in the activation of EMT
inducing factors [47]. Furthermore, TFAP2A and TFAP2C
have been implicated in mammary gland tumorigenesis
and metastasis formation [16, 19]. Our data demonstrates
that TFAP2A activity dynamically changes in the early time
points of the TGFβ1 induced EMT in NMuMG cells, and
thus suggests that TFAP2A regulates early steps in this
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Fig. 5 TFAP2A overexpression in NMuMG modulates epithelial plasticity. a Expression of either GFP or TFAP2A was induced by 72 h doxycycline
treatment in NMuMG cells stably transduced with either pCLX-GFP or pCLX-TFAP2A. Morphological changes and sparse cell arrangement are
visible in phase contrast microscopy upon TFAP2A expression. Scale bar: 50 μm. b Gene expression log2 fold changes of EMT markers (TFs) were
calculated from mRNA-seq samples of doxycycline-induced, TGFβ1-treated (72 h, 2 ng/mL) pCLX-GFP (pCLX-GFP + TGF-beta), doxycycline-induced
pCLX-TFAP2A (pCLX-TFAP2A), as well as of doxycycline-induced, TGFβ1-treated (72 h, 2 ng/mL) pCLX-TFAP2A (pCLX-TFAP2A + TGF-beta) cell lines
relative to doxycycline-induced pCLX-GFP (pCLX-GFP) cell line. Shown are the mean log2 fold changes (+/- 1 standard deviation) from two
experiments. TFAP2A overexpression is apparent in both TFAP2A-induced samples (dark green and dark blue) but is not induced in cells
treated with TGFβ1 alone (light blue). The EMT-inducing TFs have increased expression upon TFAP2A induction. * indicates a p-value≤ 0.05 and
** a p-value≤ 0.01 in a two-tailed t-test. c The transcriptional activities of TFAP2{A,C} and SNAI1..3 motifs in different conditions, as inferred with ISMARA
from mRNA-seq data as described in (b). The two replicates from each condition are plotted next to each other
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process (Fig. 2c). Although our analysis of the EMT time
series indicated that the expression of Tfap2a is negatively
correlated with the expression of its targets (reflected in
the motif activity, Additional file 1: Figure S4), overexpres-
sion of TFAP2A induces changes that are similar to those
occurring upon Tfap2a downregulation during EMT. This
observation can have multiple causes. One is that TFAP2A
activity is regulated post-translationally, similar to the core
EMT TFs [41]. For instance, the SNAI1 protein has a rapid
turn-over and its stability and activity are regulated by
post-translational phosphorylation, lysine oxidation and
ubiquitylation [41]. Indeed, it has been demonstrated that
the sumoylation and phosphorylation of the TFAP2A pro-
tein can affect its transcription activation or DNA binding
functions [48, 49]. Therefore, it is possible that during
EMT, the activity of TFAP2A on its targets changes from
repressive to activating and its mRNA levels may decrease
due to a feedback regulatory mechanism. A regulatory step
at the protein level is also suggested by the fact that the
highest increase in TFAP2A activity is observed in the first
6 h of treatment whereas the changes in the Tfap2amRNA
are delayed to a later time point (Fig. 2c and d). Alterna-
tively, TFAP2A may activate some of its targets and repress
others, so that which effect dominates overall will depend
on other factors or on TFAP2A expression levels. The dual
transcription activity of TFAP2A has also been reported
before [16]. Yet another possibility is that depending on its
mode of expression and of post-translational modifications,
TFAP2A may form distinct complexes with other factors
to activate or repress its targets. Additional experiments
will be necessary to address these possibilities. Neverthe-
less, our data provides evidence for a direct regulatory link
between TFAP2A/C and the core EMT regulators ZEB1
and ZEB2 in both human and mouse. In mouse, we found
that TFAP2A binds to the Zeb2 promoter (Fig. 4), and that
Zeb2 levels increase when TFAP2A is overexpressed
(Fig. 5b). These results indicate that TFAP2A regulates
EMT-inducing factors transcriptionally. Although we have
not investigated it in detail here, our TFAP2A-ChIP-seq
data suggests that other critical regulators of EMT such as
Snai1, Sox4, Ezh2 and Esrp2 may also be targets of
TFAP2A (Additional file 1: Figure S5). This further
strengthens the hypothesis that TFAP2A is part of a
densely-connected network of genes that are essential for
EMT [50–52]. Consistent with exogenous TFAP2A-
induced activation of EMT markers, the NMuMG cells
that overexpressed TFAP2A underwent phenotypical
changes that were indicative of the acquisition of a mesen-
chymal phenotype (Fig. 5a). Furthermore, an EMT signa-
ture of positively regulated genes was significantly
represented among genes that were up-regulated in
TFAP2A-overexpressing NMuMG cells compared to con-
trol, GFP-expressing cells (Additional file 1: Table S4) [35].
Genes involved in cellular adhesion and glycosphingolipid
metabolism, which has been recently suggested to regulate
cellular adhesion via St3gal5 and, more upstream, Zeb1
[53], seems to also be affected by TFAP2A overexpression
(Fig. 5b; Additional file 1: Figure S3b and S3c). Cell adhe-
sion is concomitantly affected (Fig. 5a). Thus, our results
support the link between TFAP2A and ZEB TFs, although
overexpression of TFAP2A leads to cellular that are ob-
served upon TGFβ1-induced down-regulation of endogen-
ous TFAP2A. One cannot exclude that the observed
induction of an EMT response upon TFAP2A overexpres-
sion is due to a phenomenon similar to the so-called
‘squelching effect’ [54]. The activity of TFAP2A does not
appear to be sufficient for the induction of a complete
EMT phenotype in the absence of TGFβ1 (Fig. 5a, c). Pre-
viously, ChIP-chip-based measurements of SMAD2/3
binding in human keratinocytes upon TGFβ stimulation
indicated that SMAD2/3 binding sites co-occur with those
for TFAP2A/C TFs, leading to the hypothesis that TFAP2A
is involved in mediating the TGFβ signaling [55]. However,
maintaining a high TFAP2A level in the context of TGFβ
signaling may interfere with the activity of EMT TFs
(Fig. 5c), consistent with our observation that EMT factors
such as SNAI1 have less repressive activity when TFAP2A
is overexpressed during TGFβ1-induced EMT. This in turn
could be the rationale for the moderate downregulation in
Tfap2a levels that we observed in the later phases of the
TGFβ1-induced EMT time course (Fig. 2c). Consistent
with previous studies that suggested that TFAP2A activa-
tion is connected with the luminal breast phenotype, thus
promoting the epithelial state [16], here we found that
endogenously-encoded TFAP2A is down-regulated upon
TGFβ1-induced EMT. Interestingly, PRRX1, another TF
that promotes EMT in a developmental context, was found
to both induce the transition, and reduce the metastatic
potential in tumors [56]. This suggests that the two pro-
cesses are not always coupled and that a tumor suppressor
can also activate EMT. This may be the case with TFAP2A
as well; while it mediates the initiation of EMT, its sus-
tained expression may interfere with EMT signaling. Our
data thus connects TFAP2A to the core regulatory network
that orchestrates the epithelium-to-mesenchyme transition
in normal development as well as in cancers.
Conclusions
Applying recently developed computational methods to
a set of epithelial plasticity datasets we have construct a
conserved transcription factor motif interaction network
that operates during the epithelium-to-mesenchyme
transition. Our analysis recovered the known core EMT
TFs and further linked the TFAP2A/C motif to this core
network. Employing the NMuMG model cell line we
provided further evidence that TFAP2A is involved in
EMT, most likely in the early stages. We found that
TFAP2A binds to the promoter of the Zeb2 master
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regulator of EMT and that TFAP2A overexpression in
NMuMG cells induces an increase in Zeb2 expression.
Finally overexpression of TFAP2A in NMuMG cells pro-
moted the expression of EMT markers and of cellular
features related to the acquisition of a mesenchymal
phenotype. Overall, our data links TFAP2A to the core
TF network that is regulating EMT in normal develop-
ment as well as in cancers.
Reviewers’ comments
Reviewer’s report 1: Dr. Martijn Huynen, Nijmegen Centre
for Molecular Life Science, The Netherlands
Reviewer comments
The manuscript describes an elegant computational ana-
lysis of the regulatory motifs associated with the EMT
transition, followed by the experimental validation that a
new factor, TFAP2A, plays an important role in this
process. In general I do find the first part of the paper
very convincing, it computationally identifies the factor,
confirms the results in independent data, and confirms
binding of the factor to a predicted target. I do get a bit
confused by the results of the overexpression of
TFAP2A, and the arguments used to make these results
consistent with the first part of the paper.
Author’s response:We thank the reviewer for the positive
assessment of our computational analysis. Although we
did find publicly available data that supports our conclu-
sions about the involvement of TFAP2A in EMT, we never-
theless sought to validate its role ourselves. We tried to
explain better the rationale and the results in the revision,
even though some results remain paradoxical.
Does Fig. 1 contain the complete set of motifs that are
predicted to be "differentially active" in the transition? If
so, is it a coincidence that they are all connected to each
other?
Author’s response: We have described the selection of
the motifs that we show in the legend of the Figure.
Briefly, we only showed motifs with an absolute z-score >
2 and arrows that represent predictions with probabil-
ities larger than a threshold (0.35 for human and 0.15
for mouse). For the readability of Fig. 1, only motifs that
have at least a predicted interaction with another motif
at the mentioned thresholds are considered. However,
realizing that motifs with significant activity that are not
connected to other motifs may also be of interest, we have
now included the full tables of motif activity changes
upon EMT as Additional file 1: Tables S2 and S3.
I am surprised by the low level of conservation
between the species. Are there some motifs from e.g. hu-
man that are just below a threshold? The authors argue
"The motif interaction networks derived from mouse
and human EMT models suggest that only a small frac-
tion of the TFs has a highly conserved and significant
role in both species." How reliable are those species-
specific predictions, and how reliable is the absence of a
signal in these analyses, with these data.
Author’s response: Although we selected sequencing
data sets obtained from systems where EMT presumably
occurs for both species, we unfortunately did not have
matching systems available for human and mouse. So in-
deed, the precise scores of the different motifs depend on
the data sets that we used and given sufficient data,
other motifs may emerge as having similar behaviour in
mouse and human EMT systems. Nevertheless, we found
it reassuring that the core EMT factors that were exten-
sively studied so far, such as SNAI and ZEB emerged
from our analysis. That the TFAP2A,C motif also has a
conserved function was unexpected and prompted us to
study it further.
If I understand the manuscript correctly, the downregu-
lation of TFAP2A is associated with the epithelial to mes-
enchymal transition. Why then overexpress TFAP2A?
Even is this has to do with technical limitations, I would
like to see that mentioned explicitly to better understand
the logic of the approach.
Author’s response: Our initial analysis indicated that
the expression of TFAP2A is down-regulated during EMT
(Fig. 2), while its motif activity increases, suggesting that
TFAP2A may function as a repressor. Therefore, we over-
expressed TFAP2A, reasoning that this should perturb
the process of TGFb1-induced EMT. Indeed, this is also
what we observe. However, analysis of the sequencing
data obtained after TFAP2A overexpressionoverexpres-
sion also revealed some paradoxical results, which we
addressed in our discussion.
I find the discussion why "overexpression of TFAP2A
induces changes that are similar to those occurring upon
Tfap2a downregulation during EMT" lengthy and un-
convincing. The authors first perform a very thorough
quantitative analysis of gene expression and motif occur-
rence data, based on the simplifying but defendable as-
sumptions of their linear model, confirm their findings
in independent breast cancer data (Fig. 3). Then they
use a large number of ad-hoc arguments to explain the
inconsistencies in their results. They may all be true, but
they are not convincing. Given the apparent contradict-
ory results of the overexpression, I am surprised by the
sentence "Finally, we confirm that overexpression of
TFAP2A in NMuMG cells modulates epithelial plasticity
and cell adhesion" in the abstract as those results do not
confirm a specific hypothesis based on the results of the
quantitative analysis.
Author’s response: We have revised the discussion to
hopefully make it more streamlined. We agree with the
reviewer that the initial computational analysis sug-
gested a clear picture of TFAP2’s involvement in EMT.
However, as we tried to go deeper into the mouse model,
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the results that we obtained were more complex than we
anticipated. We felt it was important to show the unex-
pected overexpression results, but in the revision we have
included only the initial characterization of this cell line,
without following it into the phenotypic analysis. We
hope that our revised description of the results makes it
clear what we have learned from the different systems
about the behaviour and role of TFAP2A.
In Fig. 5c there is a line connecting the various
constructs. I take it this is not meant to implicate some
sort of continuity? I do fully support publication once
these issues have been handled.
Author’s response: Thank you for pointing this out. We
have removed the lines to prevent the illusion of continu-
ity of the data points.
editorial: The legend with Fig. 3 could use some work
"ABasal" or "Basal A"?
Author’s response: We thank the reviewer for pointing
this out. We have fixed this issue and made the labels
easier to read.
TFAP2A expression was found to be less organized in
breast cancer compared to normal mammary gland. - >
glands
Author’s response: We think that the original formula-
tion is correct.
what is "substantially expressed"
Author’s response: We have explained that only
Tfap2a (and not the other family members) has read
coverage in all exons.
It would be nice to specify which TFs of the core EMT
network of ref 33 are retrieved and which are not.
Author’s response: We have expanded the text
accordingly.
"transcriptional" can often be replaced by "transcrip-
tion", e.g. in "transcriptional regulation" page 18,
Author’s response: We have changed the term in all
places where we thought it makes sense.
line 20 "the interactions of the TFAP2{A,C}" appears
redundant.
Author’s response: We removed the redundancy.
page 22. "in untreated NMuMG cells lead to morpho-
logical changes" – > "led"
Author’s response: Fixed.
"an EMT signature of positively regulated genes were
significantly represented" – > "was"
Author’s response: Fixed.
Reviewer’s report 1: Dr. Nicola Aceto, Department of
Biomedicine, University of Basel, Switzerland
Reviewer comments
Dimitrova et al. present a manuscript in which they high-
light the transcription factor TFAP2A as a novel EMT
regulator. They suggest that TFAP2A target genes, such as
ZEB2, are upregulated during EMT in the NMuMG mouse
model. Further, they conclude that the interaction between
TFAP2A and ZEB2 promoter affects ZEB2 expression,
hence modulating the EMT process itself and providing
evidence for a role of TFAP2A in cancer progression.
Altogether, this is an interesting manuscript yet requiring a
few modifications and clarifications to convincingly argue
in favor of TFAP2A’s role in cancer progression.
(1) Introduction: the authors write their introductory
paragraph arguing that e.g. “cancer progression, metasta-
sis and chemotherapy resistance have all been linked to
EMT”. However, the role of EMT for each of these pro-
cesses is highly debated in the field, and I would suggest
the authors to provide a more balanced introduction,
where it is clearly stated (and referenced) that the role/
requirement of EMT in all these processed has still to be
fully understood, especially in clinically-relevant settings.
Author’s response: We have rephrased and provided
additional references to make the introduction more
balanced.
(2) Fig. 2a: I remain unconvinced about the degree of
EMT that is triggered by TGFb in NMuMG cells. For
instance, why only a small fraction of control cells ex-
press E-cad (roughly 30%)? Looking at the TGFb-treated
cells, this ratio appears to remain the same (3/9 cells, i.e.
roughly 30%). TFAP2A-positive vs negative cells in con-
trol vs TGFb also do not seem to change much, and nei-
ther does actin. I would suggest the authors to provide
more quantitative data here (% of positive cells for each
marker, or signal intensity) that comprise several fields
of view.
Author’s response: To answer the reviewer’s questions,
we have redone the experiment, and imaged the cells
with higher magnification. The results in the revised Fig.
2 clearly show that TFAP2A is abundantly expressed
and nuclearly localized in control cells, while this stain-
ing pattern is abrogated upon TGFb1 treatment. In
almost all control cells, the expression of E-cadherin is
clearly visible, as is its localization close to the plasma
membrane, features which are also abrogated by the
TGFb1 treatment. E-cadherin levels estimated by West-
ern blot (Fig. 2e) also indicate down-regulation upon
TGFb1 treatment.
(3) Fig. 2c: how relevant is a Z-value of 3, with an
activity range varying from -0.02 to 0.01? Looking at
Fig. 1 (Z-values ranging from -19 to +19), can the
authors convincingly state that TFAP2 target genes (and
TFAP2 activity, respectively) significantly change upon
TGFb treatment in NMuMG cells?
Author’s response: Please note that Fig. 1 was generated
based on multiple data sets and that is why the z-scores
cover a much larger range. Based on a standard normal
distribution of z-scores we consider values larger than 2 (in
absolute value) significant.
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(4) Fig. 2d: somehow related to the previous point.
Changes in TFAP2A protein levels are not very impres-
sive. Is the change statistically significant? Control does
not seem to have any error bar, was it repeated more
than once?
Author’s response: We have repeated this experiment as
well, using three biological replicates, adding an additional
control (actin, in addition to lamin and GAPDH) and also
Ponceau staining (current Fig. 2e). Although the overall
protein levels are similar between conditions, TFAP2A’s ex-
pression decreases upon TGFb1 treatment (as apparent
also from the immunofluorescence staining, Fig. 2a). The
controls that we initially used, lamin and GAPDH, also
decrease to some extent upon TGFb1 treatment, which is
probably why the relative change in TFAP2A in our initial
figure was not very impressive. However, relative to the
total protein level as well as to actin, TFAP2A expression is
clearly reduced by the TGFb1 treatment.
(5) Fig. 3: The authors observe a correlation between
low TFAP2A expression and basal type of breast cancer.
Two questions arise here: (a) is basalB more EMT-like
than basal-A?
Author’s response: In the original publication (Ringner
et al. PLoS One, 6:e17911, 2011), the basal B type is
considered “more stem like”.
(b) how are TFAP2A target genes behaving in the
larger dataset with 1500 samples?
Author’s response: Unfortunately we could not carry
out this analysis on the GOBO web server.
(6) Fig. 5: could the authors elaborate more about their
conclusion “TFAP2A perturbs the course of TGFb-
induced EMT in NMuMG cells”? It seems here that
TFAP2A mRNA expression and activity are somewhat
disconnected here, yet in previous experiments they seem
to be going along quite well (e.g. see Fig. 2b-c and Fig. 3).
Author’s response: The reviewer, as reviewer #1 as well,
rightly points out that the TFAP2A that is expressed from
the exogenous construct seems to behave differently than
the endogenously-encoded gene. This is also apparent
from the quantification of TFAP2A expression in TGFb1-
treated control cells, that only express endogenously
encoded TFAP2A (which is down-regulated by the
treatment) and in TFAP2A overexpressionoverexpres-
sion (where the expression is up-regulated, as
expected, Fig. 5b). We discuss possible causes for this
discrepancy in our manuscript (Discussion section). Al-
though we did not identify the precise cause for it, we felt
that it was important to show these results.
(7) Fig. 6: In some instances (i.e. in TGFb-treated
samples), actin staining seems to extend to regions that
do not display any Hoechst staining. For example, in
TFAP2A + TGFb sample, actin staining shows cells on
the lower right corner of the image, but those cells do
not show up in the Hoechst staining.
Author’s response: We think that this had to do with
the intensity of the signal. However, we removed this
figure from the revised version of the manuscript.
(8) Differences in the aggregation index are not very
impressive, and when taken per se would not be a strong
argument of the involvement of TFAP2A in EMT. In-
stead, what would be the effect -in terms of EMT genes
expression- of depleting TFAP2A in NMuMG cells
treated with TGFb?
Author’s response: Because endogenous TFAP2A is
down-regulated upon TGFb1 treatment, we initially
sought to perturb the course of EMT by overexpressing
TFAP2A and we carried out most of the experiments
with this construct. It turned out that the overexpression
of TFAP2A leads to similar molecular signatures as the
downregulation of endogenous TFAP2A that takes place
upon TGFb1-induced EMT. We agree with the reviewer
that presenting the results with this construct as well as
with the siRNAs makes the interpretation very difficult.
We therefore decided to remove this figure and close the
study at the point where the exogenous construct showed
paradoxical results.
The authors show in Additional file 1: Figure S3 some
EMT genes, but it seems that genes such as Vim and
Ocln are missing.
Author’s response: We have regenerated panel b in Fig. 5
based on the mRNA-seq samples that we used to infer the
motif activities shown in panel c of the figure and we have
included also Ocln, aside from Vim, whose expression we
also estimated by qPCR. Both of the markers behave as
expected in EMT. The additional qPCR validations are
now shown in Additional file 1: Figure S3c.
Also, what is the TFAP2A knockdown level with the
siRNAs?
Author’s response: As we explained above, because the
results of perturbing TFAP2A expression were difficult to
interpret, we decided to not pursue too far the perturb-
ation experiments. Therefore, we removed Fig. 6 and we
did not include the siRNA quantifications in the revised
manuscript.
(9) Generally, it would be great to show some func-
tional assays related to EMT (e.g. Boyden chamber, etc.)
to reinforce the involvement of TFAP2A in this process
Author’s response: We agree with the reviewer that it
would be exciting to carry out these studies. However, as
the reviewer probably appreciates, this regulatory net-
work is very complex and the perturbation experiments
did not turn out as we expected. We therefore decided to
follow the suggestion of reviewer #1, concentrating on the
comparative analysis of the different systems that yielded
consistent results and not trying to resolve the specific
mechanism of TFAP2A, which likely depends on the
precise form of the protein that is expressed from the
endogenous locus.
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Reviewer’s report 2: Dr. Martijn Huynen, Nijmegen Centre
for Molecular Life Science, The Netherlands
Reviewer comments
This reviewer provided no additional comments.
Reviewer’s report 2: Dr. Nicola Aceto, Department of
Biomedicine, University of Basel, Switzerland
Reviewer’s comments
Dimitrova et al. present a revised version of the manu-
script that addressed and discussed some of the initial
concerns. While I find the manuscript worthy of publi-
cation, a few points are still worth mentioning: (1) In an
answer to my previous question #5 (see 1st review) the
authors argue that Basal B is considered more stem-like
(therefore more mesenchymal) than Basal A. However,
EMT and stem-like are two very different features of
cancer cells as well as normal tissues, which may or may
not overlap depending on a variety of factors. For instance,
a number of tumor cell lines that are fully epithelial can
display stem-like features (tumor initiation, self-renewal,
differentiation). My original question was more whether
by looking at gene expression data of Basal B, this tumor
type expresses significantly more EMT markers than Basal
A. This would reinforce their conclusions.
Author’s response: To answer the reviewer’s question we
have used the GOBO tool to compare the expression levels
of various epithelial and mesenchymal markers in Basal A
and Basal B tumor types. As shown in the new Additional
file 1: Figure S6, epithelial markers have higher expression
in Basal A tumors, whereas mesenchymal markers have
higher expression in Basal B tumors. This is in line with
the concept that Basal B tumors are more mesenchymal.
(2) Regarding patient data it would be more convincing
to check the expression of TFAP2 (as well as its target
genes and EMT markers) in several independent datasets
to reinforce the conclusions of the authors.
Author’s response: To answer the reviewer’s second ques-
tion, we have used yet another data set, namely expression
profiles of tumors and normal tissue samples from The
Cancer Genome Atlas, to further examine the relationship
between the expression of TFAP2A and that of various epi-
thelial and mesenchymal markers. These results, summa-
rized in the new Additional file 1: Figure S7, show that the
TFAP2A expression is positively correlated with that of epi-
thelial markers and negatively correlated with that of mes-
enchymal markers. This is again consistent with the results
we obtained in our experimental system (Fig. 2).
Additional file
Additional file 1: Supplementary information. (DOCX 19403 kb)
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Table-S1. Datasets used for the generation of Figure 1. 
 
Accession Species Description Reference 
GSE44727 human 
iPS cells vs iPS derived neural 
crest cells 
1
 
GSE23833 mouse 
NM18 cells transfected with 
25nm scrambled siRNA for 48hrs 
vs transfected with 25nm 
scrambled siRNA for 48hrs and 
treated with TGFβ1 for 40hrs 
2
 
GSE49151 mouse 
NMuMG/E9 cells treated with 
Control siRNA 1 or Control 
siRNA 1  and TGFβ1 
3
 
GSE21668 human 
Undifferentiated embryonic stem 
cells, H9 vs mesodermal 
progenitor population 
4
 
GSE9691 human 
HMLE cells untreated vs TGFβ1 
treated 
5
 
GSE55711 
 
mouse 
Py2T untreated vs 
Py2T 5 days TGFβ 
6
 
GSE55964 mouse Neuroepithelim vs neural crest 
7
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Table-S2. Motif activity changes derived from human EMT models (sorted by 
absolute z-scores). 
Motif Z-Score 
SNAI1..3.p2 -24.288498 
ZEB1.p2 -15.499399 
TFAP2{A,C}.p2 13.229919 
bHLH_family.p2 -9.973254 
ARNT_ARNT2_BHLHB2_MAX_MYC_USF1.p2 -9.771872 
ATF6.p2 9.291562 
HBP1_HMGB_SSRP1_UBTF.p2 9.226859 
MAFB.p2 9.049806 
UCCAGUU 8.346224 
TGIF1.p2 8.153858 
AAUACUG 8.008944 
GTF2I.p2 7.767217 
ZNF238.p2 7.406887 
TFEB.p2 7.375766 
GAGGUAG 6.920853 
NR4A2.p2 -6.870112 
IKZF2.p2 6.531350 
ESRRA.p2 -6.402536 
ZNF384.p2 6.350658 
XBP1.p3 6.286392 
FOX{I1,J2}.p2 6.271248 
HNF4A_NR2F1,2.p2 -6.229455 
ZNF423.p2 -6.162108 
HOX{A6,A7,B6,B7}.p2 6.099096 
SREBF1,2.p2 6.086621 
CUCCCAA -5.966596 
KLF12.p2 5.946872 
RFX1..5_RFXANK_RFXAP.p2 5.541792 
CRX.p2 -5.209987 
TEAD1.p2 5.085874 
MYOD1.p2 -5.075488 
SRF.p3 5.044129 
GUAAACA 5.000653 
UCACAGU 4.838087 
RXR{A,B,G}.p2 4.822125 
FOXN1.p2 4.817176 
TFAP4.p2 4.809295 
IKZF1.p2 -4.799092 
NKX3-1.p2 -4.792145 
POU5F1_SOX2{dimer}.p2 -4.723304 
NR6A1.p2 -4.421826 
UGUGCUU -4.412173 
DBP.p2 4.382192 
NFE2L1.p2 4.332266 
REST.p3 -4.301219 
TFDP1.p2 4.187116 
PAX5.p2 -4.168027 
FEV.p2 4.160352 
NFE2L2.p2 -4.136635 
MTF1.p2 -4.071565 
GAUUGUC 4.043714 
PITX1..3.p2 -4.039921 
HLF.p2 -4.017240 
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PBX1.p2 4.008166 
MYBL2.p2 3.965618 
HAND1,2.p2 -3.960443 
TCF4_dimer.p2 -3.950222 
GGAAUGU 3.914362 
STAT2,4,6.p2 3.882966 
AACACUG 3.866572 
UUUUUGC -3.861829 
SPIB.p2 3.848118 
LHX3,4.p2 -3.825488 
GAGAUGA 3.706771 
BPTF.p2 3.694402 
AAGUGCU 3.625894 
NHLH1,2.p2 3.563439 
ESR1.p2 -3.563007 
POU6F1.p2 3.556815 
SRY.p2 -3.501360 
FOX{D1,D2}.p2 3.460886 
NR1H4.p2 -3.444054 
AGUGGUU 3.428867 
UUGGCAC 3.428561 
POU1F1.p2 -3.427446 
AHR_ARNT_ARNT2.p2 -3.402815 
ACAGUAU 3.396875 
SOX17.p2 3.388932 
ZIC1..3.p2 3.380114 
EN1,2.p2 -3.358870 
PRRX1,2.p2 3.351237 
GATA6.p2 3.313266 
AGCACCA 3.258944 
AGCAGCG -3.188248 
PAX4.p2 3.186388 
SOX5.p2 -3.159007 
STAT1,3.p3 3.158086 
YY1.p2 -3.150770 
NFKB1_REL_RELA.p2 3.142962 
UUGGCAA 3.116745 
CACAGUG 3.073683 
SPZ1.p2 3.050127 
NKX2-3_NKX2-5.p2 -3.014212 
TFAP2B.p2 -2.951623 
AGCAGCA 2.933069 
GUAACAG 2.918261 
HOXA9_MEIS1.p2 -2.883912 
ZBTB16.p2 -2.880101 
UCACAUU -2.879964 
CUUUGGU 2.874260 
RBPJ.p2 -2.843359 
UUGGUCC 2.837260 
ETS1,2.p2 -2.824302 
HES1.p2 -2.801785 
MSX1,2.p2 -2.768325 
NRF1.p2 2.764340 
EHF.p2 -2.747095 
GUAGUGU 2.740297 
AAGGUGC 2.704792 
Page 83 of 124
TBP.p2 2.627495 
UUGUUCG 2.612341 
ACAUUCA 2.609181 
HNF1A.p2 -2.574668 
RORA.p2 -2.552431 
CDC5L.p2 -2.543031 
UCAAGUA 2.485514 
EP300.p2 2.478716 
TBX4,5.p2 2.452506 
SOX{8,9,10}.p2 2.443552 
CREB1.p2 -2.429477 
JUN.p2 2.416194 
CEBPA,B_DDIT3.p2 -2.399835 
FOX{F1,F2,J1}.p2 -2.253559 
HIF1A.p2 -2.245699 
GCAGCAU 2.223872 
RXRA_VDR{dimer}.p2 -2.208193 
PATZ1.p2 -2.199593 
GFI1.p2 2.060710 
ZNF148.p2 -2.056085 
MYB.p2 2.050658 
UGCAUAG 2.024762 
AGGUAGU 1.984808 
POU3F1..4.p2 -1.981746 
CDX1,2,4.p2 -1.969056 
LEF1_TCF7_TCF7L1,2.p2 1.949589 
ZBTB6.p2 -1.941322 
FOXP3.p2 -1.914797 
TFCP2.p2 1.888318 
EOMES.p2 1.885703 
MEF2{A,B,C,D}.p2 -1.881713 
TAL1_TCF{3,4,12}.p2 -1.876640 
AACAGUC 1.861035 
CAGUGCA 1.830254 
CCUUCAU 1.823326 
NANOG{mouse}.p2 -1.809389 
UCCCUUU 1.803226 
GUGCAAA 1.799525 
BACH2.p2 -1.778019 
GGCUCAG 1.772541 
CTCF.p2 1.734880 
GGCAAGA 1.734210 
EBF1.p2 -1.724006 
GCUACAU 1.657170 
ZFP161.p2 1.629917 
NFY{A,B,C}.p2 1.620166 
HMX1.p2 -1.605599 
FOXL1.p2 1.586486 
AUGGCUU 1.583830 
CCAGCAU -1.563745 
NFIX.p2 -1.550922 
T.p2 -1.545058 
ONECUT1,2.p2 -1.463027 
AGCUGCC -1.446600 
FOXD3.p2 -1.313682 
NKX2-2,8.p2 1.311760 
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MAZ.p2 1.311673 
PAX6.p2 -1.307375 
AACCUGG -1.306978 
AUGGCAC 1.279688 
ARID5B.p2 -1.251386 
UAAGACG 1.223018 
CCAGUGU 1.199163 
AIRE.p2 1.197368 
ZNF143.p2 -1.163473 
ADNP_IRX_SIX_ZHX.p2 1.112200 
CAGCAGG -1.112018 
AGUGCAA 1.106508 
GCUGGUG 1.105037 
AAUCUCU -1.096328 
DMAP1_NCOR{1,2}_SMARC.p2 -1.088310 
FOXO1,3,4.p2 1.083276 
UAAGACU 1.079116 
HSF1,2.p2 1.069167 
ELF1,2,4.p2 1.041648 
NKX2-1,4.p2 -1.019541 
RXRG_dimer.p3 0.998680 
STAT5{A,B}.p2 0.989426 
AR.p2 -0.987129 
HOX{A4,D4}.p2 -0.963680 
ACUGCAU -0.961381 
CGUGUCU -0.915790 
FOXA2.p3 -0.889308 
UAAUGCU 0.882457 
ATF4.p2 -0.880505 
LMO2.p2 -0.852996 
CUACAGU -0.851979 
TLX2.p2 0.838461 
AUGACAC -0.836765 
NR3C1.p2 0.830968 
GGAGUGU -0.802679 
ACCCUGU -0.777607 
NFIL3.p2 -0.769865 
ACAGUAC 0.769100 
PAX2.p2 0.761529 
NFE2.p2 0.736988 
ALX1.p2 -0.736058 
FOXQ1.p2 -0.692554 
GGAAGAC 0.671442 
CGUACCG 0.656731 
GAUCAGA 0.656140 
PDX1.p2 0.650568 
HIC1.p2 0.635679 
EGR1..3.p2 0.629637 
GGACGGA -0.612295 
ACUGGCC -0.610809 
POU2F1..3.p2 -0.610074 
AAUGCCC -0.584786 
GATA1..3.p2 0.581988 
NFATC1..3.p2 0.581690 
SMAD1..7,9.p2 -0.561780 
NKX3-2.p2 0.551091 
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NKX6-1,2.p2 0.543763 
NR5A1,2.p2 -0.534370 
ATF2.p2 -0.522030 
FOX{C1,C2}.p2 0.519247 
GZF1.p2 0.514649 
AGCUUAU 0.509781 
PPARG.p2 0.485195 
IRF1,2,7.p3 -0.472821 
VSX1,2.p2 0.470825 
EWSR1-FLI1.p2 -0.452944 
UAUUGCU -0.435356 
E2F1..5.p2 0.425908 
UGAAAUG -0.412954 
UGCAUUG -0.406212 
AAUCUCA -0.403747 
AUGUGCC 0.398050 
UGUGCGU -0.380793 
GFI1B.p2 -0.379048 
AAAGUGC -0.378342 
SOX2.p2 -0.378160 
ELK1,4_GABP{A,B1}.p3 0.340488 
GAGAACU 0.334635 
CCCUGAG 0.306717 
GTF2A1,2.p2 -0.297972 
AACGGAA -0.286985 
MZF1.p2 0.286773 
GLI1..3.p2 0.268608 
GGCAGUG -0.258552 
GUCAGUU -0.257585 
TP53.p2 -0.220073 
PRDM1.p3 -0.216004 
RREB1.p2 -0.206545 
AACCGUU -0.202728 
AAGGCAC 0.200079 
EVI1.p2 0.198591 
KLF4.p3 -0.184265 
HOX{A5,B5}.p2 0.176179 
PAX8.p2 -0.161384 
FOSL2.p2 0.138129 
POU5F1.p2 0.137880 
AUUGCAC -0.119868 
PAX3,7.p2 -0.115442 
NANOG.p2 0.104343 
ATF5_CREB3.p2 0.094706 
GAUAUGU -0.084700 
SPI1.p2 -0.081698 
TLX1..3_NFIC{dimer}.p2 0.080810 
UGACCUA 0.076086 
MYFfamily.p2 0.069070 
FOS_FOS{B,L1}_JUN{B,D}.p2 0.068486 
HMGA1,2.p2 0.055254 
CUX2.p2 -0.036901 
RUNX1..3.p2 -0.033572 
SP1.p2 -0.023642 
ACCCGUA 0.014366 
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Table-S3. Motif activity changes derived from mouse EMT models (sorted by 
absolute z-scores). 
Motif Z-Score 
HNF1A.p2 -18.319605 
TFAP2{A,C}.p2 13.139745 
HNF4A_NR2F1,2.p2 -10.316133 
SNAI1..3.p2 -9.802821 
NFY{A,B,C}.p2 -9.260140 
NFIL3.p2 -9.153861 
PATZ1.p2 9.037959 
GTF2A1,2.p2 8.129773 
E2F1..5.p2 -8.107501 
XBP1.p3 7.993492 
SOX{8,9,10}.p2 7.578368 
JUN.p2 7.391577 
ESRRA.p2 -7.092741 
ZEB1.p2 -6.970979 
ZFP161.p2 -6.773266 
RUNX1..3.p2 6.677799 
GAGGUAG 6.640954 
TFCP2.p2 6.502995 
RXR{A,B,G}.p2 6.232599 
HBP1_HMGB_SSRP1_UBTF.p2 6.211917 
ZBTB16.p2 -6.189857 
GATA1..3.p2 6.074720 
GUGCAAA 5.968291 
SMAD1..7,9.p2 5.715875 
HES1.p2 -5.703150 
GUAAACA 5.658502 
DBP.p2 -5.514266 
FOXA2.p3 -5.288262 
FOSL2.p2 5.275215 
EN1,2.p2 -5.001922 
STAT2,4,6.p2 4.958305 
YY1.p2 -4.954490 
AGCACCA 4.928008 
SOX2.p2 4.919780 
PRDM1.p3 4.820454 
TLX2.p2 4.812390 
MYB.p2 -4.762636 
ATF6.p2 4.710928 
bHLH_family.p2 4.694504 
ZNF238.p2 4.656929 
PAX2.p2 -4.622154 
RFX1..5_RFXANK_RFXAP.p2 -4.531748 
UAUUGCU 4.389541 
MYFfamily.p2 4.378652 
KLF12.p2 4.358762 
ZNF423.p2 4.227038 
NR1H4.p2 4.225841 
LMO2.p2 -4.188487 
NFATC1..3.p2 4.178978 
HOX{A6,A7,B6,B7}.p2 -4.123296 
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GLI1..3.p2 4.085050 
AGCUGCC -4.051388 
ESR1.p2 3.971369 
MEF2{A,B,C,D}.p2 3.903434 
NKX2-2,8.p2 3.857453 
IRF1,2,7.p3 3.845818 
FOXL1.p2 3.817527 
NR5A1,2.p2 3.787010 
ACAGUAC 3.741890 
NFE2L2.p2 3.715022 
CEBPA,B_DDIT3.p2 3.686488 
POU1F1.p2 -3.601421 
EBF1.p2 3.576447 
PAX5.p2 -3.448711 
GFI1.p2 -3.441597 
CCCUGAG 3.391263 
ZBTB6.p2 -3.359916 
ZIC1..3.p2 3.355679 
AAGUGCU -3.342459 
AGGUAGU -3.290403 
AUGGCAC 3.285942 
UUGUUCG -3.273784 
CCAGUGU 3.246929 
FEV.p2 3.164132 
UCACAUU -3.154298 
AGUGCAA -3.125763 
UUGGUCC 3.098766 
EGR1..3.p2 -3.096638 
AGCAGCA 3.094618 
SPIB.p2 3.082550 
FOX{I1,J2}.p2 -3.035529 
UGUGCUU 2.945159 
TFDP1.p2 2.916955 
RORA.p2 -2.858638 
GGCAGUG 2.851382 
TLX1..3_NFIC{dimer}.p2 -2.774303 
NANOG{mouse}.p2 -2.761615 
TFAP2B.p2 2.759048 
BPTF.p2 -2.699265 
EP300.p2 2.671825 
EOMES.p2 -2.609712 
CTCF.p2 2.570247 
NKX3-2.p2 -2.518638 
IKZF1.p2 -2.497992 
ARID5B.p2 2.487411 
CREB1.p2 -2.472282 
AUUGCAC -2.444454 
REST.p3 2.442849 
GGAAUGU 2.441918 
MTF1.p2 2.431261 
SOX5.p2 -2.409517 
FOX{D1,D2}.p2 2.387016 
AAGGUGC 2.379286 
NKX2-3_NKX2-5.p2 2.367255 
ALX1.p2 -2.352391 
UGCAUAG 2.323399 
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ZNF148.p2 -2.252424 
UCACAGU -2.232014 
HIC1.p2 2.222399 
PBX1.p2 -2.212457 
ATF5_CREB3.p2 -2.152149 
KLF4.p3 -2.127946 
ACAGUAU -2.127841 
EHF.p2 -2.110093 
IKZF2.p2 2.100513 
GAUUGUC -2.083073 
DMAP1_NCOR{1,2}_SMARC.p2 -2.044785 
SPZ1.p2 2.036622 
MYOD1.p2 -2.020948 
AAUACUG 2.010256 
FOX{F1,F2,J1}.p2 1.951040 
STAT5{A,B}.p2 1.944012 
UGAAAUG -1.941875 
ELK1,4_GABP{A,B1}.p3 -1.931232 
LHX3,4.p2 1.906492 
SRY.p2 1.894688 
ZNF384.p2 -1.824031 
AGUGGUU 1.818739 
MYBL2.p2 1.784815 
GATA6.p2 -1.762058 
TFAP4.p2 1.760603 
TAL1_TCF{3,4,12}.p2 1.682352 
AGCUUAU -1.675293 
ONECUT1,2.p2 -1.633590 
UCAAGUA 1.596472 
FOX{C1,C2}.p2 -1.549272 
FOXD3.p2 1.515649 
UUGGCAA -1.504195 
HLF.p2 1.501009 
HMX1.p2 -1.489057 
ADNP_IRX_SIX_ZHX.p2 -1.482936 
UCCAGUU -1.457275 
SRF.p3 1.452882 
PRRX1,2.p2 1.451130 
NANOG.p2 1.449412 
NKX6-1,2.p2 1.447207 
NFIX.p2 -1.431007 
AHR_ARNT_ARNT2.p2 -1.397611 
ZNF143.p2 -1.383203 
ACUGGCC -1.362517 
HSF1,2.p2 -1.360968 
UCCCUUU -1.357800 
TBX4,5.p2 -1.348500 
NFE2L1.p2 1.343626 
GCAGCAU 1.331934 
CAGUGCA 1.306031 
STAT1,3.p3 1.298060 
AACAGUC 1.292869 
HAND1,2.p2 1.287578 
UUUUUGC -1.280302 
GFI1B.p2 -1.267603 
FOXQ1.p2 -1.246515 
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GZF1.p2 1.202089 
ELF1,2,4.p2 1.198595 
NRF1.p2 -1.197642 
T.p2 1.190501 
GGACGGA 1.116742 
CUX2.p2 -1.071701 
HOXA9_MEIS1.p2 -1.064329 
LEF1_TCF7_TCF7L1,2.p2 1.056026 
TGIF1.p2 -1.034514 
UAAUGCU -0.996918 
HOX{A4,D4}.p2 -0.983296 
POU5F1.p2 -0.980397 
PPARG.p2 -0.965255 
AIRE.p2 0.924218 
GUAACAG 0.910750 
NFKB1_REL_RELA.p2 -0.905472 
NR6A1.p2 0.882506 
CDC5L.p2 -0.862852 
TEAD1.p2 0.852762 
GGAGUGU -0.843095 
FOXP3.p2 -0.838785 
AUGACAC -0.812233 
GCUGGUG 0.807405 
CUCCCAA 0.798569 
RXRA_VDR{dimer}.p2 0.780997 
AR.p2 0.736254 
BACH2.p2 -0.736097 
AACCUGG -0.734849 
TP53.p2 -0.723473 
UAAGACU -0.715628 
SPI1.p2 0.704271 
GUAGUGU -0.702330 
RREB1.p2 -0.698246 
HOX{A5,B5}.p2 0.693836 
GTF2I.p2 0.678249 
MSX1,2.p2 0.626156 
POU5F1_SOX2{dimer}.p2 0.624742 
AAUCUCU -0.614284 
UGCAUUG -0.601594 
ATF2.p2 -0.587577 
MAZ.p2 -0.569641 
GCUACAU -0.562374 
UAAGACG -0.562314 
AGCAGCG 0.559258 
AUGGCUU 0.542322 
CGUGUCU 0.538620 
GUCAGUU 0.505634 
FOS_FOS{B,L1}_JUN{B,D}.p2 0.498148 
CRX.p2 -0.489037 
ACUGCAU -0.478429 
POU6F1.p2 -0.463786 
CCAGCAU 0.459199 
TCF4_dimer.p2 0.445521 
MAFB.p2 0.424878 
AACACUG -0.405680 
TFEB.p2 -0.371070 
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CDX1,2,4.p2 -0.369270 
TBP.p2 0.349531 
CGUACCG -0.336247 
SP1.p2 0.333897 
GAGAUGA 0.331195 
PAX6.p2 -0.323456 
EWSR1-FLI1.p2 -0.319026 
GGCUCAG 0.318037 
AACGGAA 0.309046 
POU2F1..3.p2 0.299161 
AAUCUCA -0.293698 
GAUCAGA 0.292939 
CACAGUG 0.279905 
PAX8.p2 -0.271819 
ATF4.p2 -0.259694 
GAUAUGU 0.255698 
AAGGCAC -0.242607 
HIF1A.p2 -0.238108 
PAX4.p2 0.236628 
CUUUGGU -0.231595 
NKX2-1,4.p2 -0.226075 
NKX3-1.p2 0.225196 
UGACCUA -0.218150 
PDX1.p2 0.209241 
GGCAAGA -0.203007 
PAX3,7.p2 -0.200453 
POU3F1..4.p2 0.190423 
MZF1.p2 0.186999 
FOXO1,3,4.p2 -0.166946 
GGAAGAC 0.161723 
AACCGUU -0.161281 
GAGAACU -0.154159 
PITX1..3.p2 -0.139404 
VSX1,2.p2 -0.132444 
SOX17.p2 -0.122967 
UGUGCGU 0.122439 
NFE2.p2 0.119513 
ARNT_ARNT2_BHLHB2_MAX_MYC_USF1.p2 -0.105121 
ACCCUGU -0.094109 
UUGGCAC 0.088067 
EVI1.p2 -0.087064 
CUACAGU 0.079026 
RXRG_dimer.p3 -0.061463 
RBPJ.p2 -0.057384 
AAAGUGC -0.054632 
ACCCGUA -0.043866 
ACAUUCA 0.043493 
NHLH1,2.p2 -0.033172 
HMGA1,2.p2 -0.032751 
ETS1,2.p2 0.031012 
AAUGCCC -0.025423 
CCUUCAU 0.019178 
CAGCAGG 0.016615 
SREBF1,2.p2 0.010177 
FOXN1.p2 -0.009457 
NR3C1.p2 -0.006974 
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 Table-S4.  Fisher test of EMT signature genes represented in differentially 
expressed genes in response to TFAP2A overexpression. 
 
EMT 
Signature 
Set
5
/Tfap2a 
EMT Sign. 
Genes: 
Changing 
EMT Sign. 
Genes:  Not 
Changing 
All Genes: 
Changing 
All Genes: 
Not 
Changing 
Pval 
Up/Up 18 42 2007 12798 0.0007559 
Up/Down 6 55 1538 13267 0.6181231 
Down/Down 19 87 1538 13267 0.0130989 
Down/Up 27 79 2007 12798 0.0008046 
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Figure-S1: Expression Profile of AP-2 family members. mRNAseq libraries from 
the following conditions NMuMG CTRL cells or cells treated for 14 days with 
growth factor, were generated and read coverage of the genomic region spanning  the 
genes from the family of AP-2 transcription factors is shown in a mouse genome 
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browser (www. clipz.unibas.ch 
8
). High densities of the reads (reads per million unit) 
are only present for the Tfap2a gene, while sporadic reads can be assigned to the other 
family members suggesting they have no or little expression. Mapping, annotation 
and visualization of deep-sequencing data was done with the CLIPZ server 
8
. 
 
 
 
 
 
 
 
 
 
Figure-S2: Overexpression of TFAP2A protein is detected by Western Blot. 
Lysates from NMuMG cells stably transduced with pCLX-TFAP2A or pCLX-GFP 
treated for 72 hours with 2 μg/mL doxycycline (Dox) or not (Nox) were probed for 
TFAP2A expression by WB. GAPDH is used as normalization control. 
Overexpression of TFAP2A is detectable only in the pCLX-TFAP2A doxycycline- 
induced cells.  
TFAP2A 
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Supplementary Figure S2
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Figure-S3: TFAP2A overexpression in NMuMG modulates epithelial plasticity. 
Quantitative RT-PCR of EMT markers on extracts from the doxycycline induced 
pCLX-TFAP2A or pCLX-GFP cell lines, treated or not with 2 ng/mL of TGFβ1 for 
72 hours. The results represented in the figure are the mean values from three 
experiments for cells non-treated with growth factor (light and dark green) and two 
independent experiments in the case of TGFβ1-induced samples. a) EMT markers that 
do not show differential expression upon TFAP2A induction. b) Set of genes 
(Stg3gal5, Tln1, Tnc, Zyx) involved in focal adhesion that are unregulated in both 
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TGFβ1-induced EMT and upon TFAP2A induction. In addition, the St3gal5 gene that 
was recently involved in cell adhesion downstream of TGFβ1 signaling and Zeb1 is 
also significantly changing in both conditions 
9
. The genes that displayed significant 
enrichment in the TFAP2A cell line versus the GFP cell line, as estimated from the 
performed one-tail paired t-test, are indicated with asterix (*) for p<0.05 and (**) for 
p < 0.01, respectively. (c) Quantitative RT-PCR of EMT markers (TFs) in extracts 
from the doxycycline-induced pCLX-GFP and pCLX-TFAP2A cell lines, treated or 
not with 2 ng/mL of TGFβ1 for 72 hours. Shown are the means from three 
experiments on cells not treated with growth factor (light and dark green) and two 
independent experiments in TGFβ1-induced cells. TFAP2A expression in TGFβ1-
induced cells was only measured once. TFAP2A overexpression is apparent in both 
TFAP2A-induced samples (dark green and dark blue) but is not induced in cell treated 
with TGFβ1 alone (light blue). The EMT-inducing TFs have increased expression 
upon TFAP2A induction. 
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Figure-S4: Correlation between TFAP2A/C activity and mRNA expression levels 
during EMT time course.  mRNA-seq samples in two replicates form independent 
wells were prepared from a time course of NMuMG cells treated for 14 days with 2 
ng/mL of TGFβ1, and the data was consequently analyzed with MARA 10. The figure 
emphasizes the correlation between TFAP2A/C transcriptional activity and mRNA 
expression levels during the time course.  
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Figure-S5: TFAP2A binds directly to crucial regulars of  
EMT. ChIP-seq libraries from TFAP2A ChIP or Input  were generated and the 
coverage of the genomic region spanning Snai1 (a), Ezh2 (b), Esrp2 (c), Sox4 (d) 
genes by reads is shown in a mouse genome browser (www.clipz.unibas.ch and 
8
). 
The results of a representative experiment are presented. Mapping, annotation and 
visualization of deep-sequencing data was done with the ClipZ server 
8
. 
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Figure-S6: EMT marker expression in breast cancers. 
Box plots of marker gene expression in a panel of breast cancer cell lines 
grouped in the basal A (red), basal B (grey) and luminal (blue) subgroups based 
on the annotation from Neve et al. 11  All plots were generated with the GOBO 
online tool 12. 
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 Figure-S7: Correlation of log2 expression values of TFAP2A and EMT marker 
genes in normal and tumor breast tissues.  
The plots show the correlation of TFAP2A expression with the expression of the 
indicated epithelial and mesenchymal markers in normal breast tissue samples 
(n = 98) and of breast cancer samples (n = 1080). Normalized expression values 
of the indicated genes were obtained from The Cancer Genome Atlas project in 
Breast Invasive Carcinoma (TCGA-BRCA), more specifically from the Broad 
Institute TCGA Genome Data Analysis Center (2016): Analysis-ready 
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standardized TCGA data from Broad GDAC Firehose 2016_01_28 run. Broad 
Institute of MIT and Harvard. Dataset. https://doi.org/10.7908/C11G0KM9). 
 
 
Supplementary methods 
 
 
Analysis of mRNA-Sequencing data 
 
Mapping and annotation of sequencing reads was done using the CLIPZ webserver 
8
. 
Differential gene expression analysis was conducted using the Bioconductor DESeq 
package 
13
, whereat genes with an adjusted p-value < 0.05 were considered 
differentially expressed. Gene ontology (GO) analysis of differentially expressed 
genes was done with the topGO package 
14
 using the ”weight01” algorithm with a 
node size of one and ”Fisher” statistics. 
 
Analysis of EMT signature genes enrichment 
 
 
The differentially expressed genes between NMuMG cells that overexpress TFAP2A 
and NMuMG cells that overexpress GFP were compared to the EMT signature set of 
up- or downregulated genes 
5
. Those with an adjusted p-value < 0.05 and following 
the defined direction of modulation (Up or Down) were considered as changing, 
whereas those with an adjusted p-value > 0.05 or not following the defined trend were 
defined as non-changing.  In this manner four categories of genes sets comparing the 
signature gene set vs the genes differentially expressed upon TFAP2A overexpression 
were created  Up/Up, Up/Down, Down/Down and Down/Up and for each category 
the number of genes Changing and Not-Changing is calculated. A Fisher statistics 
was used to calculate the enrichment of the genes in each of the four categories as 
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compared to all genes up- or downregulated upon TFAP2A overexpression 
(http://www.quantitativeskills.com/sisa/statistics/fisher.htm), the one sided p-value 
p(O>=E) is represented. 
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 Discussion and Perspectives 
 
During embryonic development cells with initially epithelial charachteristics gain 
mesenchymal and migratory capacities, due to phenotypical plasticity events (Thiery, 
Acloque et al. 2009). Epithelial to mesenchymal transition is involved in normal 
development; wound healing or pathological conditions such as tumor progression, 
metastasis and invasiveness, and fibrosis (Lamouille, Xu et al. 2014). A highly 
complex program at transcriptional, post-transcriptional and post-translational level 
ensures that cells expressing epithelial features will acquire mesenchymal phenotype 
during the transition (Tiwari, Gheldof et al. 2012; De Craene and Berx 2013).  
With the aim to identify conserved regulatory modules that operate in both cancer and 
normal development, we analyzed and compared several transcriptomics datasets 
from mouse and human EMT models, including neural crest differentiation, 
mesoderm specification and breast cancer. We used MARA (Motif Activity Response 
Analysis), an online tool that models the predicted regulatory sites for transcription 
factors (motifs) that explain the measured genome-wide expression changes in the 
input datasets (https://ismara.unibas.ch/fcgi/mara) (Balwierz, Pachkov et al. 2014). 
Further, we have constructed motif-motif interaction networks of both mouse and 
human EMT models. Next, we identified that TFAP2A/C motif increased activity is 
conserved between mouse and human and it has a central place in both EMT motif–
motif interaction networks. Moreover, the interaction between TFAP2A/C and ZEB 
motifs is also maintained in between the two mammalian networks. Consequently, to 
validate the predicted observations we used NMuMG cells; mouse breast cancer cell 
line that is widely used as an in vitro model of TGFβ induced EMT. Performing 
MARA analysis on transcriptomics data from this model we confirmed that 
TFAP2A/C motif changes are reproducible and in line with the previous observations. 
In addition, in the course of the transition the expression levels of Tfap2a mRNA are 
negatively correlated with the TF predicted activity change. What is more, we have 
demonstrated that TFAP2A directly interacts with Zeb2 promoter in vitro as well as in 
NMuMG cells.  The overexpression of TFAP2A in NMuMG cells, followed by its 
increased activity, is translated in altered cells epithelial phenotype.  TFAP2A 
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 induced: i) changes in cellular morphology and cytoskeleton rearrangements; ii) a 
decrease in cellular adhesion, iii) increased mRNA levels of EMT master regulator 
TFs and iv) elevated expression of genes implicated in focal adhesion. Overall our 
results support a role of TFAP2A as a general modulator of EMT, which promotes the 
transition and it is probably involved in the initial step of the process. Those results 
are in a contradiction with recently published reports suggesting that TFAP2A and its 
homologue TFAP2C both govern the luminal cell phenotype and hence the epithelial 
cell state in breast cancer. Both studies from Weigel laboratory demonstrate that 
TFAP2C and/or TFAP2A modulate the expression of certain luminal genes, such as 
CD44 and ESRα (Bogachek, Chen et al. 2014; Cyr, Kulak et al. 2014). In addition, 
they show that TFAP2A activation by sumoylation inhibition abrogates the tumor 
formation capacities of breast cancer cell lines in xenografts, and leads to an increase 
in CD24
hi
/CD44
low
 cells population (Bogachek, Chen et al. 2014). However the 
CD24
low
/CD44
high
 phenotype and  tumor formation capacity of breast cancer cell lines 
are not directly related with EMT (Ocana, Corcoles et al. 2012). A recent study 
identified that increased expression of PRRX1 is a potent EMT inducer in cancer, 
while in the same time leading to reduction of the cancer stem cells population 
(CD24
low
/CD44
high
) thus uncoupling cancer stem cells formation and EMT (Ocana, 
Corcoles et al. 2012). A loss of function/ gain of function study of the roles of 
TFAP2A and TFAP2C in cancer cell lines confirmed that both TFs reduced the 
proliferation, but instead increased cells migration and invasion properties (Orso, 
Penna et al. 2008). Furthermore, TFAP2A knockdown led to increased adhesion, 
while the TF overexpression had the inverse effect (Orso, Penna et al. 2008). 
Therefore the results described by Weigel and colleagues can be mostly explained by 
the TFAP2A and TFAP2C effect on proliferation and depletion in cancer stem cell 
population, rather than directly relating them to the EMT phenotype. Furthermore our 
observations are also in line with previously described role of TFAP2A in neural crest 
specification, where it controls the expression of EMT, inducing transcription factors 
such as SNAIL and ZEB (Rada-Iglesias, Bajpai et al. 2012).  
In a perspective, TF luciferase reporters will be used to further confirm the predicted 
changes of TFAP2A activity. The most intriguing part of our results is the negative 
correlation between the mRNA levels of Tfap2a and its activity, suggesting that the 
TF either functions predominantly as repressor or that a negative auto-regulatory 
feed-back loop is operational. In both cases the luciferase reporters will be 
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 instrumental to elucidate the precise mode of action of TFAP2A. In the case of auto-
regulatory loop one can further hypothesize that post-transcriptional or post-
translational mechanisms activate TFAP2A, to allow it directly or indirectly inhibit its 
own expression. Different splicing isoforms of TFAP2A were shown to have 
variations in transcriptional activity, as well as post-translational modifications, 
including ubiquitylation and phosphorylation, which are known to modulate its 
activity (Garcia, Campillos et al. 1999; Bogachek, Chen et al. 2014). For example, a 
K10R mutant of TFAP2A might be overexpressed in parallel together with wild-type 
TFAP2A in NMuMG cells and consequently observe for any phenotypical 
differences. Proteomic analysis by mass spectrometry can identify phosphorylated 
residues in the transcription factor and their relative proportion can be estimated with 
high precision using Single Reaction Monitoring/Multiple Reaction Monitoring 
(SRM/MRM) label-free method (Wolf-Yadlin, Hautaniemi et al. 2007). In addition, 
the link between TFAP2A expression levels and NMuMG adhesion properties needs 
to be studied in more detail, in order to confirm that the genes significantly affected at 
mRNA levels are also changing at protein level. Next, the siRNA-induced depletion 
of TFAP2A and the consequent effect on adhesion and EMT-TF in the presence or 
absence of TGFβ also needs to be addressed. Last but not least, results obtained in 
NMuMG cells needs to be validated in other EMT models ideally of both mouse and 
human and thus to confirm the general applicability of the model.  
A similar computational approach was applied to elucidate the mechanism by which 
miR-290-295 cluster functions in maintenance and differentiation of ESCs (Leonardo, 
Schultheisz et al. 2012). To better define the direct targets of miR-290-295 
microRNAs, we have carried out an extensive analysis of data sets derived from 
mESCs that either expressed or were deficient in expression of miR-290-295 cluster 
miRNAs. In this manner, we determined direct and reproducible transcription factor 
targets of the miRNAs that mediate the effects of these miRNAs in pluripotency. An 
initial computational analysis of these data predicted a set of miR-290 transcription 
factors that might be involved in the differentiation processes. The computationally 
predicted targets were validated with luciferase reporters in a mouse cell line. Finally, 
we demonstrated the expression variation of IRF2 in response to miRNAs depletion 
in ESC and, importantly, the involvement of nuclear factor kappa-B (NF-kB) pathway 
in the miRNA-dependent regulation in mESCs. This study provided a deeper 
understanding of the mechanism, by which miR-290 regulates pluripotency, and also 
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 propose a extended vision of how microRNAs are implicated in cell cycle, innate 
immune response, and chromatin modification in mESC.   
Pluripotency maintenance and embryonic stem cells differentiation, as well as 
epithelial tissues homeostasis and plasticity, are complex processes that are regulated 
by inter-connected networks at transcriptional, post-transcriptional and post-
translational level.  An intensive research effort was dedicated in understanding the 
molecular mechanisms that operate in both networks. Recent advances in 
computational biology and systemic approaches allow for a new more explicit and 
accurate models of the regulatory organization of those processes.  Therefore the 
improvement and application of the newly emerging strategies will lead to 
identification of new entities that reproducibly and faithfully control critical 
circuitries in ESCs pluripotency maintenance or in EMT. 
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